<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-832-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FABRAZYME 5 mg powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AGALSIDASE BETA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2129.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GENZYME IRELAND LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GENZYME IRELAND LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sanofi B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fabrazyme contains the active substance agalsidase beta and is used as enzyme replacement therapy in Fabry disease, where the level of &alpha;-galactosidase enzyme activity is absent or lower than normal. If you suffer from Fabry disease a fat substance, called globotriaosylceramide (GL-3), is not removed from the cells of your body and starts to accumulate in the walls of the blood vessels of your organs.<br />Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.<br />Fabrazyme is indicated in adults, children and adolescents aged 8 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Fabrazyme</strong><br />- if you are allergic to agalsidase beta or any of the other ingredients of this medicine (listed in section 6).<br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before using Fabrazyme.<br />If you are treated with Fabrazyme, you may develop infusion associated reactions. An infusion-associated reaction is any side effect occurring during the infusion or until the end of the infusion day (see section 4). If you experience a reaction like this, you should tell your doctor immediately. You may need to be given additional medicines to prevent such reactions from occurring.<br /><strong>Children and adolescents</strong><br />No clinical studies have been performed in children 0-4 years old. The risks and benefits of Fabrazyme in children aged 5 to 7 years have not yet been established and therefore no dose can be recommended for this age group.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fabrazyme is given through a drip into a vein (by intravenous infusion). It is supplied as a powder which will be mixed with sterile water before it is given (see information for Health Care Professionals at the end of this leaflet).<br />Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />Fabrazyme is only used under the supervision of a doctor who is knowledgeable in the treatment of Fabry disease. Your doctor may advise that you can be treated at home provided you meet certain criteria. Please contact your doctor if you would like to be treated at home.<br />The recommended dose of Fabrazyme for adults is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.<br /><strong>Use in children and adolescents</strong><br />The recommended dose of Fabrazyme for children and adolescents 8 &ndash; 16 years is 1 mg/kg body weight, once every 2 weeks. No changes in dose are necessary for patients with kidney disease.<br /><strong>If you use more Fabrazyme than you should</strong><br />Doses up to 3 mg/kg body weight have shown to be safe.<br /><strong>If you forget to use Fabrazyme</strong><br />If you have missed an infusion of Fabrazyme, please contact your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />In clinical studies side effects were mainly seen while patients were being given the medicine or shortly after (&ldquo;infusion related reactions&rdquo;). Severe life-threatening allergic reactions (&ldquo;anaphylactoid reactions&rdquo;) have been reported in some patients. If you experience any serious side effect, you should contact your doctor immediately.</p><p>Very common symptoms (may affect more than 1 in 10 people) include chills, fever, feeling cold, nausea, vomiting, headache and abnormal feelings in the skin such as burning or tingling. Your doctor may decide to lower the infusion rate or give you additional medicines to prevent such reactions from occurring.<br />List of other side effects:<br />Common (may affect up to 1 in 10 people):<br />&bull;chest pain<br />&bull;sleepiness<br />&bull;fatigue<br />&bull;difficulty in breathing<br />&bull;increased heart beat<br />&bull;flushing<br />&bull;pallor<br />&bull;abdominal pain<br />&bull;pain<br />&bull;itching<br />&bull;back pain<br />&bull;throat tightness<br />&bull;abnormal tear secretion<br />&bull;rash<br />&bull;dizziness<br />&bull;feeling weak<br />&bull;low heart rate<br />&bull;palpitations<br />&bull;tinnitus<br />&bull;lethargy<br />&bull;decreased sensitivity to pain<br />&bull;nasal congestion<br />&bull;syncope<br />&bull;burning sensation<br />&bull;diarrhoea<br />&bull;cough<br />&bull;wheezing<br />&bull;redness<br />&bull;abdominal discomfort<br />&bull;urticaria<br />&bull;muscle pain<br />&bull;swelling face<br />&bull;pain at the extremities<br />&bull;increased blood pressure<br />&bull;joint pain<br />&bull;nasopharyngitis<br />&bull;sudden swelling of the faceor throat<br />&bull;decreased blood pressure<br />&bull;hot flush<br />&bull;oedema in extremities<br />&bull;chest discomfort<br />&bull;feeling hot<br />&bull;vertigo<br />&bull;face oedema<br />&bull;hyperthermia<br />&bull;stomach discomfort<br />&bull;exacerbated difficulty inbreathing<br />&bull;decreased mouth sensitivity<br />&bull;muscle spasms<br />&bull;muscle tightness<br />&bull;musculoskeletal stiffness<br />Uncommon (may affect up to 1 in 100 people):<br />&bull;tremor<br />&bull;itching eyes<br />&bull;low heart rate due to conductiondisturbances<br />&bull;red eyes<br />&bull;ear swelling<br />&bull;increased sensitivity to pain<br />&bull;ear pain<br />&bull;bronchospasm<br />&bull;upper respiratory tract congestion<br />&bull;throat pain<br />&bull;runny nose<br />&bull;red rash<br />&bull;fast breathing<br />&bull;heart burn<br />&bull;(mottled purplish) skin discoloration<br />&bull;itchy rash<br />&bull;skin discomfort<br />&bull;coldness of the extremities<br />&bull;feeling hot and cold<br />&bull;musculoskeletal pain<br />&bull;injection site blood clotting<br />&bull;difficulty swallowing<br />&bull;rhinitis<br />&bull;skin discoloration<br />&bull;infusion site pain<br />&bull;influenza-like illness<br />&bull;oedema<br />&bull;infusion site reaction<br />&bull;malaise<br />Not known (frequency cannot be estimated from the available data):<br />&bull;lower blood oxygen levels<br />&bull; serious inflammation of thevessels<br />In some patients initially treated at the recommended dose, and whose dose was later reduced for an extended period, some symptoms of Fabry disease were reported more frequently.</p><p><strong>Reporting of side effects Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2340. reporting hotline : 19999E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />Unopened vials<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />Reconstituted and diluted solutions<br />The reconstituted solution cannot be stored and should be promptly diluted. The diluted solution can be held for up to 24 hours at 2&deg;C &ndash; 8&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Fabrazyme contains<br />- The active substance is agalsidase beta, one vial contains 35 mg.<br />- The other ingredients are:<br />- Mannitol<br />- Sodium phosphate monobasic, monohydrate<br />- Sodium phosphate dibasic, heptahydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Fabrazyme looks like and contents of the pack
Fabrazyme is supplied as a white to off-white powder. After reconstitution it is a clear, colourless liquid, free from foreign matter. The reconstituted solution must be further diluted.
Package sizes: 1, 5 and 10 vials per carton. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder</strong><br />Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, The Netherlands</p><p><strong>Manufacturer</strong><br />Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom<br />Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي فاب ا ر ا زیم على المادة الفعالة أغالسیداس بیتا التي تستخدم في العلاج التعویضي للإنزیمات في مرض<br />فابري حیث یكون نشاط إنزیم ألفا جالاكتوزیداز معدومً ا أو أقل من المعدل الطبیعي. إذا كنت تعاني من<br />مرض فابري، فلن تتم إ ا زلة مادة دهنیة تدعى غلوبوت ا ریوسیل سی ا رماید جي إل -</p><p>globotriaosylceramide GL-3&quot;&quot; من خلایا جسمك وتبدأ في الت ا ركم في جد ا رن الأوعیة الدمویة<br />للأعضاء لدیك.<br />فاب ا ر ا زیم مُعد للاستخدام كعلاج تعویضي للإنزیم على المدى الطویل لدى المرضى ممن تأكد تشخیصهم<br />بمرض فابري.<br />فاب ا ر ا زیم مُعد للاستخدام لدى البالغین والم ا رهقین والأطفال من عمر 8 سنوات وما فوق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم فاب ا ر ا زیم</strong><br />- إذا كان لدیك حساسیة نحو أغالسیداس بیتا أو نحو أي من المكونات الأخرى لهذا الدواء المُدرجة في<br />الفقرة<br />رقم 6.<br /><strong>التحذی ا رت والاحتیاطات</strong><br />تحدث إلى طبیبك أو الصیدلي قبل البدء باستخدام هذا الدواء<br />إذا تلقیت العلاج بفاب ا ر ا زیم، فقد تواجه ردود فعل مرتبطة بالتسریب الوریدي. التفاعل المرتبط بالتسریب<br />الوریدي هو أي عرَض جانبي یحدث أثناء التسریب أو حتى نهایة یوم التسریب الوریدي (انظر الفقرة رقم 4).<br />إذا واجهت رد فعل مثل هذا، یجب علیك إخبار طبیبك على الفور. قد تحتاج إلى تلقّي أدویة إضافیة لمنع<br />حدوث مثل هذه التفاعلات.<br /><strong>الأطفال والم ا رهقون</strong><br />لم یتم إج ا رء أي د ا رسات سریریة عند الأطفال بعمر 0- 4 سنوات. وكذلك لم یتم تحدید مخاطر وفوائد</p><p>استخدام فابر زاا یم لدى الأطفال الذین تت ا روح أعمارهم بین 5- 7 سنوات، وبالتالي لا یمكن التوصیة بأي جرعة<br />لهذه الفئة العمریة.<br /><strong>أدویة أخرى وفابر زاا یم</strong><br />أخبر طبیبك أو الصیدلي إذا كنت تتناول حالیًا، أو سبق وتناولت أو قد تتناول أي أدویة أخرى.<br />أخبر طبیبك إذا كنت تتناول أي أدویة تحتوي على كلوروكوین، أمیودارون، بینوكوین، أو جنتامیسین. هناك<br />خطر افت ا رضي لانخفاض نشاط أغالسیداس بیتا.<br /><strong>الحمل والرضاعة الطبیعیة والخصوبة</strong><br />لا یُنصح باستخدام فاب ا ر ا زیم أثناء الحمل. لا توجد تجربة لاستخدام فاب ا ر ا زیم لدى النساء الحوامل. قد یُفرز<br />فاب ا ر ا زیم في حلیب الأم. لا ینصح باستخدام فاب ا ر ا زیم أثناء الرضاعة الطبیعیة. لم یتم إج ا رء د ا رسات لفحص<br />آثار فاب ا ر ا زیم على الخصوبة.<br />إذا كنتِ حاملا أو مرضعة، تعتقدین أنك قد تكونین حاملا أو تخططین لإنجاب طفل، استشیري طبیبك أو<br />الصیدلي قبل استخدام هذا الدواء.<br /><strong>القیادة واستخدام الآلات</strong><br />تجنّب القیادة واستخدام الآلات إذا واجهت الدوخة أو النعاس أو الدوار أو الإغماء أثناء أو بعد فترة وجیزة من<br />تلقیك فاربا زا یم (انظر الفقرة 4). تحدث إلى طبیبك أولا .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یتم إعطاء فاب ا ر ا زیم من خلال التنقیط في الورید (عن طریق التسریب الوریدي). یتوفر فابرا ا زیم على شكل<br />مسحوق یخلط بالماء المعقم قبل إعطائه. ( ا رجع المعلومات الخاصة بأخصائیي الرعایة الصحیة في نهایة<br />هذه النشرة).</p><p>استخدم هذا الدواء دائما وف قًا لإرشادات طبیبك تماما. استشر طبیبك إذا كنت غیر متأكد.<br />یستخدم فاب ا ر ا زیم فقط تحت إش ا رف طبیب واسع الاطلاع في علاج مرض فابري. قد ینصحك طبیبك بأنه<br />یمكن علاجك في المنزل شریطة أن تستوفي معاییر معینة. یرجى الاتصال بطبیبك إذا كنت ترغب في<br />العلاج في المنزل.<br />الجرعة الموصى بها من فاب ا ر ا زیم لدى البالغین هي 1 مجم/ كجم من وزن الجسم مرة واحدة كل أسبوعین. لا<br />توجد ضرورة لتغییر الجرعة للمصابین بأم ا رض الكلى.<br /><strong>استخدامه لدى الأطفال والم ا رهقین</strong><br />الجرعة التي یُنصح باستخدامها للأطفال والم ا رهقین من عمر 8 &ndash; 16 سنة هي 1 مجم/كجم من وزن الجسم<br />مرة واحدة كل أسبوعین. لا توجد ضرورة لتغییر الجرعة للمصابین بأم ا رض الكلى.<br /><strong>إذا استخدمت من فاب ا رزا یم أكثر مما یجب</strong><br />ثبت أنّ الجرعات التي تصل إلى 3 مجم/كجم من وزن الجسم آمنة.<br /><strong>إذا فاتتك إحدى جرعات فاب ا رزا یم</strong><br />إذا فاتتك إحدى جرعات فاب ا رزیام بالتسریب الوریدي یرجى الاتصال بالطبیب.<br />إذا كان لدیك أي أسئلة أخرى حول استخدام هذا الدواء یرجى م ا رجعة الطبیب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع سائر الأدویة یمكن أن یسبب هذا الدواء أع ا رضً جانبیة وإن كانت لا تحدث مع جمیع من<br />یستخدمه.</p><p>لوحظت الأع ا رض الجانبیة خلال الد ا رسات السریریة بشكل رئیسي أثناء إعطاء المرضى الدواء أو بعد<br />الانتهاء من التسریب الوریدي بفترة قصیرة (رد الفعل المتعلق بالتسریب). تم الإبلاغ عن ردود فعل شدیدة<br />تهدد الحیاة (تفاعلات شبیهه بالتأق) لدى بعض المرضى. إذا واجهت أي أع ا رض جانبیة خطیرة، یجب علیك<br />الاتصال بطبیبك على الفور.<br />تتضمن الأع ا رض الشائعة جدًا (قد تؤثر على أكثر من شخص من كل 10 أشخاص) قشعریرة وحمى<br />والشعور بالبرد والغثیان والقيء والصداع ومشاعر غیر طبیعیة في الجلد مثل الحرق أو الوخز. قد یقرر<br />طبیبك خفض معدل التسریب أو إعطاءك أدویة إضافیة لمنع حدوث مثل هذه التفاعلات.<br />قائمة الأع ا رض الجانبیة الأخرى<br />الشائعة (قد تؤثر على ما یصل إلى 1 في كل 10 أشخاص)<br />&bull; ألم في الصدر<br />&bull; النّعاس<br />&bull; إعیاء<br />&bull; صعوبة في التنفس<br />&bull; زیادة سرعة ضربات القلب<br />&bull; احم ا رر الوجه<br />&bull; الشحوب<br />&bull; ألم في البطن<br />&bull; ألم<br />&bull; حكة<br />&bull; ألم في الظهر<br />&bull; الشعور بالضیق في الحنجرة<br />&bull; إف ا رز غیر طبیعي للدمع<br />&bull; طفح جلدي<br />&bull; دوخة<br />&bull; الإحساس بالضعف<br />&bull; تباطؤ ضربات القلب<br />&bull; خفقان<br />&bull; طنین الأذن<br />&bull; خمول<br />&bull; تدني الإحساس بالألم<br />&bull; إحتقان الأنف<br />&bull; إغماء<br />&bull; الشعور بالحرقة<br />&bull; إسهال<br />&bull; سعال<br />&bull; صفیر بالصدر<br />&bull; إحم ا رر<br />&bull; عدم ارتیاح البطن<br />&bull; شرى (أرتیكاریا)<br />&bull; ألم عضلي<br />&bull; تورّم الوجه<br />&bull; ألم في الأط ا رف</p><p>ارتفاع ضغط الدم<br />&bull; ألم مفصلي<br />&bull; التهاب الأنف والحنجرة<br />&bull; تورّم مفاجىء للوجه والحنجرة<br />&bull; انخفاض ضغط الدم<br />&bull; هبّات ساخنة<br />&bull; وذمة في الأط ا رف<br />&bull; ضیق في الصدر<br />&bull; الشعور بالحرّ<br />&bull; دوار<br />&bull; وذمة في الوجه<br />&bull; ارتفاع الح ا ررة<br />&bull; عدم ارتیاح المعدة<br />&bull; صعوبة متفاقمة في التنفس<br />&bull; تدني حساسیة الفم<br />&bull; تشنج عضلي<br />&bull; شدّ عضلي<br />&bull; تبّس هیكلي عضلي<br />غیر شائعة (قد تؤثّر على ما یصل إلى 1 في كل 100 شخص)<br />&bull; رعاش<br />&bull; حكّة في العینین<br />&bull; انخفاض معدل ضربات القلب<br />بسبب اضط ا ربات التوصیل<br />&bull; احم ا رر العینین<br />&bull; تورّم الأذن<br />&bull; زیادة الحساسیة للألم<br />&bull; ألم في الأذن<br />&bull; تشنج قصبي<br />&bull; احتقان الجهاز التنفسي العلوي<br />&bull; ألم في الحنجرة<br />&bull; سیلان الأنف<br />&bull; طفح جلدي أحمر<br />&bull; تنفس سریع<br />&bull; الشعور بالحرقة في المعدة<br />&bull; تغیّر لون الجلد إلى الأرجواني<br />المُبقّع<br />&bull; طفح جلدي مصحوب بحكّة<br />&bull; الشعور بالانزعاج في الجلد<br />&bull; برودة في الأط ا رف<br />&bull; الشعور بالحرّ والبرد<br />&bull; ألم هیكلي عضلي<br />&bull; تجلّط الدم في موضع الحقن<br />&bull; صعوبة في البلع<br />&bull; التهاب الأنف<br />&bull; تغیّر لون الجلد<br />&bull; ألم في موضع الحقن<br />&bull; مرض شبیه بالإنفلون ا ز<br />&bull; وذمة<br />&bull; تفاعلات في موضع الحقن<br />&bull; توعّك</p><p>غیر معروفة (لا یمكن تحدید تك ا رر حدوثها من البیانات المتاحة)<br />&bull; تدني مستویات الأكسجین في الدم<br />&bull; التهاب شدید في الأوعیة الدمویة<br />تم الإبلاغ عن حدوث بعض أع ا رض مرض فابري على نحو أكثر توات ا ر لدى بعض المرضى الذین عولجوا<br />في البدایة بالجرعة الموصى بها ومن ثم تم تخفیض الجرعة لهم في وقت لاحق لفترة طویلة.<br /><strong>الإبلاغ عن الأع ا رض الجانبیّة</strong><br />المملكة العربیة السعودیة: المركز الوطني للتیقّظ والسّلامة الدوائیّة ( (NPC<br />فاكس: 7662 - 205 - 11 - 966 +<br />هاتف: 2038222 - 11 - 966 + ، تحویلة 2317 &ndash; 2356 &ndash; 2340 . خط الاتصال المباشر: 19999<br />البرید الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: www.sfda.gov.sa/npc<br />سانوفي للتیقّظ: KSA_pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعیدًا عن م أ رى ومتناول الأطفال.</p><p>لا تستخدم هذا الدواء بعد مرور تاریخ انتهاء الصلاحیة المُدرج على المُلصق بعد كلمة &quot; EXP &quot;. یُشیر تاریخ<br />انتهاء الصلاحیة إلى آخر یوم في ذلك الشهر.<br />القواریر الغیر مفتوحة<br />تُحفظ في الثلاجة ( 2- 8 درجة مئویة)<br />المحالیل المعاد تشكیلها والمُخفّفة<br />لا یمكن تخزین المحلول المعاد تشكیله من المسحوق وینبغي تخفیفه فو اً ر. یمكن الاحتفاظ بالمحلول المُخفّف<br />لمدة 24 ساعة عند درجة ح ا ررة 2- 8 مئویة.<br />لا تتخلص من أي أدویة عبر الصرف الصحّي أو النفایات المنزلیّة. إسأل الصیدلي عن كیفیّة التخلّص من<br />الأدویة التي لم تعد تستخدمها. ستساعد هذه الإج ا رءات في المحافظة على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتویات فاب ا ر ا زیم<br />- المادة الفعّالة: أغالسیداس بیتا، تحتوي كل قارورة على 35 مجم.<br />- المواد الأخرى:<br />&bull; المانیتول<br />&bull; فوسفات الصودیوم أحادي القاعدة، أحادي الهید ا رت<br />&bull; فوسفات الصودیوم ثنائي القاعدة، سباعي الهید ا رت</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">الشكل الصیدلاني لفاب ا ر ا زیم ووصفه وحجم عبوته<br />یتوفر فاب ا ر ا زیم على شكل مسحوق لونه أبیض إلى أبیض مُصفرّ . بعد إعادة تشكیل المسحوق على هیئة</p><p style="text-align:right">محلول یصبح سائل صافٍ لا لون له وخالٍ من الجسیمات الغریبة. ینبغي تخفیف المحلول المركز المُتكون<br />بعد إعادة تشكیل المسحوق قبل الاستخدام.<br />حجم العبوة: 1، 5، 10 قواریر في الكرتون الواحد. قد لا تُسوّق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسویق</strong><br />جین ا زیم الأوروبیة بي في، غُوي میر 10 ، 1411 دي دي ناردن، هولندا.</p><p>&nbsp;</p><p><strong>المُصنّع</strong>:<br />جین ا زیم ذ.م.م، 37 طریق هولاندز، هافر هیل، سوفولك CB9 8PU ، المملكة المتحدة<br />جین ا زیم إیرلندا ذ.م.م، أي دي إیه إنداست﷼ بارك، طریق كیلمیدین القدیم، واترفورد، إیرلندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2018/02
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fabrazyme 5 mg powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fabrazyme 5 mg powder for concentrate for solution for infusion
Each vial of Fabrazyme contains a nominal value of 5 mg of agalsidase beta. After reconstitution with 1.1 ml water for injections, each vial of Fabrazyme contains 5 mg/ml of agalsidase beta. The reconstituted solution must be diluted further (see section 6.6).
Agalsidase beta is a recombinant form of human α-galactosidase A and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture. The amino acid sequence of the recombinant form, as well as the nucleotide sequence which encoded it, are identical to the natural form of α-galactosidase A.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
White to off-white lyophilised cake or powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (&alpha;-galactosidase A deficiency).<br />Fabrazyme is indicated in adults, children and adolescents aged 8 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fabrazyme treatment should be supervised by a physician experienced in the management of patients with Fabry disease or other inherited metabolic diseases.<br /><em><u>Posology</u></em><br />The recommended dose of Fabrazyme is 1 mg/kg body weight administered once every 2 weeks as an intravenous infusion.<br />Lower dosing regimens have been used in clinical studies. In one of these studies, performed in adult male patients, after an initial dose of 1.0 mg/kg every 2 weeks for 6 months, 0.3 mg/kg every 2 weeks may maintain clearance of GL-3 in certain cell types in some patients; however, the long term clinical relevance of these findings has not been established (see section 5.1).<br />The initial infusion rate should be no more than 0.25 mg/min (15 mg/hour) to minimise the potential occurrence of infusion-associated reactions. After patient tolerance is established, the infusion rate may be increased gradually with subsequent infusions.</p><p>Infusion of Fabrazyme at home may be considered for patients who are tolerating their infusions well. The decision to have a patient move to home infusion should be made after evaluation and recommendation by the treating physician. Patients experiencing adverse events during the home infusion need to immediately stop the infusion process and seek the attention of a healthcare professional. Subsequent infusions may need to occur in a clinical setting. Dose and infusion rate should remain constant while at home, and not be changed without supervision of a healthcare professional.<br /><em><u>Special populations</u></em><br />Renal impairment<br />No dose adjustment is necessary for patients with renal insufficiency.<br /><em><u>Hepatic impairment</u></em><br />Studies in patients with hepatic insufficiency have not been performed.<br /><em><u>Elderly</u></em><br />The safety and efficacy of Fabrazyme in patients older than 65 years have not been established and no dosage regimen can presently be recommended in these patients.<br /><em><u>Paediatric population</u></em><br />The safety and efficacy of Fabrazyme in children aged 0 to7 years have not yet been established. Currently available data are described in sections 5.1 and 5.2 but no recommendation on posology can be made in children aged 5 to 7 years. No data are available in children 0 to 4 years<br />No dose adjustment is necessary for children 8-16 years<br /><em><u>Method of administration</u></em><br />For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Life threatening hypersensitivity (anaphylactic reaction) to the active substance or any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Immunogenicity</u></em><br />Since agalsidase beta (r-h&alpha;GAL) is a recombinant protein, the development of IgG antibodies is expected in patients with little or no residual enzyme activity. The majority of patients developed IgG antibodies to r-h&alpha;GAL, typically within 3 months of the first infusion with Fabrazyme. Over time, the majority of seropositive patients in clinical trials demonstrated either a downward trend in titers (based on a &ge; 4-fold reduction in titer from the peak measurement to the last measurement) (40% of the patients), tolerised (no detectable antibodies confirmed by 2 consecutive radioimmuno-precipitation (RIP) assays) (14% of the patients) or demonstrated a plateau (35% of the patients).<br /><em><u>Infusion associated reactions</u></em><br />Patients with antibodies to r-h&alpha;GAL have a greater potential to experience infusion-associated reactions (IARs), which are defined as any related adverse event occurring on the infusion day. These patients should be treated with caution when re-administering agalsidase beta (see section 4.8). Antibody status should be regularly monitored.<br />In clinical trials, sixty seven percent (67 %) of the patients experienced at least one infusion-associated reaction (see section 4.8). The frequency of IARs decreased over time. Patients experiencing mild or moderate infusion-associated reactions when treated with agalsidase beta during clinical trials have continued therapy after a reduction in the infusion rate (~0.15 mg/min; 10 mg/hr) and/or pre-treatment with antihistamines, paracetamol, ibuprofen and/or corticosteroids.</p><p><em><u>Hypersensitivity</u></em><br />As with any intravenous protein medicinal product, allergic-type hypersensitivity reactions are possible.<br />A small number of patients have experienced reactions suggestive of immediate (Type I) hypersensitivity. If severe allergic or anaphylactic-type reactions occur, immediate discontinuation of the administration of Fabrazyme should be considered and appropriate treatment initiated. The current medical standards for emergency treatment are to be observed. With careful rechallenge Fabrazyme has been re-administered to all 6 patients who tested positive for IgE antibodies or had a positive skin test to Fabrazyme in a clinical trial. In this trial, the initial rechallenge administration was at a low dose and a lower infusion rate (1/2 the therapeutic dose at 1/25 the initial standard recommended rate). Once a patient tolerates the infusion, the dose may be increased to reach the therapeutic dose of 1 mg/kg and the infusion rate may be increased by slowly titrating upwards, as tolerated.<br /><em><u>Patients with advanced renal disease</u></em><br />The effect of Fabrazyme treatment on the kidneys may be limited in patients with advanced renal disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies and no in vitro metabolism studies have been performed. Based on its metabolism, agalsidase beta is an unlikely candidate for cytochrome P450 mediated drug-drug interactions.<br />Fabrazyme should not be administered with chloroquine, amiodarone, benoquin or gentamycin due to a theoretical risk of inhibition of intra-cellular &alpha;-galactosidase A activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em><br />There are no adequate data from the use of agalsidase beta in pregnant women.<br />Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal development (see section 5.3).<br />Fabrazyme should not be used during pregnancy unless clearly necessary.<br /><em><u>Breast-feeding</u></em><br />Agalsidase beta may be excreted in milk. Because there are no data available on effects in neonates exposed to agalsidase beta via breast milk, it is recommended to stop breast-feeding when Fabrazyme is used.<br /><em><u>Fertility</u></em><br />Studies have not been conducted to assess the potential effects of Fabrazyme on impairment of fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fabrazyme may have a minor influence on the ability to drive or use machines on the day of Fabrazyme administration because dizziness, somnolence, vertigo and syncope may occur (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of the safety profile</u></em><br />Since agalsidase beta (r-h&alpha;GAL) is a recombinant protein, the development of IgG antibodies is expected in patients with little or no residual enzyme activity. Patients with antibodies to r-h&alpha;GAL have a greater potential to experience infusion-associated reactions (IARs). Reactions suggestive of&nbsp;immediate (Type I) hypersensitivity have been reported in a small number of patients (see section 4.4).<br />Very common adverse reactions included chills, pyrexia, feeling cold, nausea, vomiting, headache and paraesthesia. Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction. Anaphylactoid reactions have been reported in the postmarketing setting.<br /><em><u>Tabulated list of adverse reactions</u></em><br />Adverse reactions reported from clinical trials with a total of 168 patients (154 males and 14 females) treated with Fabrazyme administered at a dose of 1 mg/kg every 2 weeks for a minimum of one infusion up to a maximum of 5 years are listed by System Organ Class and frequency (very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10 and uncommon &ge; 1/1000 to &lt; 1/100) in the table below. The occurrence of an adverse reaction in a single patient is defined as uncommon in light of the relatively small number of patients treated. Adverse reactions only reported during the Post Marketing period are also included in the table below at a frequency category of &ldquo;not known&rdquo; (cannot be estimated from the available data). Adverse reactions were mostly mild to moderate in severity:</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAMwNQAAkpIAAgAAAAMwNQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNyAxMDoxNDo0MAAyMDIxOjA2OjI3IDEwOjE0OjQwAAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjdUMTA6MTQ6NDAuMDQ3PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAygB9QMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APePFniWHwh4budbvLK7vLa1G6ZbTyy6r/ew7qCB7HPtWjp9219p8F09rNaGZA/kTlC6Z7HYzLn6E1zXxQ03UtZ+G+raVouny397ew+THFHJGmCT94mRlGBj1J9q8/8AEPhPxFqPiefV7DwhdxyPDphR/tForiSCbdKeJvvbMKDnnGM4px1dn3CWiuv62PZNRvf7O024vPs1xdeRGZPItY98smBnaq9yewrM17xVbeHpNIW8s7uRdVvEs43iVMRSP93eGYEDg9Aeled694G1W+8O+Mobjw4dS1m/Mwsr8TwgTxSOrRoQzjBi2j7w+XHyE5IqPUvBviS58S2uoNoUl1IutWF8t0Z4A1vapEFeDmTOUfc2Fyp3ZBJzRHW1/L81cJaJ28/w2PZKK8Pu/hx4hbwdrsV1YX2p6xd3qEqZrNYZwtx5izoflbcI8rmRtw+6MjGLtr4M1yS2jt9S8NyTaOmvXlxLpD3EH7y3mB8uRcSbQUYlsFlIPI5ApLX+vT/P8Aen9ev+X4nsdFeeaL4P1S3+Kmoa3qL3otwVNlLHLAYTCYghgfKmY7WBYDOzJ3dc5r634T1y68ey36Wn2mKS7gmjvP3X7q0SIrLaYZg37xucY2HOSRih9A7+R2Ph3xPa+JlupdPtrtLaCUxx3M0YEdzglS0ZBOQCpHOD7YIJ155DDbySrE8pRSwjQjc+B0GSBk+5Arzvwh4e1TQ/gtdaQPDgt9U2XONPa4jiE7OzFf3kTkDIKjO4EY7cGsHTvAniGytvs8ujK+kw6+LwaTHJAI5YGtwvyruCDZKd+045GRk4y2t0u39f5gtrvzPTvC3iS08W+G7XW9Phnht7oNtjuFUOu1ipyFJHUHoTWvXjvhn4caja6P4TfUNCtUvbX7XYaqlwYpCbOUu2QQSG524HX526AmpL/wCH+sS33jKeW1urp7u2ng06OJ7RbeeF4gscJBAkBRhwGYIOo5JBJaXt5/18xpapf1/X/APXqK8zfwO40bw7Nb+HgdStvJkuIbmSKSNJQsaM7AuQGCxjEkZLAjoQWFXPAPhLVdG8S61qWtyXhubi4mHmF7cwXMTSbo2ARfNLKvy/vD8oyF46Oyva/chNuKfoegUV5MfAurzaT44NlpZ0zVLy/nl0q4MsQ8yORYw4G1mC7zGc7gOoOOuKHiL4f63ceC7TStG0Se4eO1uJ7eS+ubZZbC4JQpGiRbYk5DYZAduMAqCala2+X4q/4F9bebPZ3dY0Z3YKqjJYnAAqla6tFe3iw20Nw8MlslzHdiP9y6sThQ397HOMdCK88/4QrU71PFq6rpC3GpahbzJY6o8yYaKSJVW3YA7vlde4KjJIOSaxYfAWvQvcRaT4dOkRTaDZW0pRrZVmlil3zREJIeXUldxGDzk45prfXy/J/lZC6f13X53f3HtdFeJ6r4D1u4TTGHhhri3iutQlis1e1X7DbywFIrfmQLjcQdqkqPXgV0Xhnwxq1tqHha/1HRWF9aWEdrez3ksMpgCRFSUdWLBmZsYG5WAycEChK/8AXr/XzE9NvP8AD/Pc9Kqhd6vBY3jxXcU0UEds1zJeMmII1UgFS/Zuc49Aa838bfDOfUvEmq6poml2kj3Nvb3kbMIwzX1vKSo+boHRiC3tz1qn4z+Hmo32o6lDofhyMwXHh02gnQwRpJc+cJMYLBsnnkrjJ696S6fP8n+v6dx9ben5r9H+fY9L03xLban4k1TRYre5iuNNSGR5JAmyVZQSpQhif4TncAap+JvGSeGtU0ywfRdT1GXVJDDbNZmDaZApbYfMlTB2qTnp754rzzVfCGvDxgb3R/Ck8NrFcaU1s0M1rH5UcG/zgo80bRtfbgdeR0rpviRoepa/r3heO00fUbuysr03F3cWV7HbNGhjZMK3mo+csD8vbPJ6U2lpbvb8tf67Cvvftf8A4B22mXsuoWKXE9hc6fIxIa2utnmJg452MynPUYY8GqegeIrbxCNQ+zW9xA2n3sllMs4UEumMkbWIKnIx0PsK4bx/4R1vU9Q09dB0dJxpkVq1tqDXKecrJOpdQGI2/uwSWHLZwTgYMNt4F1iLxm18dPWJf7ZutQkvFeMma1kiKC267sswViCNuMHORijTV+v4Nf8AB/4IP/L8n/wD1aivIdJ8B39v8MdJ0y48KRPqDypBqENzcRkJCjyMr7VcxyY38Kc9c4O0Cqln4K1R/wDhDIfEngsagdKtFF7eu9pI3mKSscbM8m7ylBLnaDk7eDzRbVrzH/ke00V4/qHw9Enw38Q6boOk2GphndNCa28oMIZXSY/OxVQA/Q56IOpqrZ+B9es/Gy6taeG5Lbbr6zx3CzW+YrRrcpJwJM4Mh3FRyTzgmi39fd/nr6MHovv/AA/zPaqht7uC78z7NKsoikMTlTnaw6j6iuG+F/hPU/Dlrey6696dQuG2XJme3MM7KzYmQRKGJYNyZDv4APAFcza/Dy/tLjSUfwukgi8TXd3eTRNbjfayiQKxO8Mww6jbjOFPHTJbW39dAez/AK6M9lqG6u7eyhEt3KsUZdUDMcZZmCqPqSQPxrzKPwPrFl4x13UY4Ly5jS2KaVGl1DHDLF5AjFtI5HnrhhkYYLk7s7s5xYfhzrh0O8srrw9bm0bW9Pv49PVoDH5aoguFVS20chsgn5vUk8is2vl+Lt+C1B6fj+X9I9torxC5+HmqT+JJJX8I77B/ENxcyLvttslo8AXG3zOjSKG2n0BI4qzoPgTxRLc+E21+LUYIdN0+OIpBPaM1rPFITlmbedjptUmI7iBtbgmhapfL8r/hsD0v/XW3/BPZXdY0Z3YKqjJYnAApltcRXdrFc2ziSGZA8bjoykZB/KvCtO+HviJGubdPC8llDdWmr27M09tsHnuHtwQshO0YxgA7Sfqa9f8AB+nf2R4M0mwNgunPBaxpJbKEHlvj5vuErktk5BOc0La/p+v+S+8HpKy8/wBPz1+42qKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJeONNsdX1TwjY6rZ299aS60/mW9zEskb4sLsjKsCDggH6iuNgi8CjxHqtnf8Ahbwpb/2dI/m6c2hr9rWBAT56YU+crDadqJwCeSRiu78Uf8jF4M/7DUn/AKb7yquseHZDeQavqcx1K30l5LyC3hsd14Xw3yLJu5Xa2AgXJwMselLqPdWMV7f4TJa29x/wiulNHcxJNCU8MsxkRwWBAEOTwpJ/ujk4yKgjHwpa61SKXwhpUQ067Fozf8I8G82TZvIQLES2BkkDJAG44XBrai8DK/gyHSbC9e0jEjzW8lxblpbZWYlAmCpjZEO1eeO4IyDn6l8JodRuLiWe/trkPq41WOK+08Tx5MQieORC4DggZB+Ug+tXpd/11X6XF0/rz/PQr3DfB21nlhl8P6GXiljiby/D+8F5E3xgFYiG3L93GcngZPFaVvoPwvuvDf8Ab0Phrw8dNwT5zaPGpBDbSuwx7t27jbjOeMZqld/CmebVprm01i0tLZtRsb6K2j03AiFsm1YxiUDB46AY9K0rP4dmPwDc+G7/AFNbhpb171LmK2MYRzP5ygpvOQH/ANoZHp1paW/ry/4P3B2/rv8A8D7zMlh+EUAg87w5oiGeOaREbw/hgIgDIGXysqyg8q2G9qZD/wAKfuLqeCHw9ojG3he4eUeHv3Xlq21mWTytjDd8vBOTx1rR074c3Fh4n03W/wC14XnguLu6vEFkwFxJcKqts/enywAgwDv+tcl4Z8P+JrvWvEFisNroqXMM0UOqW9nex3Fpuk3BVE37naeSRA2M/NnJzSWrS8g8/M15Ln4NRQxyS+H9GQSLOQreHCGHk/60Mvk5VlHJUgHHOMV1Nv4A8BXVtFcW3hHw9JDKgeN10uDDKRkEfL6VyM/wZvDc3L2niO3iine+co+mFipuo1RsETAYXaCOK9I0PT5dJ0Cw06edLiS0t0hMqRmMPtUDO0k46dMmmrW+79b/AKC1v9//AADJ/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukopDPDbfw/pGk+AfAGqL4Z8JyWF9b2EGq3F9oqTTKZY1xLv3KOWIBLA8tnnpXWXPhvwLoVxcy+I/D3hZbOWYrZLb+H18xEUfO0hAfKgnl8Kqjk9ataH4eh8V/AHRNEuZDCl5oFoglC7jE3koVcDjkEA/hVrxD8OrLX7jQZrlrW4bRw0Zj1GyW7juEcAPuViMPlQQ3OD2NC7Pv8Ah/X5jdv6/rr+hhXkvwdsUunufDmjhbSd4Jynhtn8t027gdsJ4w6nPQg5BNbJ8MfDZLG9vJvCehwW9j/x8Sz6IkQX5Q2RujG4YYcrnnjrxRbeGV8NaV4jXU9+sWWt3pka1stPO+JJAsRUqHbcoUAkgDABOOw0brwdFqPw5/4RW8vbhg1qkLXZIaQuuCHPYncM0+l/T7+v3C6/f/wDnfs3wkFvBM/hvQ0WYuMSaAFaII21zKpizEoJALOFAJHPNQTv8Hra4lgl8OaOJYriS1ZF8OFmMqAMyACH5jg5AGcjJGQDWprvw7ufESI+oaxF9pm09tN1CSOyKrPAzBj5a+Z+7fI+8S45PHTFL/hVl4utLfx69bqsesSaokR09jjdD5IjJ87nC857nsKOn9d/8tf61Sv/AF6f56f1pBNL8G4I0kl0LQRE9rFeCQaCCvkyNtWQsIsAbuDn7vfFSRx/CKWx+1J4c0TZ5zQsh8P4lRlAZt0Zi3qoDAliAACCTis9vgrftoTaY3ie22NpCaVvGltkKs/mh/8AX9e2Px9q0H+E1y+ralqf9uwC7vpZvm+wNtjimiSKRMeby2I1Ibsc5BHAHbW3n+en4f10Gul/60/z/rqPe3+EUesnSn8PaCt2JIY9p0JdhMwJiw/lbSGwQGzjPGc8V0f/AArjwR/0Jvh//wAFcH/xNcxdfCa7bVPP0/Xre3tUk08xQSae0jKtnnYpfzhksTycD6V6XTdraf1t/wAEWt/63PO7zwD4OX4k6Nar4T0NbeTSb+R4hpsOxmWazCsRtwSA7AHtuPqaztI8OaD4nn1C90HwX4QTS7G6mtEjuNIjaW8ePgkOMCJd+Ryr5AzxXY33/JU9C/7Aupf+j7GodP8ACN9ompXv9hawlrpd/dPdz2klp5kkcj/fMMm8BATzhkfknGKlb6/1/Wo+n9f12MCeD4SWkd6134d0FP7PjeS4K6EGXCELIUIiIk2EgNs3bT1xTYR8IJ9Wj02Pw9oZupJhAqnw/tAkK71UsYtoLLyuT83bNLffCAXdrf20WsrFBJBeRWQNoWa3+1uHlLnzB5nouAuAed1B+FWof2pLejxDbb5dQsr9l/s1sZto9m3/AF3Ruue3vTVuv9a/5ahLRaef/AKjah8FktlnbQNGEbRvKD/wjbZ2IxV2x5OQFIO7+7wTgEVqTaZ8KbfUHsn8N6C06JuIj0NXUnZ5mwMsZUybPm8sEsRzjFZY+Dd99hW3bxLbkiwv7IsNMYZF1JvZsed/CeAO9aMXwreK5jkGsRFElW82fY25u1tvID583/V4+by+uf48cUaW/rv/AJD0uSeH9K+FXilmXQvDfh+5KwR3GDoqRkxvnaw3xjIJUjjoRg1uf8K48Ef9Cb4f/wDBXB/8TWT4G+Hl54O1JLifWoL+JNLh04RpYmFsRMxV9xlb++cjHp0791Tla+hKv1Ob/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukoqRnN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNdJRQBzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTXSUUAc3/wrjwR/wBCb4f/APBXB/8AE15zf+HtA0P4Sa5r9h4U8Mz3un6lqRX7fpEcytGl/MipxtIAUADnAAAxXtVcRo2h23ib4cazot8WWC+1PV4XZPvLm/uOR7jrSew42vqYl/4f8H+Hfsd/4l8P+E4tLNmjXLQ+GQW85mVQQVLbEJYcFTju3NWpIPhFFp/21/D2g+SJ5IGxoQLo8ZxJuQRblC9SxAABBzg5rT1vwRq2v+EZdJv9dtPtTeUi3UemkIscbh8eX5uSxKjJ3Y44UVT0v4aX+maxHq0evwNfx6hc3YYaeRGY7jb5kRUyk5+UYYEY7g1ejevn+f8Aw/3ffOtv67f5jLmx+E1pJepP4c0EfYY3kmZdCVlwgy4VhEQ5UfeVckdwKqxP8HZ9Qhso/D+h+fM8caBvD+1cyAGPLGLaoYEbSSATkDkGrd/8KVu2vli1VYoJftslqjWpZoZbpdsrM3mDeOTtUBcZ5Jqk3wj1BpJJP+Ejtt0jaax/4ljYH2Pp/wAtv4j19Bxz1pRtdc3l/wAH7hvZ28/0t+oyW9+DEERkk8P6MB+94Hhti37ptsvAhz8p+96Dk8c1ptpXwqW+jtB4b0B5ZI1dDHoiOh3LuVd4jK72XkJncR0BrPHwivxJG/8Awkdtuj/tLH/EsbB+2cn/AJbfwn8x6dat2PwoNkbRf7Xjkiha2uJl+yMDLcW8XlRuD5nypgAlOSSPvCl0+7/gg93bz/4A/wAP6d8KPFEvlaH4c0C4cwC5CtoixExlim4b4xn5lIOOh64re/4Vx4I/6E3w/wD+CuD/AOJrF8EfDi+8I6tbXc+uW99Hb6adP8tLBoWYea0obcZW5yxGMV31N26f1r/kLW/9dv8AM5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia6SikM5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJrpKKAPIIPBWkj4f313oXhTwtPqiazfxQjUtJSVHUahNGkeRtKgDaAckADGKTQLfwTrEI1S78LeFdPsLaB01Gxl0KM3NtdI4Rk3g4IywwAhJyMHmur8P2N9qHg24h0y7t7SUa/qMhkuLZp1IXUp2xtDpySBzn8Km1z4c6XrF5ql5G5tbnUooBMyLlTLDIHjkK5GTkAHnkAcjFC0f9dv6+YPVGHHb/AAtuNc0zSrTwfpM0+oiUqBoAHleXgMJAYsoQSAQ2MZ5xxml9g8F2HjfXdK1bwToT2dmlq1qbDw0biYmVXLBxGjkgeXwdqjsa6HRvh22k+KLXXzqiS3oe6kvALYqk7T7Cdg3kx48tcZLcZ+tRap8PdRu/Gt54l07XLW0u5Tbm28zT2kMHlqysCRMu8OrsCMDt3GafRB3/AAM/T/8AhTupwyS2uheHwkVu9y5m0NYcRo+xz88Q5DDBHUcccikl/wCFQwNAkvhjShJceYEi/wCEZYuGjTe6svk5VgvzbWAbGCBzVe2+DFx5P2fUvEMFxbmyuLUrDpzRNmWfz94Jmb7rgcY5Ax3zW9H8N0dFnvtREmoPq66pcTw2/lo5EflNGqF2Kq0fyn5ieSfajT+vX/LUXV/10/z0MrHwh+y2Nz/wjWkeRqDRray/8I222VpFLIAfJxkgHj6eorc0nwd8Otd0m31PSvCnh64s7lN8Ug0mJdw+hQEH2IyKpSfDWaHQdF0zTNYigXSdUN+jTWRk3AFtkWBIuAqsFzk52it/wV4cm8J+EbPRLi9S+a0DATpAYQwLFvulm559aNNfw9A10If+FceCP+hN8P8A/grg/wDiaP8AhXHgj/oTfD//AIK4P/ia6SikM5v/AIVx4I/6E3w//wCCuD/4msjU/CfhzQfFvg+60PQNL024fVpY2ls7KOF2U2F2SpKgHGQDj2Fd3XN+KP8AkYvBn/Yak/8ATfeUAdJRRRQBzfij/kYvBn/Yak/9N95XE+PvGep6j4R1SfRreeysrLUo7ZNTt75o5DLHcxxyI0YAIVgzYILAgHIHGet8cSX0WqeEX0q3t7m7GtP5cVzcNDG3+gXecuqORxk/dOTxx1HIGwtPFV5qmnW2k+E76e4lE9/Z2PjS6BEiMPnaOO3GxtwGSACSBnOKF8S/rqgfwm9N8SbqDX9Q0n+wPOngtZrm1EF35rTCKRUYOFQ7D8wbCmRsZBAb5a0dM8ZXl/rOm2cum2cMN7CX+0pqBdXb58rD+7Akxs5BKsM/d4Ncy/h1vD91BdTeGfDGnzSyPDBJL4sukLvLIJGVS1tyxdQwA5B6YrVs/D+u2E1pLa+EtCVrNmeHd4mu2AdhguwNqQz4J+dst8zc8nLVrK/9b/8AAB7u39f1qd9RXLTax4wtmiFxovhuIzOI4xJ4hmXexGdozacng8e1S/bvG/8A0L3h/wD8H0//AMh0gOkorm/t3jf/AKF7w/8A+D6f/wCQ6Pt3jf8A6F7w/wD+D6f/AOQ6AOkorm/t3jf/AKF7w/8A+D6f/wCQ6p2niTxNqF1dW1hpvhW5ns32XMUPiSV2gb0cC0yp4PBoA7Ciub+3eN/+he8P/wDg+n/+Q6Pt3jf/AKF7w/8A+D6f/wCQ6AD4cf8AJLPCn/YFs/8A0QldJXnfgG88Yr8NvDS2ehaHLbjSbURSS61MjsvkrgsotWCkjqATj1PWug+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AC+/5KnoX/AGBdS/8AR9jXSV53eXnjH/hZOjM2haGLgaTfhIxrUxRl86z3Et9lyCCFwMHOTyMAHoPt3jf/AKF7w/8A+D6f/wCQ6AOkorm/t3jf/oXvD/8A4Pp//kOj7d43/wChe8P/APg+n/8AkOgDpKK5KLX/ABVcX9xZQaV4Ylu7YKZ7dPEcpkiDDKllFplc9s9as/bvG/8A0L3h/wD8H0//AMh0AdJRXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AdJRXLpqvjKSWSOPQ/DjyRECRF8QTEoSMgEfY+ODmiDVfGVzAk1tofhyaJxlZI/EEzKw9QRZ80AdRRXN/bvG/wD0L3h//wAH0/8A8h0fbvG//QveH/8AwfT/APyHQB0lFc39u8b/APQveH//AAfT/wDyHR9u8b/9C94f/wDB9P8A/IdAHSVzfgP/AJF26/7DWq/+nC4o+3eN/wDoXvD/AP4Pp/8A5Drn/Bd54xXQbkWuhaHIn9rakS0mtTIQ326fcMC1PAbIBzyADgZwAD0SiuRtfEPim+hmlstL8L3EdvI0UzxeI5XEbr95WItOCO4PSp49U8ZzQLNFoXh14nUOsi+IJirKRkEH7H0oA6eiuT/t3xWbOK7GkeGPs02zypv+Eil2SbyAuG+yYOSQBjrkVY+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6ADwH/yLt1/2GtV/wDThcV0led+C7zxiug3ItdC0ORP7W1IlpNamQhvt0+4YFqeA2QDnkAHAzgdB9u8b/8AQveH/wDwfT//ACHQB0lFc39u8b/9C94f/wDB9P8A/IdH27xv/wBC94f/APB9P/8AIdAHSUVzf27xv/0L3h//AMH0/wD8h0fbvG//AEL3h/8A8H0//wAh0AdJRXN/bvG//QveH/8AwfT/APyHR9u8b/8AQveH/wDwfT//ACHQB0lFc39u8b/9C94f/wDB9P8A/IdH27xv/wBC94f/APB9P/8AIdAHSVzfij/kYvBn/Yak/wDTfeUfbvG//QveH/8AwfT/APyHWRqdz4jm8W+D11zStLs7f+1pSslnqclw5b7Bd4BVoIwBjPOT0HHOQAd3RRRQBzfij/kYvBn/AGGpP/TfeV5PdeNYNK8Z+Jv7H8UWdlcXXiexiZVlgcywGNI5eHB4XnJGMEcntXrHij/kYvBn/Yak/wDTfeVtWV99te6X7Lc2/wBnnMOZ49olwAd6eq84z7GhfFf+t0/0sD2t/WzPCbLxW/iXxB4VurzW4NVvYrTVALHNuVuJIpP3O5Av3nCqeMfdyuOc6uj+NvFt/b6MNV1+x06x1YuyarAUna3uAo22sqtAiL8+4bfv8bd2fmPqEvim0j8XR+HYra7uLoxCWaWGINFbK27Z5hzkbtjYIBGQM4yM7ZIAJJwB1NNaa/1u/wCvkD3PC7vxHqGn+OZTda/50h8VC1TTbtLbb5f2UFGXdH5iEsQoKsBz6kksm+JHiNNCW4bX1hYtp7XE7R2+La4mmKz2ZBToiDdg/vFxktg17la3UF9aRXVpKs0EyB45FOQ6noR7VUOswNfQW1tFPdCWaSF5oE3RwMi5Ikb+H0+vFOLtZPpb8LL8f6829b/11b/r+reZaF451PU4dPmk8SLNHFrE9jNHapAZrkfaNsWVKYYeWCSI9jAfPyAavfEHxrfaD4stLfTtXkgSGWzF3aNbRiMxTzGMu0jKScAcbSoUjndnA9PopdvIXfzPB9A+KHiGa1nFvrcGu3h0a/uYLcpDuaWG4KxkCMKSTHyR3C5AHNdL8Lb6G98f+MJY9WXVWlh0+QXWY8yjyTlsIAuM8cAV6nRTv/XzuD1/r0/y/EKKKKkDi/BWpXVj8M/Bsdtot9qKy6NaB5LV4FWH9yn3vMkQnr/CG6Vt2euahc3NvFP4W1azSXO+aeW0Kw4z97ZOxOf9kN15xVT4cf8AJLPCn/YFs/8A0QldJQAUUUUAFFFFABRRRQAUUUUAc1f/APJU9D7f8SXUv/R9jXmjfEuezSAXHjmOQXk97aq5S03J5d0qRODtVQxRjlmyuAG2nBz6Zff8lT0L/sC6l/6Psa6ShbjvpY8fsvHOum006aXVftt6I5ohp9sIS1zOjzL+8XYrMMInMe3bnLIARhJPGeoreWUieNd2izTwrc6k0Nsq27yRzGSFiY9qlDGhGfmXd85avYayda0BdaudMme/u7Q6ddC6Rbfy8SMAVw+9GOMMw4weevSn1Etvk/8AgHkMXjaez1m71S+8SW9vd29vYRSF/JT7ZD9tnQM6kfKGhdZPl2/eU8Dgyj4i382peS3jNba3urqzNrI62isyyTSRzIFKHAUBTglmU43Nztr2+infW7HJ3TXVr9LHlHiLV/EWhaR4itZvFV9Dc6NE9/FqEtvagTwtHiGNv3ITJlDjgBjt6jcAKGp/ES5gW+s4PGMD+Veoq3Mc1jHMFe2EigNKBDsEhI+b5ioIBJFes2GmfYprmeS6nu57h8tLPsyqgnag2Ko2rk44zzySeag1jRH1Se1nt9Vv9Mnti22SzMZ3K2MqyyI6noOcZHYjJqelguvz/r/I8gHiqW9mtIr74jB4rDVoluNSt5rLZGHsnY5YReWV80MoLD25IGOg8I+NLzWL7wzJP4h+2pe2yq8Nt5B8yQI5kaRdoYAEL80ZwpOGUZBr020tY7K1S3gzsQdWOSTnJJPqTzU1VdX/AK7C6W8rBRRRUgFFFFABXl91rMmhfDd7uDWRpDt4qu4TM3lYZX1WZXU+YpH3CzcYI25zgGvUK5vwH/yLt1/2GtV/9OFxR1Q07HmsvjCLw9qGprF42ijE2q3VtK8r2u4slkpEx+TG8SIq4AC5bG3OKVPiW0kDXf8Awn1sIvPs4iA1ptTzrfMnOz+FwSM9CCDkcV7bRQ9VbyS+7/Mm1n9/4/5HhNn43mivLHWbrxv5U19b6OWtpHtRHcK8jLPhTHuAX5ydhGCTnoAPRfAmtXOqXWqwXuqPqUsDxsWURmGPduO1Cqqw4AJSQblyMlt2a7Girck76f1oJJ9woooqCgooooAKKKKACiiigDm/Af8AyLt1/wBhrVf/AE4XFdJXN+A/+Rduv+w1qv8A6cLiukoAKKKKACiiigAooooAKKKKACub8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8oA6SiiigDm/FH/ACMXg3/sNSf+m+8ryq98B65NrU5HgiZ7carqN0jiWzCvFPAURQPOzy4BIIA6E816Z4402x1fVPCNjqtnb31pLrT+Zb3MSyRviwuyMqwIOCAfqK4XTLfwnaeKdetPFfhrwjHYWOoxadaG08NfPJJKgdNzAuB12/dAJ5yM4pWu7eX6r9bDvZX8/wBH+lzMsfAfiySx1Zk8OzaZqVxodhaC7kmtGe4khYeem4O/+sUKAWGDt+boBXRW/wAPLm1a1W00me43Wk0Bl1Z7V2tUaN8InlACM75NuxA0e1exC1Ygn+Ddwk7ReH9EIt7eW5kz4dK/JGQJMZh+ZlJG5Rlh3FOif4OzahFZR+H9D8+Z441DeHtq5kAMeWMW1QwI2kkAnIGSCKuTc7rv+t/+CJe78v0t/wAA56PwD4ghsfDEdj4VgsbjR49PLXMdxCJNyyn7SAA2FyPmJXl93JJAAiT4ba9Z6pC+k+H0sL43erF9Yga3XCTqwgYkOJCBuHGMrg8V0qy/B1omkHh3RtqQzzsD4cIISBtsvHk5yp6jr3xip4IPhHc2M93b+HdCljgeNGVNBBkYyIHQLH5W58qcjaDwD6Ghycrvvf8AH/hgtZpdv0/4c5qfwHrjNp0ieGH+xw6raz/2ej2qmFY4WWeX/WBf3jkHAOTjLAE4rU8A+Eda0ybw5cap4ea3u7GJ7Wea7lgl8iJQ+0xMjllJ3hdoypCnIUhSd2+0L4X6dptpfz+F9Bktr0A27W2iJOZQV3bgscbHAXknGAOtUmh+Eq29xM3hbShHbXTWkp/4RpspKF3bceTnpjB6EkAZJAou03/XS39eorJpL5fmz0mivMSvwqXWI7BvCGlR7rFr55pfDwjWKMNt+fdENpJDDDY5GOpApbg/B+1RGufDuixb4JLja3h0hlSNgsm5fJypUkZU4IHJGOan+v6+4Z6bRXCaDoPww8Si5/sbwvoM5tXVJlfREiK7l3KcPGCVIOQwyCOhrX/4Vx4I/wChN8P/APgrg/8AiaAD4cf8ks8Kf9gWz/8ARCV0led+AfAPg+8+G3hq6vPCehz3E2k2skssumws8jGFSWYlckknJJroP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgAvv+Sp6F/2BdS/9H2NdJXnd54B8Hr8SdGtV8J6GLeTSb+R4hpsOxmWazCsRtwSA7AHtuPqa6D/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkrm/Af/ACLt1/2GtV/9OFxR/wAK48Ef9Cb4f/8ABXB/8TXP+C/APg+60G5kuvCehzOuralGGk02FiFS+nVVyV6BVAA7AAdqAPRKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgA8B/wDIu3X/AGGtV/8AThcV0leX+H/C3gOw8JXV/rXhfRpFTWNRhVv7ISeQgX8yRoqqhZsAKoUA8AADipok+EM88cUfhzRS0iwspPh7ChZiRGSxiwAWBXJIw3ynB4o32A9KorzQr8IRMYv+Ea0cuJUhGPDhIZnLBCp8nDKxRgGGVJGAc8Vm2Z+HEviW6hm8MeHH0poLd7SSLw7+8SR5JI2jl+Q7SHjA+ZUwW2nnFNK47PXyPXaK8o1iD4ef8IyNQ8O+EtBeeQO8Iu/DRCssUipKGBRNhBOBuI56A9K0zYfCcXN5A3hvQhJZAmXOhLhsPsIjPlYlIchcJuO4gdeKQj0SivL4j8KptU+yp4P0oRC1Nw1w/h7aqkSGPyyDFkPuBG04OcAAk4qxFp/wsubiIxeH/D0UXkzyypceHxGyiIqHDFkHlsu4ZRhuIYHA7gdbHpFFebeE/DvgzxFfa2p8HeHTb2V2kduToK28mxokfDpIu7cCx5wuRjiul/4Vx4I/6E3w/wD+CuD/AOJoA6Sub8Uf8jF4M/7DUn/pvvKP+FceCP8AoTfD/wD4K4P/AImsjU/CfhzQfFvg+60PQNL024fVpY2ls7KOF2U2F2SpKgHGQDj2FAHd0UUUAc34o/5GLwZ/2GpP/TfeVzN18MNZutcvr5vEtgsV7q9vqjxDSX3K0G0Igb7R0IUZOOvIx0rpvFH/ACMXgz/sNSf+m+8rzvxr421C58QaZfaMlzDZ2t7f2TKmpyQC8MNu5fcgUquGX5WIY5HQUr2d+3/A/Ww7cyt/Wz/S5qj4P3624iTxJbAeXqUZJ0xjxeHLf8tv4T09akb4R37SySf8JHbbpG01j/xLGx/ofT/lt/EfyHr1qa1+JTaXoMc+oaa62kGkw3UctzfF7m6LImMDywHG59rOGyDyUAIJsD4l3r6xbaRDoUEuovdz2M8a35CRzRwCZdrmIblYEDJCkHsa0s4ysun6P/Mnm5ld9f11f5FG4+EV61xcmz8RQRQzR6hEqS6cZGVLxgz5YTLkqw4OBxxjvUTfBmW5jl/tLWbC8bzrOaJJdJ3QhreLysSRtKQ6spORkYPINVNa8dXF14y8Paki3VhplrqN7aXKx3rn7R5MDtIHhGEIDL8pJYnHbvsWHxVvNRj0loPDM0f9q3f2aFriSWBWDQtKjqZIV3j5SGxwD0LjBqVtp5fndDe+vn/wfyOl1nwmuoeHbfSdPlt9NS3UCForQAQHoGiCsvlsBu2kHjPIIyDRs/D8GqX2uX0cdzbC/CWs9vqFqDHK8RKtJsOAwdAg3Z5AGMVd0DxLf6rrl5p+o6THpj26Bgj3e+ZumTs2AFMnh1Zhxg7TxXR0fqF+nY86vvhR/advNFf648wudIOmzlrfJ/1plR0Jc4VScbW3ZUAZ6kx6j8JWu7eGKy1DS9MRdLurCWOy0cRRu04UNKqLKAv3FODnPPPTHpNFL/g/je/5sFo7/wBdP8kcl4Q8GXXhjVb68uNUhvVu7W0twkdoYinkR7N2TI2c8nGBj3rraKKbbbuxJJKyOL8FaLa6p8M/BstzLfI1vo1oUFrqE9upzCn3ljdQ/T+IH9a27Pwrp9jc288FxqzPb52CfWbuZTnP3leUh+v8QOO1VPhx/wAks8Kf9gWz/wDRCV0lLYYUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6Psal/wCEM0z7Ybn7VrfmF9+P7evdmc5+5523HtjHtUV9/wAlT0L/ALAupf8Ao+xrpKAKmmaZBpNmLW1kupIwxbdd3cty+T/tyszY9s4q3RRQAUUUUAFFFFABRRRQAUUUUAFFFFABXIeFdNg1bwfeWt091HG2t6oS1rdy2z8ahcfxxsrD6Zrr65vwH/yLt1/2GtV/9OFxQBM/g3TJC5a61ob3Dnbrt6MEZ6Ym4HPQcHjPQVvDgUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw2i6Tca14HurS1vRZv8A2/qLszRl1dV1KclGVWUkEccMPxHBzYfhbq9raTWtp4jsY4TDawQKdIb92lvO0yA4nAJJYg4CjGMAVPbatqOi+AZLrSGtVmbxPeW7C6haRSsuqzRnAV1II35zz0xjnipF4+8VfaL0zafZJYW0stj9uljVE+0o20ERid5WDnOI9gI+X5yDkC7r+rW/4BWqV/6/rS5U1fwbqnh64tL+LU5NQ1C8vbSOSeLR5p8GOWRxNKEdjgCQhslRwMFelaJ+GGrJJqUsPiS0D6g0MspfSmbEkdw1wSAJxwXdhjqFxyTkl+geNvEPiALbRHSbK8tFlkuzdwuqzolzJCdgEh8sgR7iSXALKO+aydJ8Y65pymXWJ9Mvp5hIkF19jaN4N1/5HzsZG3RjIbaNvCgZ71Sumkur0/r5Eyk03fyv9/8Awf61N4eFptd0vxAdNu5NOTVJ1MBvrB/3Q+UyssTFHXe4J+Y9RnkGmT/DO+udWk1ObxBGb4lmjn+wkspEyTR7syncqMhXbwCpwMHLHPvfHfiq0v7+zJ0cvp1reSyzfZJds7W4hfKjzflDLNtIJO1lJy33a9MtZvtFnDMRtMkavj0yM0krJSXy/r5A136/oclqvgnUtZuUu7vXIFuhBGrPFYFVEsUwljdVMhwoYcqSxIP3hVC++Gl5qN61zca7Cj3KTm8MNgR5kkixqGjzKQgXyY/lIfOGyeePQaKS02/q4HP+G9A1PSNR1S81XVbfUH1F4pWENkYNjrGIzjMjZBCg46g55PboKKKYBXN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033lIDpKKKKAOS8cSX0WqeEX0q3t7m7GtP5cVzcNDG3+gXecuqORxk/dOTxx1HEanpuma2t/qd7pnhNo7W5Z7yeDxxdQx28zL5bbtkAWNmHysON3fNegeKP8AkYvBn/Yak/8ATfeVw2vWIN9qni/wPcW99Os8thrdrazBxcREBQzbScSRZyM87cihK8rf10Heyv8A11NSx8M37aXbpaeFPD11Ym18mDf4pu54zEwAyu62IOVAG7rgAZxT4fCWrwXNhcx+E9H8/T53uIJW8WXzOZHAVndjbZkJUAfPu446VzOuePPFtvY+Mr3+1bLS49Jd4orYyI08JEi+S4jaHG2RSclnbORt2kGupu7jxDaeKdIhHia9u9O1+CeOB4LW222suBJGwPlnI2b+WJB2iqV3Zrr/AMOS0lo/66Mjn8H6nc6wupzeDtBN0tw1yMeJ7xUErLsZvLFts+ZeG4+bvmiLwhq0MOmRReEtGSPSZ/PslHiy+xA3IwP9G5UAkBTlQCQBgmucv/G/i5odbjsr6UX9va6hLLbRwwu2mmCQC3O3YT+9XJO/O7OV2gU638f6pfW+tvF4rQxWN5C6G3W2MzQPbowWPKFGzI2ADy33VYGiKfTyf42RUlZ6+aO0t7HxPa6rJqUPhfQRdSIULt4juWCqW3MFU2hC5PJwBnAz0FaH27xv/wBC94f/APB9P/8AIdZ/jDVL+11PSEtNZm0+C4dInitoomnkd2AUhZUYMAA5IXDDG7kAisiG/wDE8XhO8k1LxBPaX2nTvaTz3MVvEk22QuZkYxbVJhxgsCgycjI3VPT+v66/iL9f6/Q6f7d43/6F7w//AOD6f/5Do+3eN/8AoXvD/wD4Pp//AJDry7VPGXiCy1i+vrTWLsK9hpYAvVhgEMUpfzLhh5T7CpxlgrKN3IIAwviP4g+KNEm1CK48S2aXVnY6fMY7cQyRM8k5jkILRhipQq3QYJBGAea5Xe3nYP8AK56h9u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHVH4ca/c61Y6zb32qLqkul6rPZrdYjDyIuCpYRgLnkjgDOK7Kl/X3iPM/AmueJIPA3hXTrfTfDjSSaLbPbRT6/JHPNEsSDf5YtTjqM4JAJxk9a6j7d43/wChe8P/APg+n/8AkOvPRq9vpvgr4e51yLSLlPDLTRylot422kZ4EgI7eh4z9RWX4k+ILuaa/bX9LsbJYl3WySpJP5TIu24jiMWMb25kaUxqM5XKnMx10G9LHoV/r3ivS7N7vU9J8MWdtHgPNceI5Y0XJwMsbQAZJAqwL/xuRkeHvD5H/Yen/wDkOvLtZ8ZajqPgXU7HXdeW1aOyvVSTZETqDpLInlMdgGREEb5AhO4N90HOj/wsTUDq14bTxAs2lyo22YRwn7EqXEaPIiqpOFiffmRnyMPtVeDfLsglodymveK5NQlsI9J8MPeQoskluviOUyIp6MV+yZAODg1Y+3eN/wDoXvD/AP4Pp/8A5Drz3V/FsGlatPeweOLS7ntNKjkF0Ps6/a0N0dqtxtI2sAWQLk8jb0rZ8FeNNU1DX7ybxDrmixWLFo/sP2xfOtZTLtiG3yk2hwf4nfcSCpwcUoq/4/gxN2b+X4nU/bvG/wD0L3h//wAH0/8A8h0fbvG//QveH/8AwfT/APyHXSUUhnN/bvG//QveH/8AwfT/APyHR9u8b/8AQveH/wDwfT//ACHXSUUAed3l54x/4WTozNoWhi4Gk34SMa1MUZfOs9xLfZcgghcDBzk8jAB1LnxL4ls7r7Nead4Vt7jyjN5UviWRX8sHBfBtM7QSBnpVy+/5KnoX/YF1L/0fY15b4k8bSW2sW2qXXipbDULdb2M2ciQp9jZZoQIvnTJ3oMndkkZZSBQt7B0PUvt3jf8A6F7w/wD+D6f/AOQ6j/tbxkLkW50Pw555QuIv+Egm3FQcE4+x5xkgZrhrvx/pv2/UrpPiosdijGOCCGTT2eSTdnEYMRKoB8gZywJJOcAE51x8Q301Hg/4WhaX9z9mjlZw9iyRy+egMalYl3Dy2OT14JG3oBatLuEtF/XkenfbvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh15zdePvEE2rPpejeJ9JKW15NFHf39zFEty6su2BtkDqxwT8q+W7cYbg5vXfi/VI49TEviVo2hmR5XiNuEiQ+YRFGzxjY5AjykwBOflf5gaN4qXcOrXY7j7d43/wChe8P/APg+n/8AkOj7d43/AOhe8P8A/g+n/wDkOpLrWhd+Drq70jUYBdRQ7TK+P3MpUHEigNsbkZBBxnkGuAXxxqj2YW112ZZ4bfzdNFxHbt/bcomkVogyLtcBVTBi2nDbjgcB21sLePMd39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHXmkPxDumwkvj+BRJ/aalz9j3RfZ5MwkfJjLL1yCCvQA/NTLP4o6mLGK+tfE1vq1xNdXEMNhiDEn+hiZQNihyRLhBzznBycGhK/3XHL3Xbza+49GuNd8WWtxbwXWkeGYZrpykEcniKVWlYDJCg2nzHAJwOwqx9u8b/9C94f/wDB9P8A/Idef6h4ucXmmsuuwa7apqMUun3cjRIZpmt5w1uPLCqdreWOmQZADk1V03xvr891pI1XxvpltDqF2YnW0nglkg/cSM6Pvt0EZR1j2qdzDcQxbIotv5D7el/zPSvt3jf/AKF7w/8A+D6f/wCQ6Pt3jf8A6F7w/wD+D6f/AOQ64PRfiDqesaP9uh8QQtqUFkstrpUcUTjVj5JLMMDfuEgKnYcLtO4c8dL8PPEt5qNvKuva/pF/JcyD7ELW8WWTO3MkRxFENy4zt2llB+YnqSzu12E9DX+3eN/+he8P/wDg+n/+Q65bwvrviPTPD8hm07w3DFPreoRRvd6/JCXma+nzGo+ynJ3bgvOWABwCcD02vKtTu7e0+F0hubuK03+LZ1SSVgACNZkbvwcAE/QGkt0vNfmNK52P27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdcZpviTWr0iSz8UT6hBNdXejI8ENs/k3Ic+RO+2Lj5Ac5+X7pxzWY/jjxNZ6c503XRrl9BLd299bzRQp9iijuCiXL+XHlTt65UqcZC8HJ0v/AF/W33hbW3nb+vx+49G+3eN/+he8P/8Ag+n/APkOj7d43/6F7w//AOD6f/5Drz6w8Yaybx4b7xxaTNDpVzeoNLa3vBKI3UoSTDHvO0uG2bQdnG0hqpnx74rlRLC08QabD/pUyx6pqN1DGkp2RPDGzpbsjbhIx2qqFgPlfjJpRb/rzsTdf16XPTG1Dxsqlm8P+HwAMknXpuP/ACTqCx13xZqdlHeabpHhi8tZRmOe38RSyI4zjhhaYPNcNrXiK+uHmTUvFU1otvqNpLPJbG3W3tIzcBcEyRh4yBg4lBzjIJXisq3+IF1o2lQQeH9fs7tb1buURvLEFtFF9tMwZUZseW8jEsHUBN23AIKSuv67XFf3rHqj6j41jRnfw/4eVVGSx1+YAD1/486SLU/Gk8KSw6D4dkjkUMjpr8xDA8gg/Y+RXAR+MtctoVbWvGFmw+zzeTPpUsEsbARu4lcyQpvx+7HmRgpu4KDNX7T4gXM3ibw+w1+J7CeOAX8biFIgJLV5PMzjccuuN25UByuCQcFtbf11/wAiv8m/usdn9u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHXQW9xDd28dxayxzQyqHjkjYMrqeQQRwQfWpKQHN/bvG/wD0L3h//wAH0/8A8h0fbvG//QveH/8AwfT/APyHXSUUAeX+HbTXtY8Lz2t/4R8M6parrOoyeXf6pIwWX7dPuwptGHDFgG6kc4XOBsXGka1dXVxc3XgPwdNPdReTcSyam7NNH/cYmyyy8Dg8VZ8K3k9j4PvJ7XTbrUpBreqAW9q0Suf+Jhcc5kdF4/3q0X8Q6mpfb4O1p9rhRtmsvnBz8wzcdBjvg8jAPNCAxDo2ss8Dt4C8GlreUzQk6m+YpDjLr/oXDcDkc8VGnhzUY7u4uo/h34JW4ulZbiZdQYPMG+8Gb7Flge+etd6OnpRQBwMnhrUJY4o5fh14IdIYTBGragxCRk5KAfYuF5PHTmtW1k8YWVrFa2Xhfw3b28KBIoYtbmREUcAACzwAPQV1NFAHN/bvG/8A0L3h/wD8H0//AMh0fbvG/wD0L3h//wAH0/8A8h10lFAHN/bvG/8A0L3h/wD8H0//AMh0fbvG/wD0L3h//wAH0/8A8h10lFAHN/bvG/8A0L3h/wD8H0//AMh1kanc+I5vFvg9dc0rS7O3/taUrJZ6nJcOW+wXeAVaCMAYzzk9Bxzkd3XN+KP+Ri8Gf9hqT/033lAHSUUUUAc34o/5GLwZ/wBhqT/033lTa74tttA1rS9NubG9nfVDKsEluqModELlSCwbJAOMAjPpUPij/kYvBn/Yak/9N95Xl/i3wB4jvtRlkPhptYk/tK9me7EtsPPglgZIVxJIpxGWAwemMrnNJspJf18z26zuftljBc+TNB50ayeVOm2RMjO1h2I6EVNXjcXgPxA2ibbHSf7P1OfRUtZ7m5lhaRGRI08uORGLBW2HKnKDIYEEkU6DwHqc3iHR5brw2U0caldP9h3W6jT7SS2WLyyFkxhnyxWMsMe/FaNLmaX9amcW+VN/1oekat4ottH8RaNpFzaXTvrEjxQTxhDGjohch8sGHAOMKRW1XjF54D8Sp4otZrPTGaaDVbuUawJov9RJAyQdX3kRlgMY4xkZyaZpfw71a1tfCv2zR767kh1LztUjnms9kIMLRSOnl7Mo5KsertglhnrK1X3fj/kU9H9/4X/M9nmj86F497JvUruQ4ZcjqD2NQ6dZf2dp0Nqbme6aJQrT3DBpJT/eYgAEn2ArlfDHhg6D4x1Ca00lbeymhx9qlZHlYhgFRXB3sm1c4kGVJAUkZA7Ojp6h1sFFFFIAooooA4rwT4h0XR/hj4Ui1bV7Cxk/sKzl2XNykZ2eUg3YYjjJAz6mt+68V+HbC5kt77X9LtpokWSSKa8jRkViArEE5AJIAPfIrzLTrlm0v4ZWFj/Zk1/ceGWRLe/ufLBVreAEjCsScBuMcgMMjrUl/wDC/wASrYC006TS7hIbZrOJp7qSANG0MaF2RImG8GPqSxIP3lAxRHVXf9bhLTY9LtfE+gX12trY65ptzcNGZVhhu43coDgttBzgEEZ6cUz/AIS3w4bWC5Gv6YYLmUwwSi8jKyyDqinOCR3A6VxXiX4e674k1S4kaextIJg4BhncFBJa+U2VVF3sGA+Ytkrx8mMF1p8P9Vs4o57C2sbC/lkBuZjq11eFh8gLEzofMBWNR5ZUYwMOMU7C6Gvp/wATdD1HW0ggvtPGmyRSbL5r5RmZJRGYipGATuUr82SD0HGdy+1vw+32y2v9XsE+wqst5G92qmBeoMg3fKp/2uDXAXfgLxbLa31pDBohjexvbO3me/lDH7RceYHZfIO3A4wCee9Sad8M9QtZJ57q1s7i8WWSa3um1q8JBklErII8bIiGA/eKDnaCU5Io05V/XXT+v1BXu7/1ov6/4B248XaHtubh9a0lbG2iieS4+3p+735xvB4QEYKkn5sngY52IZormCOa3kSWKRQ6SIwZWU8ggjqK80TwX4wN88k76PIrw2sTSrcMkpEZlLEYgARv333lwTtP3d/y9r4R0m40HwdpWk3rRNPY2qW7NExZW2jGQSAeQM/49adlqM2aKKKkDm77/kqeh/8AYF1L/wBH2NQaT8QNHuNNnm17UNL0a5tp5op4JdQQhAkzRB8sFO1ivBIHXFT33/JU9D/7Aupf+j7GuRHhTUNP2z+K/wCw7XSN2pC9m/tBwQt3KHXG6JQSCAvJHOCPSgpWt8/8zup/F/hq2u5bW58Q6VDcQhTLDJexq8YbG3ILZGdy4z1yPWrR1zSRqUmnnU7MXsUXnSWxuE8xI/75XOQvv0ry2WC9l8R6Hpkkul3eu6loV39qF9KYmxIYVD7ArMWCJ93jOxuRg1qP8OtZXT/7Lin02W3tZprq0vLjLyyPJC0flyRlCuz5+u45AA207af13a/4PnsT1/rtf+vvO2XxV4efT4b5Ne0xrO4l8mG4F5GY5JOmxWzgt7DmqmreO/DOjeat5renrNFPHbyRG6QGKRzgB+fl9TnoBmuFf4V6tcXr3Gora3sM8s3n2Z1q7hDJMkQcmSNAWw0RGwrtYEfcwBWtN4J8QRF/7P8A7NEMFzBcW1s91JskZJ/Nb5jGzxZGeAZATzhaLK6v8/L+v62YruzaWv8AVjb8N+L9IvdHuL69utP026QyS38DX4k8gK7R72ZtpCHZwSFFaV34t8P2cMMk+u6XF9phM9uZb1EWWMDO8HPK/wC0MivNrz4a+LL/APsnzU0mEWDXEsi2+q3MZmeS5EwXekSsoG0DcDkHnBxg683gLWbPToYfDltptkTCyzRy6lcTKSTI20tJG5f5pCRJhGHPBB20pfDdf1/X9dAje9n/AF/X9dTubXXtMuLyGw/tKwOpSQLP9kiuldyhGdyjhivo2BmqWu+KIPD2r6dDqRtLbT7wS+Ze3F0IhCyLuAIIwQeedwxxwa5Gx8IeKNN1LTtVni0qRtNUMIIbuVVk/wBE8k5CwZZtyrhyGbacADbhun1vTNT1RtG1OytrP7XZ72ks7yVlT95HtYb1Vjlc/wB3npx1pysvhFG9tf67l+TxX4diRnl17TEVZTCxa8jAEgXcU6/e2/NjrjmoYvG/hSdykHifRpGGzKpqERI3EBejd8jHrkVxkPw98QaLZrZ6M2l3cMVxZ3SNczSQM7QxCNkwsbhQdoIPPpjvVeXwD4rfw1a6attofmQ+HX0gyG+lx5jMvzj9x93amfXJx2yWkr6/1p/noU/Ly/P9Fqd3/wAJhoERm+2a7o8Ajdwv/EwjPyoQrFs42kMcEc4455xT73xB4bh1m0sb/WtOi1EsGt7WW9RZHLcKRGWy2c8cH2rh18IeM5NQmuLjT/D4DteyKBqczFWniVAObYcApye4PTjnO8NwT2fjq3tbx9MkuLKaLzNOttUPmrKLdIGuBA1uHcbSRu8xU287cjJUVdpPsv8Agi1s36/8D7z2KuI0LxDpfhjwTdahrd3HaW39valF5kjBRubUp1HJ475J7AE9q7evP7LSbzWvh5d22meQbqPxHe3Ea3EhRHMWrSybSwViM7cZwcZ6UuqKW+prP4j8K317Fqn/AAmOnyW1sFCQpf25gWRtyq+R824/MoBbbwcDIzUfh2/8MeGdNn09PF9reiOe4uJXu7233xnfulzsCgBWYk5HGcHtXNSfDnW76wtm1SCxklivL6SWxt9ZureKaK5k3kmaONW3Lyu0qVYZ6Z4W28C+J7PU7WeCw0ExWurNfoDqM25k+y/Z0UkwMc/xZJOOmT1p9/6/r+kKW+n9b/n+vU7+TxLoUM0cUutafHJLAbmNGukBeIDJkAzyoHO7pip9N1jTNagafR9RtNQiRgrSWs6yqpIBAJUnnBB+hFeaaD8PPFGnaImnXw0hwLmC9E0d3KXjlhVVWNcxD5G8sZbgqHYbW613ngzSr3Q/BelaVqi263VlbLBJ9mkZ422jGQWVTzjPTjPfrTsrP+v67fiD/r+v67G3RRRUgFIyh0KnOCMHBIP5ilooAZBDHbwJDCu2ONQqr6AU+iigAooooA5vwH/yLt1/2GtV/wDThcV0lc34D/5F26/7DWq/+nC4rpKACiiigAooooAKKKKACiiigArm/FH/ACMXgz/sNSf+m+8rpK5vxR/yMXgz/sNSf+m+8oA6SiiigDm/FH/IxeDP+w1J/wCm+8rpK5vxR/yMXgz/ALDUn/pvvK6SgAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/AGBbP/0QldJXN/Dj/klnhT/sC2f/AKISukoAKKKKACiiigAooooAKKKKAObvv+Sp6F/2BdS/9H2NZOpfFnQ9It5p7+2uoYlnaCBnlt0FyV3b9paUBSu05VyrdMKSQDrX3/JU9C/7Aupf+j7Gqdx8N7CbXjrseq6nb6uoCQ30TQ+ZDHzmMboyHU5OfMDHpgjAwdR9CGy+Kej3372Kw1IWhl8pbsxxmNiYBOhAVyxDRnI+XgjB2nGZZfiRZ22nWd7eaPqcEF3MsQc+QyIGZVVt4lKsCXHCFm68cGmS/DaGW7kuP+El1xJJL4XxKvb5Egi8rgmHONnHXPfOeabJ8LtLlkklbUtSEsrO8simAb2ZkIOPKwpBjT7oG7HzbsmnpcUttCvp3xIW4upW1nTNR0uKFr3Y58iSGdYJRGR8rtJvBI4wAST14NXX+I0Ed4llJ4f1lb8s6NaFYN6MsfmAE+bt+ZASCCRwQSDxUU3wv0+4vHkn1jVpLZ/tX+hboREPtDbpMERB/vYYHdwQMccVM/w8iku4Lx/EOsNexFy10fs5eUtGYxuHk7flUnGABkknJOaXTQbtfTa/4G9FqMer+GF1HTZpIo7u08+CUKN6BkyrYYEZGRwQRXAQ/GXS9N0DTbfUJG1DW5NNimlSOWBC07QiQKULqw3eqqVGcEjgV12heF7rRdDm0X+2765s1gW3s5JhAZrdAm3grEqnHGNwbpkk5xVHTfhvZaVYmytdZ1YWststvcwl4cXIVPLVnIjBDBAq/KVBCjcDzlyt73L8vx/4AR2V/wCtihoHje8/tO4XW7XUDFdS2whUxwEWbSwhth2NlgzA4xvIyMkVah+J1ncTpb2+g6xLctdmz8hfswdZPJMyhszYXcgPBIIIwwWmf8KwiMbJL4p16TdNDMWP2UHMSbEHywDAxj34Bz1y+y+GNnp+oafd2uuasDYSxyrD/owSVkjMYLAQ5+4xU7SOuevNPS+pKulr2/H/ACI7r4p2ts8pXw5rc9vHG8xuYxahPLSTy3fDThgA3ByAe+Mc11un6kNRkuwtrPCttMYRJIU2zYAJZNrHjnHODkHiuB0Hw/qumS6lcT6JqMzX29L62l/s4pdFyQGSVAsrquTzM27bwFJ6dfomh3ejWmk2kV9I1tZ2hinjdg/nycfOSV3ZzuOd3c5B6hLbX+v6/UHublFFFIYVzfgP/kXbr/sNar/6cLiukrm/Af8AyLt1/wBhrVf/AE4XFAHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/kXbr/sNar/6cLiukrm/Af8AyLt1/wBhrVf/AE4XFdJQAUUUUAFFFFABRRRQAUUUUAFc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033lAHSUUUUAc34o/5GLwZ/wBhqT/033ldJXJeOEvpdU8IppVxb212dafy5bm3aaNf9Au85RXQnjI+8MHnnocBPGurSapdafH4lsXuLOcQXO3wVqRSFz0DuJ9qg5ByTjBznHNHWweZ6ZRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUAdJRXn2meJta1iZIbDxdoTyvdS2Yjk8MXcbCaNdzoQ10MYHc8elbv2Hxv/wBDD4f/APBDP/8AJlAHSUVzf2Hxv/0MPh//AMEM/wD8mVmaNqfiXX2vl0vxRocj2FwbW5WTw1dRGOQAErh7oE8EHI4OetAHb0Vzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUAdJRXN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZQAfDj/klnhT/sC2f/AKISukrzvwDZ+MW+G3hprPXdDitzpNqYo5dFmd1XyVwGYXShiB1IAz6DpXQfYfG//Qw+H/8AwQz/APyZQB0lFc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlAHSUVzf2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUAdJRXN/YfG/wD0MPh//wAEM/8A8mUfYfG//Qw+H/8AwQz/APyZQB0lFc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlABff8lT0L/sC6l/6Psa52fxl4htbq5uLmfS4bKzuIpLqFrKQtHZtK0ZlWUTbGA27i3YbsoMYLryz8Yj4k6Mra7oZuDpN+UkGizBFXzrPcCv2rJJJXByMYPByCCx0TVtc0rUv7K1fw1DFeySW168XhaaB5GQmNw4a6BOMFckdOlC3H01IX8beJrK+nN7/ZU1rDcWWI4bSRJXhuZGRVyZSA6gK2cYPIwOtWrfxdr89jpEpuNFX/AISF0FhKIpGFrmN3ZZV8weYRsCgqyZZjwMcvuvAWpX11Jc3v/CFXM8rK8ks3hRnZ2UYUkm6ySBwD2pI/BuqT29/bK3g/yLmbddxP4RkVLiQc7mBusSdfvc896elrf1b+uv8AmIyYPiJ4lkTUbmSLShFpyQSPbrBJ5lwGnlgdY28zHzGLch2nhgpB+9W94E8W694one51PR1stMuYPOspd0QbhsFCFmdmxkHcVjwcgrVVfAGuDxENafUvDEl1HBFDbiTw25W2Ee/Bi/0rKH5yDg9AKs22h69pd/cTafqXhW3u7yUC5ktfDE2+RyCQZCl1np3b1680aX/r+v68xP8AyO3orm/sPjf/AKGHw/8A+CGf/wCTKjmt/GtvEZJPEGhFQQMR+HbhzycdFuye/wCHWkM6iiub+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkygDpKK5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TKAOkorjdTuvFejpbvqHiXQ41ubhLaNl8N3LjzHOFBK3R2gnAycDJHPNXvsPjf/AKGHw/8A+CGf/wCTKAOkrm/Af/Iu3X/Ya1X/ANOFxR9h8b/9DD4f/wDBDP8A/Jlc/wCC7Pxi2g3Jtdd0ONP7W1IFZNFmclvt0+45F0OC2SBjgEDJxkgHolFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFc39h8b/8AQw+H/wDwQz//ACZR9h8b/wDQw+H/APwQz/8AyZQB0lFcoyeMUnaKTxHoMZUISz+HrhUO4kKAxu9pORjAOeR6jM/2Hxv/ANDD4f8A/BDP/wDJlAHSUVzf2Hxv/wBDD4f/APBDP/8AJlH2Hxv/ANDD4f8A/BDP/wDJlAHSUVzMlp42iiaRvEOg7VBY7fD87Hj0Au8n6Cq+mSeLdY0u31HTvE2gS2tzGJInPh64Qsp6Ha12CPoRmgDrqK5v7D43/wChh8P/APghn/8Akyj7D43/AOhh8P8A/ghn/wDkygA8B/8AIu3X/Ya1X/04XFdJXnfguz8YtoNybXXdDjT+1tSBWTRZnJb7dPuORdDgtkgY4BAycZPQfYfG/wD0MPh//wAEM/8A8mUAdJRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUAdJRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUAdJRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUAdJRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUAdJXN+KP+Ri8Gf9hqT/033lH2Hxv/ANDD4f8A/BDP/wDJlZGp23iOHxb4PbXNV0u8t/7WlCx2emSW7hvsF3glmnkBGM8YHUc8YIB3dFFFAHN+KP8AkYvBn/Yak/8ATfeVxGhXk2mfEzxbf3MXiWO2ur5Ps9rDos5gu8QrGX8wQ5XDAgEuFxz6Gu38Uf8AIxeDP+w1J/6b7yuk60LR3+X9fcD2seU6jo/irSvDfiGHSZ9UubrT7kmwnkvp7h57eUxu42eZlmRdyryD3UgnNal/b+IrP4Uwx2l/f6jcieJppo7aaC6NoZQXVUZ2l3iMlckmQ4/vc12+l6XaaNp6WWnRGK3jJ2q0jORk+rEnHoOwwBwKt09vw/D+vzH1+/8AE8B0WDWrPxRLa2cHiqwgudX1NnmjsrvYYpYgIJGLLsZtwyCxyCOSK2L4eL4tOgj0+LXFEdrOmnsJbuQyXvmjY8u/LiIpuIWYlRyCT8pr2aihO1vLT+v63Javfzd/xv8A15HkPkeKZNI8XXNpN4gW9tdUYW0Tm4CyWreV5nkhx82Nsmzb0P3eozz9rp/ipfEWo22jHWtI0q91mST7bLp93LLzBEIHYbkdlyrglyyg43givfqKIuzv5W/L/K/qPp9/6/5nlC6drWpX3itbjU/E1l9m1GN7Ro1uRFLEYlEiqOpjLh+Im3L1U88+heGGnbwvp5u4Li3m8hd0V1K0si/7zt8xPu3zevOa1aKL6W9PwVg6hRRRSA4vwVNrEXwz8GjSLCxuom0a089rq9eBkHkpjaFifd36la27O68Tvc266hpGkwQNnz3g1WWVo+uNqm3UN26lce9VPhx/ySzwp/2BbP8A9EJXSUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7GvOHudcbUD/ZVl4itTb6zJc5+y3cUUsTXuX+QKofMTZ+fcMfdXIJHo99/yVPQv+wLqX/o+xrpKFpJSHf3eX+v61PIpxeyadZPdN4yTVn1C3TU44Re+Qp8zEjR7Bjyyhb7h2ABc4bBqnNNdx6lcWKf8Jutvby36I6x6m4ZNimH95glvnDbSCT2zg4PtNFLpb1/T8raeovtX/rr/AJ/geJfbtfu4jYiPxdvvLSzkkmeC+iWO6MUvm/MFDKu7ycojIueSQA+U0BNTsNfs7ye28ULqN5qFtJOWhvzbvG1iquZVx5QxNwdwyMdlFe3UVfNq33/rQS0VvK3/AAfU8Wum8RGysZgfFUc++2GrIq3ZxdCePeYgoIMXlednZ+7xs/ixW29/qEfw7udkfiRp7PXNkH+j3huWgFyCO3mSJ5WeTuBHB54r06ii+n9eX+Vl2RV/6/r8fM8WvL/Xbe4D6RH4tlaXUruOVJbe9IFpuVht3rtVsFtjcHsDxirt9b6g+oSR+FJfFzsukXEtkdQa9WP7QHBiVjJtBIHmACQ5PAORtr1yipWiX9dLf8H1E9b+t/xv/wAA8QuovFMOgKLPUPEt9I3m3Ns4sb628h1CHymR3eVycOR5j+XyQA/ygX9a/wCEnN5fLpja0ttNcq97ePBeM0cJZ8JHArqxIynNu4O3O5Q2QfYKKb1A8ZuodbWOzi1tvEOqy2l5p8tpcQ2FwsUtusyGR5YlLfvAQSQ+XwARj5q9moop30t53/L/ACFbUK8zm/tc/DO7GhSTRufEOoi5e3hkllWD+0bjeVSN0kJ6fcYNjOOa9MrgtK12Tw74Jkvlto7iNvEt9by+ZP5XlrLqk0e8HackFgcHHGeRUWu0vQpX6GNZ6JrtstjbnWNZ1Ea1bNA9xNNc2ht2ifzEcRPKXj3RgoTncSFLfebNzwFZ68+laq3iTVdUllntQtxbTWlza/ZpwDvMczytuznrDtQbQQFJrp4dc8ISarLqUPiDTpbn7IZSf7UDrHbqfmkVC5VFyOWAGcDJ4qwviHw1rllcW9tr2n3MT2zSSm11BQywnKl9yNlRkEbgRgjrTldxa/rr/Xy8gWjXy/T+v+HPKLCfVL7R9AuobjxfNbzx6eL6QG9JeUkeYy7edhi3bmX5CSpzu5qfxCut2Gjz2VsvjB5rWXUoYpLd76YsGBa1+dSS/O3DknHIJGSD6Lo2ueDdG0qx0rSfEGmLapCotI21NZS0eSF2szlmGQQOT0wOlaC+KvDz6fDfpr2mNZ3Evkw3AvIzHJJ02K2cFvYc1cnq7d3+P+XQmOjTfl+F/wA+p5hqunPdalcWqReLZtPWTS7vMj6iSG81jMUYncCFdCVXG3HQFThy/wBtg2dpI3iqLy7G5trqUx3kqsyXSMmSpDEmLePMQ7iDhSxG2vSz4v8ADQWQnxDpQESs8hN7H8iq21ifm4AbgnseKJPFWi24u5rzWdJgtLUxrJO1+g2M4yA+cBMggjk5B/Ob/wBfKwra/cvu1MzR9SvZ/BclpZW91b61b2BaOG9WRiHIby/3kirv5A68jowBrk4m1lYmkhXxOdCka3/tGOb7V9sSTEgm8n/lrtz5WfK+XGdnevU4lgbNxAIz5ygmRAPnGODkdRzxUlD3bKW1v6/rseRq2oaNcOqHxhdWsOrWt3DLMt3cO1q0YWQMACWG7dmIjIyCVHWsywm1iOx8PkWnie0t7K2hju4o7a9TdGVlSQLFGo+YNsOSGfoVCj5j7fRS6W/raw7/AJf1+Zy/w5hnj8B6ZLfNqZvpoEa7GqPOZRKFCt8sxyoyvQAA9ec5PUUUVUnzO4jkPCsmoxeD7xtHtbW6uv7b1TEV1ctAhH9oXGfnWNz/AOO1oveeLgX8vQ9FYBwE3azKMrzkn/RTg9OOc88jHMPgP/kXbr/sNar/AOnC4rpKkAHTnrRRRQAUUUUAFFFFABRRRQAVzfij/kYvBn/Yak/9N95XSVzfij/kYvBn/Yak/wDTfeUAdJRRRQByXjjUrHSNU8I32q3lvY2kWtP5lxcyrHGmbC7AyzEAZJA+pqz/AMLH8Ef9Dl4f/wDBpB/8VR4o/wCRi8Gf9hqT/wBN95XJaLqutap8SPEWiT+KtZiWwvkW0jj063aDyzEshSSTyPcgDeGx68mhauwPRXOt/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qszUPippWmPq0d5pmqxyaXbi6eNoog00PmeWXQGQEAHs20kYIBBFb83iEQ6HPqTaVqR8qQoLYQr5snzYDD5tu05zuLAAckjBwdLh1sU/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqw5fjFocdjBdjTtVkhms7i7LJHEfLED7JVb9595T6ZB7E1V8VePpm17Rbbw1c3UcS61a2V/KIojDKJU3mL5suGClTlQAN2Mk8BpNtLv8A52/MHom+1/wVzpv+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq6SikBzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FV0lFAHN/8ACx/BH/Q5eH//AAaQf/FUf8LH8Ef9Dl4f/wDBpB/8VXSUUAed+AfH3g+z+G3hq1vPFmhwXEOk2scsUupQq8bCFQVYFsggjBBroP8AhY/gj/ocvD//AINIP/iqPhx/ySzwp/2BbP8A9EJXSUAc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VXSUUAc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VXSUUAc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VXSUUAc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VXSUUAed3nj7we3xJ0a6XxZoZt49Jv43lGpQ7FZprMqpO7AJCMQO+0+hroP+Fj+CP8AocvD/wD4NIP/AIqi+/5Knof/AGBdS/8AR9jXPQfFHa13canoesW6WYuyI4fszxzRw3CxM/8ArN+5cjI+UHLY3YFNK7sD0Vzof+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiqoy/Ei1iupbb+wtYa4hMyyRKsGVMSI5GfNxykisOenBw3FU7z4kGC8i/szR9U1FZ75Ldo826bUNqZw0eZFzlcH5yCPm6cAoaV9vP8Da/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qqDfEvT/IheLS9Rdri0trq3Q+SnnLPu2qGaQKpGwg7iOcAbiRnpbrUza6DJqYsbuby4PP+yRqomPGduGYDd7E0P3U2+gt2kZP/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVZWtfFnQ9Ajt31S2uoBc20dzDvltkDqy7iAWlALKMZA5ORt3ZqKb4nPOIG0Twxqt9FJqC2ZmD2yq2VDgpumBO5CCM4AzzgjFHW39dhXVr/13Nr/hY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqsyX4j2lhoNtenTNZv2lhkuZIgtuJYY1k2Ev8AvFQ4YhcKWOMH3rV0nxnaatqcNmLG+tRcrIbW4nWPy7gxnEiqVdjlTn7wAOCVLDmgLob/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFV0lFAzm/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukooA5v8A4WP4I/6HLw//AODSD/4qvPv+En8P6j4Dk0+z8UeGEuP+Ejurtkv9XjhBiXU5ZgRgMTuULjjBDZz6+y1xnhzVV0bwTfXrWtxdhNa1QeVbhdxzqM46sVVR6liAO5ovbXsNHFW+s6BHNbNe+LvCsM82q3fnfZNXSZHspy0jo5OzachR3GfrisQT6D4l0Vre48W+GNKjtNQvp7ZxrAjmuS90zBZMbSiEAfMrMSCpGMc+lxfFPTrjS5b+00fVbiOOO0lVYxBmRbhiiFSZQOHUqckeoyOadb/Ea0uJLW5udM1nTrWa0muImnW3ZLgIVBXCSM+4FgAMAEnqeKe3u9g1bv8AP+vv+44WzutCtLq4a08SeCbWK4026gYTeJjfsLiYqSzGZTvUlBnJH3j8pxznvZeHri9e41Hxh4VvYZ5ZvPsz4ukhDJMkQcmWPBbDREbCu1gR9zAFeoTfESK1+1Lf+HNctJbaymvWimjgBdIiocKRKQxw6nIOCMjOQRWePH/9hW2vX2srf6hZ2uokRNHHCv2aD7PFLhiSinBkOBkueg3Ypxv07fhf/Mm35/jb+vvOKg1Kytr62nTxF4AYW99eXQ/4qUAuJYiiA5iJyM8nJ6d6r6dcW8enx2d74v8AAsaLDa25e38QqzlIoHhZlYxgoTvB+XkjK7hnNev6T4qj1e41FE0u/t4tOkeOWeYRbGZQrYUK7McqwYcexweKyU+JVu1slwdB1VYJoZZ4Zd9qUlWNA52t52MlTkc9iDgggS/hs9rL7ugRte8e7+/qM8N+OPCGleF9M0+98ZeGvtFpaxwSGHV4WQlVC5BJBxx6CtP/AIWP4I/6HLw//wCDSD/4qsjUvi74e0rT4by9juIoriNJIC8tunnK0ayMVLSgEqrrkdSThQ1Z8Hi3U5NdSa21K4vtPbWJoo4I4oAZoDp4uEQEqvIboSw64Ymqd5Sk301YRSUUl8jp/wDhY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqs3TPiPYzR2kT2GsOkiWebyeOAAi5H7p2CP3b5SFXg9tvNaOg+NoPEGsNY2ukalBH9n+0x3c4hEUkZYqCAJC4yVPDKCMc4pOLTsF01cX/hY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqukopDPO/Bfj7wfa6Dcx3XizQ4XbVtSkCyalCpKvfTsrYLdCrAg9wQe9dB/wALH8Ef9Dl4f/8ABpB/8VR4D/5F26/7DWq/+nC4rpKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqsjU/FnhzXvFvg+10PX9L1K4TVpZGis72OZ1UWF2CxCknGSBn3Fd3XN+KP+Ri8Gf8AYak/9N95QB0lFFFAHN+KP+Ri8Gf9hqT/ANN95VOD4fG11jVNQtPFOuQNq04nu4o/su1yAFCg+RuUBQBwwPfOeaueKP8AkYvBn/Yak/8ATfeV5fbeLLnwXbeM5NFbTI5116/uRa3MbM0qxxRuwRVZQPdieMj5WJxQt36fqv8Ah/kO118/0Z2k/wAHdEntruI6prCm7tZLSWXzo2cxvP55GWjPO4kZ64PrzXU6x4dh1vQotLu7y8RI3hk86F1SRzGwYbvl2kEryMY+leW+GvEeoab4h1aXR4LQQa14kSB4GgZnjeWzjcSZDqNqkEsMZOTyK2ZvHfim38LpqMp0n7Xa6lHpuoWxspVAla5EZ2N5xwNjKwznOQe+BVnovT73Z/m195La1l6/5fp+Bdn+DOjS232ZNY1iGDyLq38tHgPyXL75RloieuMHPAA983JPhZpcl1BONU1SMw3dvfMqNDtluIU2CRh5fVlADAYBxwAa5fWPFfiLw94u1pzDor38Y0yFpVgnxJDNPJGFOZcAjO7IHcg7uDTm8Ya74ju9H06dtPit7qfVbe+j+ys6XCW+5MYL8Bgeh3YIB5HFTdxjzL+ra/r95TV3Z9f1X/APXaK8u+DPiC7m0fT/AA9PHB9ntdCs7uGRFIb5y6lWySD9zORjrjHevUaqUeV2JTugoooqRhRRRQBxfgrQNH1j4Z+DZtX0mxv5bbRrQwSXVskrREwpnaWB29B09K27Pwd4Y065t7jT/Dmk2s9tnyJYLGJGiznO0hcrnJ6etVPhx/ySzwp/2BbP/wBEJXSUbAFFFFABRRRQAUUUUAFFFFAHN33/ACVPQv8AsC6l/wCj7Gse/wDhRZ31xcuviPXLaK4Fwpt4TbbEWeQSSqC0BbBcA8kkdAcVsX3/ACVPQv8AsC6l/wCj7GukoWjug6WOJf4ZxPqt1fnxPrnm3RmZ1H2XaDLGsbEfuM/dRMc/w+5yun/DK0sJEdte1i5eO4iuEaY2/wApjhMIX5YQMGM7T34BBB5rtaKA/r7zi4PhpZ20YSDXdYVVslsQrNA6+SpbYpVoiDtDkcgg8FskZroND0mXR7Z7P7VJNZRhI7SKUqxijVAuMhQT0z8249eecDUop3YHKxeALG0gtBp2pajZXNnJI0F3E8bSLG+Mw4dGUoAqAArkBBznmmr4BiS2uY017VxLNqC6glwTA0kMoXb8uYiCNoA+YMeOuea6yil/X9fcD13/AK/q55jqXgO8tLrSbO0/tjUrayV3tr3/AIl0jQzNIWLSLPF8oGRholLYJB6Cur0Twbb6PeR3TXt1cGLzGgtpGUw2ryHMhjwobBJP3mbAOBgV0dFNaKwmk3cKKKKQwooooAK4nQNEh1/wXcWlxPNbhPEGozLJDsLBk1Kdhw6spHHQg/ng121ecweILzw78P5rjTLX7Vd3HiPULWFSFKqz6jcAMQzoD9C65OBkZpMDQf4X6cbUwQaxq9ujRRRExyRZPlTGWI8xnJVmIHYg/MGPNL/wrGxez0+0uda1e4gsbea2RHeFfMWUgksViB3AhSCpGNo685wp/H3i2GSyguLTTbK7Y+ReQPCZ/JkKylXZkm2qD5anywzthjllxk7U3iTxDB4C0fWmm0o3WoXFmJENrIsaRzsilR+9J3Avnd0OMbe9Wk3t3t82Lms7fP7i5feAIdTt0XUde1i4mFtPaSXJkhV5oZQAyMFjCjG1SCoU5HJOTnPPwn0+aK4S917WbsXJcymU243B4ViYYWEAfKicjBG3ry2c24+IWv2l5DauNLnkt9RSzvfJt5MSq9wsQkXMmIh8x4JkJZWGABmqq+OPEFjptzLbJoaR21rfXkiR2UiCR4Lso+MS8eYDnPOGyfmziiKckmuv/D/8Ebbj8n+Ox3fh/wALroFtfxDVtQvmv5TNJLdGIMjFAuV8uNAOFXselU0+H+ljBmuLueX+0BftKzIrO4Ty9p2oAVKfKeMkdSTzXUI25Fb1GaWlrcStbT+rnKQfD7T7G1s49Kv7/T57KSVobqBozIqSEFoiHRlKYVAAVyAi85GapT/DFJdSkvU8V6/DI9012FQ2rBZDF5OQWgJP7v5eSfXrzXcUUirs4GD4VQWlkIIfEuuOI/svlhza8C2JMK5EHQE89ScVW8IeFtc02ZpIjf6U0kqvffak09hcsGBJV4YzI4I3DdKwfp0OTXo9FPmd7smytYKKKKQzkPCuladrXg+8s9YsLW/tW1vVGMF1CsqEjULjB2sCK0X8C+EZC5k8LaK5kcO+7TojuYZwT8vJGTz7mofAf/Iu3X/Ya1X/ANOFxXSUbAAGBgcCiiigAooooAKKKKACiiigArm/FH/IxeDP+w1J/wCm+8rpK5vxR/yMXgz/ALDUn/pvvKAOkooooA5vxR/yMXgz/sNSf+m+8qrqsPgTQdVgtNT0fTre61QzSIRpW4TtsLS7nVCu4qDnccketWvFH/IxeDP+w1J/6b7yvKPGlr4huNaS4vbPxFNeWuqXxWWwhu3jiha3dbYxGIELyQCV5znd2qWykv6+89kstN0a6tbfVNGs7OGSS1xaXkdoqvHG4BGMgEDodvHvQvh20vdFjsfEtvZay+4STtPZp5csoGN/lncAfTk49a8yiHi5tE+06b/b02pz6Kg/0v7RF9mkVIw42P8AI7sQ5BwJA2c5UjDoI/EFz4h0eBpPE0OizaldRQuDeLItobZQpnLfMp87O1pfmHUcVq17zS/rX+vufYyjL3U3/Wn9f0ztNc0zwGPFFhb6/oGlzatqrFbaWfSRKZmRc4MuwgEKOAzDgcVrJ4P8NR24gj8O6SsIkaURrYxhd7LtZsbcZK8E9xxXlGp2Xig+MNNlkttXutSstXvBHNJDNJapCbd1tmBx5YBJAYjHOd3apdLg8Vi18KvqeoeIZTd6li/iitLyE2qmFlkWQl3yvmbCG4QZymB0lK608vx/rUt6P7/wv+fQ9V03wvoGjXX2nR9D02wn8vyvNtbSOJtmc7cqAcZ5xWrXGeGLS+0/xjqEE82sXsBhyt1fSS7EwwVU2sfLZjgsGjAOPvjJBPZ0dELrYKKKKQwooooA5v4cf8ks8Kf9gWz/APRCV0lc38OP+SWeFP8AsC2f/ohK6SgAooooAKKKKACiiigAooooA5u+/wCSp6F/2BdS/wDR9jXSVzd9/wAlT0L/ALAupf8Ao+xrpKACiiigAooooAKKKKACiiigAooooAKKKKACuU8H2VrqPhC/tNQtobq2m1jVVkhnjDo4/tC44Kngiurrm/Af/Iu3X/Ya1X/04XFAFubwd4YuIBDceHNJliWJYRG9jEyiNTlUwV+6DyB0Bqn4j8Hx6t4ZttD0j+z9MsoLmGUwNYCWEpG4fyxGrIACQM9RjPHOa6WigDJbwr4eeGGF9C0xo7eIwwobOMrHGSCUUY4XIBwOOKqJ8PvBkSusfhHQkEi7XC6ZCNwyDg/LyMgH8K6GigBkMMVtbxwW8SRQxqESONQqooGAAB0A9KfRRQAUUUUAFFFFABRRRQBzfgP/AJF26/7DWq/+nC4rpK5vwH/yLt1/2GtV/wDThcV0lABRRRQAUUUUAFFFFABRRRQAVzfij/kYvBn/AGGpP/TfeV0lc34o/wCRi8Gf9hqT/wBN95QB0lFFFAHJeOLCHU9U8I2ly9wkUmtPua2uZLeQYsLs8SRsrDp2IyOOhrBt9OstV1i+ttAt9dvbPTJzb3l1J4t1CImUKCUiXzCHIyAdzIAe5rp/FH/IxeDP+w1J/wCm+8qjpXhvW/DGsaqugjTp9M1a9e9Y3UrpJaSOBvwqoRKCRnBZMZxk0Lf+t9P+CHT+tv6sVl0zwYvnpc+ItRt7i0hE13BL4uvA9quBzIDcZUDPU4ql4ig8KaN4ZvNVs9Zvr2SBGMUDeMr6MTuqb/LDCZvmKcgAHt2Oapax8OvE+pave332jSP31tqVtFGjPCu24VRGWAQ/MCpLHkknOT0FjVfhzq1zpenGwXTI71NEn0q8jeV1jLSRIomVhHliPLUcqMr3GMFO7jdb2/HX/JfeVG3Mk9r/AOX/AAfuI9Dk8K6np8t/qGqX+m2kNtbTSyyeNbtvKeVN2xx54KEcAFsbs8Ct5tA8IrcWcDeINTE1+u60jPiy93XAxnMY+0ZYY54zXK6P8O/GNnI3n/2DEki2MTstxLMwS3iaNihMK7GbIORyBkZ5zWn4J+HmseF7vTjfvpuowJp0FpcCR3Jgkgd2SSIFMNnf32lSMgmtHyuTttcyjzKOu9vxOm/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+ukoqCzm/8AhA9I/wCfzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/x+ukooA5v/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8frpKKAPO/APgrS7r4beGriW61xXm0m1dhFr99GgJhUnaizBVHoAAB0AroP8AhA9I/wCfzxB/4Ueof/H6z/BWm3V98M/BsltrV9pyxaNaF47VIGWb9yn3vMjcj/gJXrW3Z6HqFrc28s/inVrxIs74Z4rQLNnP3tkCkY/2SvTnNAFT/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+ukooA5v/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+ukooA5v/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+ukooA5v/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+ukooA87vfBelp8SNGt/tWueW+kahIzHX74sCs1mBh/O3AfMcgHB4JB2jCad/wAIBqsgitPFWoGZrp7RIW8W3geSRDgqq/aMn29QQe9dDff8lT0L/sC6l/6Psa5G6+H3iWe5kiV9LFouoG9hdbmRJH/0z7QA+IuRglQNxAI3YOfla3sx6ct+pZ1mDwxpzRix1XUL4xX0NpfqvjG+V7MSNtDMBM3IPZtvGeeKuJZeA5FkaPxbduI4PtLlfGN2dkP/AD0P+kcJyPm6c1XPhDxGmk6bpy2WhTf2ddwEXj3Miy3EEUvmfMPJO1uOVywJJbI6GvpegXlvq2m6fe3GnJqf2i6fULW0uGn3WMsrzLuBVCP3gCAkYwWx14Elb5/hZfr89yXe/l/wX/X3Go2meCE+2b/FN8v2FQ13nxfeD7OD0L/6R8oPvimwaf4Fup/JtvFd5NLs3+XH4wvGbbt35wLjpt+bPpz0qM+E/EEemfYYrfRXNrcbra+MjCeaJpvMYEmJvKb/AGlL5Iz8p5Gbo/w98RWmj6pp90dLjWS1tobSVLqWUyGCVnAlVowQrhsHDMevWl0DW9g0BvDOt39/B/a11HHZzSBZIvG19J50KpG4mUeaMriTDHOFI6nNdHp/hXw1q9il5pWsaxfWsmdk9t4pvpEbBwcMs5B5rmJvBHjKbXtQvhbeHokvPtD7ftckmx5YYUxta32thoPvHruzt4weo8Jabq/h6WTTr22glgurie7a5ju5JWjLEMFO6MA8lhndngELgnbWmnp+PUHp9/4Fn/hA9I/5/PEH/hR6h/8AH6P+ED0j/n88Qf8AhR6h/wDH66SipGc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9ct4a8N+HrPwne6hq+q6rZW0OrakrzP4jvYI1Vb6dQSRMBk4GSeWJJJJJJ9NrhNH0241TwLdQ2SRvcJr2pyx+ZcPBhl1C4IIdASpzjnDDGcgjikxoiWy8FCeQS+KLhIhtCN/wmd5uZihfBUzjHy4YcnI54FSw6f4GuVU2/iu8lDypApj8YXjbpHGUQYuPvMOQOpHSsyLwd4xi1i1lmh0K6ghns5Xla8kidvIjZTiNbfaCS+Rggcds8VbDwB4tttPlgki0PMt1aXTAXkpGYZzIVz5I6qeuOCMY5yK6/P/AC1/MjX+vn/wDW1DTfDieGdV1bQtT1PVzpkcjSRxeLr8LuQZZC6zNtOAex5oji8AmyiuJ/Ft1Ar5U7/GV2ArqMuuTcdVB5HbvWjpnhPU08M63o9/PbwxXtuba1WF2mECeWUzuZVYjnIQltvTce2UvgvXz4m0nWXg0lGt54ftMMd1JtEUUUsasp8r5nPnE4O0DYq5P3gK17PyL0t9/wDwC6uleCpLa8uIvE988VicXUg8X3m23PpIftHyfjWT4dl8H6zpMlxfa7d2F1b+c1zbjxpeyCGOOVo/MLGZTsOAQxUDkUlt4A8TW2qjVPM0qS4iNu625uJFhkMLzYXAjxGpWbIAB2so+91p2leHbmy1XTdMuLnTU1Bbi6a+trOYyb7GWV5lLKQpX94AgyCMF8HnhpL+v67/AIClpt/X9fmaraZ4IT7Zv8U3y/YVDXefF94Ps4PQv/pHyg++KjisvAc0hjh8W3cjhPMKp4xuyQu3fux9o6bfmz6c9KafCfiCPTPsMVvorm1uN1tfGRhPNE03mMCTE3lN/tKXyRn5TyMvSvh74lstMvbSX+yVKx2YtHF3LJ5xtpmkCygxgqrhsHBcj/aqVZ7/ANf12E73JdBTw3rLziTVLuFYZZxmPxrfSeZDHtImT94MoQ3J6L6mug0/wr4a1exS80rWNYvrWTOye28U30iNg4OGWcg81zUvgrxlJqd1Mtt4ejjmN64/0uR8NOI8DY1vtODF1Oc7s442nsvBuh3ug6bd2+oGJmmvZblWjuHmOJCGIZmUHIOR7jB46BrZX7fiG33v7tRn/CB6R/z+eIP/AAo9Q/8Aj9H/AAgekf8AP54g/wDCj1D/AOP10lFIZ534L8FaXc6DcvJda4CNW1JAI9fvkGFvp1HCzAZwBk9Sckkkk10H/CB6R/z+eIP/AAo9Q/8Aj9VPCtnPfeD7yC11K602Q63qhFxarEzj/iYXHGJEdef92tF/D2psX2+MdaTc4YbYbL5AM/KM2/Q575PAwRzQBD/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP10g6etFAHN/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/XSUUAc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9dJRQBzf/CB6R/z+eIP/AAo9Q/8Aj9H/AAgekf8AP54g/wDCj1D/AOP10lFAHN/8IHpH/P54g/8ACj1D/wCP1kan4ZsdG8W+D7izn1SR21aVCLzVrq6TH2C7PCSyMoPHUDPUZ5Nd3XN+KP8AkYvBn/Yak/8ATfeUAdJRRRQBzfij/kYvBn/Yak/9N95XD3/iHxRpK+NtXi8RXF3F4avF8qwuba38qaExJIyFkjVw3zkKd3YZB5rr/HF1NZap4RuLawuNQlTWn221s0ayPmwuxwZGVeM55YcDueK5M+Grma+1OW+8PeNry11W5W5vbGW50hYZmUAKDslV9oCqNu7BxznnIt/67r/gj0sa/h34lR37ESWWrXE13qMkEVu8FvG1oqrGSpIlw4G/PBLkZ+XCmrV38WNDtLC7vGtb+SG3ikniMaxH7XFHIIpJIwZBwrHBDbSeoBFYUHh+4hW9jfwz4zmhvdQ/tCWGS40nb5m4NgYmBAyq8g7hjgjJzWu/BsV3Y3tofCHjCKG4he3iWO50r/RIpJBLIkWZjwzAZLbiOgIFPTT+un+f6+RKv+P6/wCRpfEL4h3Fl4V1WPQU1PT9Ys7VrveYISIY1faruHLAo5BA2gn/AHcGr1z8X/Duny39pM811d6ZatPOlu8JZyihpFVDIGyoOeQoOCASQRWX4j0GXxNHILzwn4wgeew/s+6ktrnS1a5iB3DfmcjIbJBUDqe3FNk8PzvpWtaanhjxnFaa0mLqNLrSsByoR5FzNwzADI+73AB5pdH/AF6fh+I+q/rTT9b/ACOssfHVvf8AiGLR4tH1ZJZEEhlmijSNUIyrjL5dT0ygbaeG211FefFb+SbSpLjwl4snOl7DEHuNLw7KpUM2Jxg4Jzt2g55BHFbv/CUav/0IniD/AL/6f/8AJVN26CV+p0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUhnSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQAfDj/AJJZ4U/7Atn/AOiErpK878A+I9Ug+G3hqKLwXrlykek2qrNFNYhJAIVAZd1yGweoyAfUCug/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAOkorm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+SqAEv8AP/C0tDx1/sXUsf8Af6xrCHxK1KO0hmu/D9rCLmW4toW/tQbPOhlMbBi0YIQgbgQGY9NmcZZe+I9VPxI0ab/hC9cEiaRqCrAZ7Hc4M1mSwIuduBtAOSD8wwDzjE8O6FfjTbj/AISr4ca499LdzTq1rrNu6RB5jKpjJuk8pwcAlACdoJPYAdC8vju9a+tPEFtYSutzYLHNp0l9IsaP9sEG5QyY3At3RCR1xjFTa38QtVtotTRNHgt9T020vST/AGi7xLJEkT/dEYDgpKpBYAggjAzmsfxL4aupdLl/4Rn4c+IBfSOgxd67CkKx+eJnAAu3CksvZRgnORitltEspfKaf4b+KHZIpYm36vbt5iyjEm8m9/eEgAbmyeF9Bhq1tfP/ADQ42Urvy/BJBrPxI1nTra/tBpNkt9b6ZNcrKl80qrLHErkMBEABh8gEhjjlVBzV+x8ZasbqfT30W1OuPcrCkI1WRrd8W6ylt5hBT5TjasZy34mqX9jWRDh/hx4nkEiujiXVbZ9wePy3zm9P3lAz6kAnkZqKPw/Yxibb8PfF5kmlSZpn12JpVdVKhlkN/uQ7Tt+UjI4ORxRoJbL+uxetPibdXcwYaCqWgmtI3c3v71fPdox8mzBKyKQRuwRyD/DXReFfEU/iC3unu7SGzlgkCmBLgySRgjIEisilH9RjHoSOa4+48P6fcmQv8OfFUYkMJZYNZgiUeT/q8BL4BducjGOeevNXbGOfS9Siu9N8DeKYNu7zEOpWsgkG3CqQ16RtXsMfL/DjJy9P6/r1FqVU8W6p4Y/tcf2edSs/7VuoreW51Ny6OsXmiMhkYiPCuAQTg4AXHIvy/EW8sdR02HVdGtoYb1Vd3t9QaZ4ldHdSUEQ7Jg7ivJwu/BqG9soNQuLua6+HHiQteKyzBNRtEUll2syqt4ArlflLqAxHBOKZ/Z1sZYJG+HXid2gSJEL6pbNxHnYSDe/MQCRuOSQSCSOKhXsl6f8ABG7a28/xehTTxhrlr4qn1R9KX+z7mxsppIZNWkZLeGSWRfPCeWVDBdu5RgcfeauktvFur3uqyWlpoEEy27q07rqGCIHkdI5EDRgMSEZypIAGMMx4rl7jSJbG1mTw98NNcEl5bGwm+1avbGOO2bccLGbplbaWO1MKACQCo4rWlhSa6tbh/h14jWS1gFunlX1nGrxDokireBZFHZXBAyfWq06f1/X6vsD3/r+u/wBy7kdr8S9Svrk21roFm0/2qGBc6m2wrKjsjbxCQSDGQ23co7M2MVl674w1I6hHrK6fIunjS78iCPWJYhcrE8YZiFT924+fawBYgjJXoLMfh+whurW4h+HXiyOS0KGHZrUIA2E7Mr9uw23cwAIOAdvTim3/AIZ0vUnla5+GvigeaZSyQ6xBCuJMGRQqXwAViASoGCeSM0Kyd/62/wCHGnr/AF/XY6bTvGb3njqTw7JYRxoIJZYrhLrzGPllAwdQu1SfMBADscdQtTeA/wDkXbr/ALDWq/8ApwuKwtOtY9K1FL6x+HfiZLmPftd9StZMb8b+GvSPmKgn1YbuvNM8F+I9Uh0G5WPwXrk4OrakxeOaxABN9OSvzXIOVJKntkHBIwSaWRJ6JRXN/wDCUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lUhnSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAHgP/kXbr/sNar/AOnC4rpK878F+I9Uh0G5WPwXrk4OrakxeOaxABN9OSvzXIOVJKntkHBIwT0H/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lc34o/5GLwZ/2GpP8A033lH/CUav8A9CJ4g/7/AOn/APyVWRqes32o+LfB8V54a1TSkXVpWE15JasjH7BdjaPKmds855GODz0yAd3RRRQBzfij/kYvBv8A2GpP/TfeVyNtoWj6F8T9c8OHR7X7D4stEu0X7OpVmQ7Z0PHTBVwDxknua67xR/yMXgz/ALDUn/pvvKs6xr+g6NrWnxauwivrlJVtJDau/CrvkUSBSF4XOCRnb3xRond/1/W/yHq1ZHF/8J5qNp4ql8P6JFo1xaLb3UdhHArRrBJb7AI2csFb7+NoCgEY3Hki5pXjXW9Y1230ezm0v7RDbm4vJLi1lhEoE7ROiJ5hKOm3JyXBOBkA7q6yy0rw/fxQ6pZ6XYSC5U3Edx9kUM3mAEtkjOWGM55OOanTw/o0f2Ly9JsU+wZ+x7bZB9mz18vj5PwxT2spb9fx/r5E6NPl+XoeKeJPHWseJvAOr6drUOmvFPoV9ct5Fu6lZYLrylI3SNgEAHHUEda6T/hY2p2eswaTYyaXcW7WdxHEUikdoJ4LZJcSNvAb72CqgY4+YnIHU6vpngO316y07WNA0tr/AFd5PI8zSRIJ3xucGTYVBIGTuIJx3rX/AOES8OeWY/8AhH9L2EEFfsUeDlNh4x3Ubfpx0pa8v9b6/lf8Cvtf1tp/kVvBWq6rrvhiy1bVxZr9utYbiJbVHXbujBYNuJ/iJxg9MemT0FQWNjaaZZR2em2sNpawjEcFvGI0QegUcCp6qTTk2iY3S1CiiipGFFFFAHF+CtatdL+Gfg2K5ivna40a0CG10+e4UYhT7zRowTr/ABEfpW3Z+KtPvrm3ggt9WV7jOwz6NdwqMZ+8zxAJ0/iIz2qp8OP+SWeFP+wLZ/8AohK6SgAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY15lfx3+n+L77xS02mXGr2VzqMdtMbORcJHbBvLfEvzrgDA42ncf4iK9Nvv+Sp6F/2BdS/9H2NWIvBPhWDUPt0HhnR47wsX+0JYRCTcc5O4LnJyc/WlqnddmvyDR2v3TOV1HxvrsU+oJayab5VqIZjMLZ5TDE0JkbcglDNyPvICVDA7G61kR65eaBpOsJpceknT7i41SSOCS1Zl3xr5hJAdQUYbgVwDznPauj1v/hD/AA/dTWk/g22lFvZxT7oLC22mITBQBlgfkYhsYHquTxW1L4C8H3A/f+FNDlBdpPn06E/M2Nzcr1OBk98CnvqvNfl/kKLtZPo0/wCvvOYtvGuuxao0Uq6S9lHqIsUjjheJirWYuEO8yFRtPynjBHPy452PA2t+I9dkurjW0t47ERxm3CabNauXYZdcySHeq8DeqhWzkHtU1/4C8Kw6NdLYeF9KgkVGkiNrp1uJEkCna6bgF3jsSR9ayPAvg/SLjQ9M1tbLTIjOkN3ALDSY7LGBlWdQ8mZBuI3BuhIHBOaVm38v6/MclorFbU7680H4ga1daOthELqTTIbkS25ZpGleSINlWXkZUnOchccdQL4y8UMtlEJtGW6hvxp+qI9nIAkrylUKfvuBsAfBySCvTdx2F74Q8OahczXV54f0m4upmV3nnsY5Gd1GFZiRkkdueKwvEPhX7RoC/wBr6lpoB1CK91KSfTS8NztAQRiMyfKCAq8l/wAc0l0v3X6fpf8AATWjt/W//AOftfiN4t1DWX0vTtGtLmXT5Nl/crsWGRPPkiMqeZOrIoEZbAEmTlcr941rrxx4tsk0vW7q6024tpNLurprC2snjDsjxIMu05HV85OAo3A5zuHpcvhjQJ1tFn0PTZFsVKWoe0jP2dTwQmR8o9hiki8M+H7W3toINE02GG2L/Z40tI1WIuMPsAGF3AnOOvejT+v6+ZV1e55/J458cWvnJqNlpdjJDp93ehZ4AzSrB5TA4iuXCBlkK4LEgruyQdtWtT8Zat5k63a6V5DTQNBaT2jSb4/tEUbMJBJtZgZAcEKUYAbW611UHgrwpJaoH8IaTAFR4lifT4PlQscj5QRhuuPfnmpT4J8KtbmBvDOjmFlVTGbCLaQudoxtxgZOPTNO6uv6/roLdf1/Xc43VfiD4gttMk1KxGlPBOt0beF4JGktzbybWEpEg3bgCMgLsYqMNXYeGNXvtSk1e21T7M02nXxthJbRsiupjSQfKWYggSYPPOM8ZwKl5p3hd/FDaJeeF7OWbVrVrma4eygaO4ETINsmfmZgXQjK49DkVbj8J+GdI1L+27XSdO064gV3kuYLWKJiCPmLOFDEYz3x3PQYSsld9v6/JoGnc3q87tNX1HRfA/2rSmtA7+Kby3kF3GzKUl1SaM4KsuCNwOeRxjHOR6DBNHc28c8Lbo5FDo2MZBGQa8/s/Ds3ijwHLp8N1bW6DxJfzyi5tDcJKsepzvsK714JUA5zxnjnINpK/dfnqCehmyfEPxfJrFxo2maRaXt5pzMbu6RUSCZBIVLKJLhCmACTgyYIxxnNQ3njXxRb6Laa1M/h+aaXSru9gH9nSgxGEpuXf55yrgnoBjj72OfRZvCnh65tLW1udB0yW3swRbQvZxskGeuxSML+FZHiD4daHqfhubTdI0vR9KuDBJBbXS6Yj/ZVkzv2KpUjILdCOTk56UlpuNW5r9DmNU1LVrvxrp0ch0k6np1xL9mvktnKCOS0eTYy79xIwM4cA/KcDpUFv8TvFWr2017pGjWsVjbWqtcT3GwrFI1sswb/AF6uRlguwJyOQ/8ADXeweCfDgsLaC68P6NM0CsAV06NUDOMSFVIO3d3GTnuTT/8AhCvCu1V/4RrR9qwmBR9giwIySSg+X7uSeOnNN7Nfd/X9dyY6as5U+LdeXWtJsL86VeW1+Yku44LKRTGJo3ZQWaUqMbQMAMWBJIQYzLoGqz6T8L/CdvpptoZ75YbOGa4jLwwEoxBZVZSfu7QAwySBmuol8I+G54lim8PaVJGsKwKj2UZAjU5VMbfug8gdBUy+HdETRDoyaPp66Wc5sRaoIDk5P7vG3rz060O2vr+A1tr2/Hv/AF2OSn8X65DdSxzLpUq6fcWtpqFvEjs1w07KpeFi3yqpb7rK2SrDIxmuOvL6S4+G82gWCaZb2+n263JW6gL7i13IsflAMoXYUBzg9QBt6169/wAI7on2i2n/ALH0/wA60i8m3k+ypuhjxjYhxlVxxgcVWPgrwsbWK1PhrR/s8IcRxfYItiB/vADbgZ7+tITVzgpviX4j06wtpLy20+9mvY5UhW1hMWyVLtLfcfMm2lT5gbaWXBGN3ORoxeM/FcLW41uy0/TZFDJLFIA/mynf5YZ45nFuCFU4bcMkjfxz1cXgfwnBjyfDGjR4jaIbNPiGEbO5fu9Dk5HQ5NWI/DOgw/Z/J0TTo/sqFLfbaRjyVPBC8fKDnoKelv6/r+vIP6/r+vzKnhDVrzVtLnOqSwyXtvOYplitmg8s7VYKUZn5ww5DMCMEHmt+q1jp1lpdv9n0yzt7OHcX8u3iWNdxOScAAZJ5JqzQ9QRzfgP/AJFy6/7DOq/+nC4qdPGOmO6KLbWgXkMYzoV6ACMdSYuBz948Hnng1B4D/wCRduv+w1qv/pwuK6SkMqaZqcGrWYurWO6jjLFdt3aS2z5H+xKqtj3xirdFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf8AYak/9N95XSVzfij/AJGLwZ/2GpP/AE33lAHSUUUUAc34o/5GLwZ/2GpP/TfeV5R40tfENxrSXF7Z+Ipry11S+Ky2EN28cULW7rbGIxAheSASvOc7u1er+KP+Ri8Gf9hqT/033ldJSaGnb+vX/M8biHi5tE+06b/b02pz6Kg/0v7RF9mkVIw42P8AI7sQ5BwJA2c5UjDoI/EFz4h0eBpPE0OizaldRQuDeLItobZQpnLfMp87O1pfmHUcV7FRV813f+v6/wCD3ISsrL+tLf18jxDU7LxQfGGmyyW2r3WpWWr3gjmkhmktUhNu62zA48sAkgMRjnO7tUulweKxa+FX1PUPEMpu9SxfxRWl5CbVTCyyLIS75XzNhDcIM5TA6e1UUk7Kz8vw/wA+pT308/xv+V9DjPDFpfaf4x1CCebWL2Aw5W6vpJdiYYKqbWPlsxwWDRgHH3xkgns6KKL6IOoUUUUgCiiigDm/hx/ySzwp/wBgWz/9EJXSVzfw4/5JZ4U/7Atn/wCiErpKACiiigAooooAKKKKACiiigDmr8A/FLQwRkHRdSyP+21jXmVh4UuL/TC2h+FYzFa317DcP5kSpewfbGxCqeYu4JgnZJtTjHIYivTb8A/FLQwRkHRdSyP+21jXG6f42t9B8TTWumaXY6T4Vtp7lLtItFuIJleOMN5q7VCuCc5AXICgk4YYFvb5g3ZL1Rmjw74qsNG/syLwpqFyI7CWzjljubNU5uvMTA85cLsA4CjHAA9JfEXgnXNV07VF/wCEbabUpPthkvDLb/8AEwilD+RCcvnMTNGfmwF8r5Sc16Hc+OdBtHuEluLkyW7IskcdjO7Dcm8MAE5XbyWHyjuRUHhvxauo31zpepzR/wBoJd3EUPk2skcckcbcfMSy78EEjdnvgCnre3r+d3+Yo2j7y7r8P+GJ9IkistLn0zT9BlsmtbVZvs0YgUO7gsUG1yA+7OS2ASc5I5rzOy8EXlrook1LwuthNp+jWlwl1cNbun2+2Zmydjs2Su1d2Pu8cYAr22q93p9nqAhF/aQXQglE0XnRB/LcdGXI4YZ6jmi7vf8Arr/n+CGtI8vT+v6+Z5Bq3g9ZvEWoWGmeHof7V1HSYrlruDykFldvNM32hiSrEqTgMoLYAGME0+f4fatd6TJFe+H0nvYbYpqEzvARrkomjdJAC3UKr8ybdu/aOOa9YXR9MTWH1ZNOtF1F4/Ke8ECiZk/ul8biOBxntVyjZf1/X9eSB6u/p+SPD7n4dasv9o3Euhapf3r3GY1SawS3kh89ZEx92TdGihQHbC8hCQa1IvCuqf2kXj8HPHDa6o8tnFcNaPAkLurMyqsu6M4RuVPJfBVgTj1yilsD1PG7Twbr0ujw2lz4aeBxa+Tpzma3zo0wmkbzRtkOAVdP9Xk/JtIAqbQNK1LwhqVrqh8F3kEMTagLlraazU+VLOJIQR54yoG75R0JOBzXr1FO7QdLf1oedfEXQtR17UojaeHptUhTRryJH8yBVS4kMZi4kkUggx5zjg4IOemRL4L1nWFl/tDQfL1CXz3l1G4lgbz7eSFlS0fa5JKuycEFBs3Bia9copdLFcz08jL8M2Y0/wALabaLp403ybdENoAg8ogcj5CV656E1n+A/wDkXbr/ALDWq/8ApwuK6Sub8B/8i7df9hrVf/ThcU5O7uRFcqsjpKKKKQwooooAKKKKACiiigAooooAKKKKAOb8B/8AIu3X/Ya1X/04XFdJXN+A/wDkXbr/ALDWq/8ApwuK6SgAooooAKKKKACiiigAooooAK5vxR/yMXgz/sNSf+m+8rpK5vxR/wAjF4M/7DUn/pvvKAOkooooA5LxxqVjpGqeEb7Vby3sbSLWn8y4uZVjjTNhdgZZiAMkgfU1Z/4WP4I/6HLw/wD+DSD/AOKo8Uf8jF4M/wCw1J/6b7yvPbjxZ4gg8aa1o9r4nv5tSh1WO20qwuLGAWtwjRpI6PMIRghWcgCQNhRwx6i1lb+un+YPRXPQv+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiqy5/i34bh1TUtPjeW5utPyHjgeImRldUZQC4KYZhlpNi4yQSASFm+KOn2l9NbX+i6vafZktpLmSVYCsKTkqjHbKSQGG04B9Rkc00rq6B6Xuaf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVWFpPxKhMn2aez1i/ubm6v1hRLWAMn2dvmiwsh3EA4B/i74NWdV+KOn6W+rwTaXqSXOnWMt6kcyIn2lIyFYqC+4AEj7wXIOV3Cl0v8x2d7edv0NT/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqpWvxHsJJre3u7G7gnfyYpiTEUhuJU3pCSJCdzDkEZXkZYHiobT4o2V5aaVeRaDrS2WqSRxR3TxwrHG7uyAOTL1yp6Z6j1FO2tvkTdWv8AM0/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq29Pu2vrGO5e1mtC+f3U+3cBnAJ2sw56jnoas0hnN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVdJRQB534B8feD7P4beGrW88WaHBcQ6TaxyxS6lCrxsIVBVgWyCCMEGug/4WP4I/6HLw//AODSD/4qs/wVr+j6P8M/BsOr6tY2Etzo1oII7q5SJpSIUztDEbuo6etbdn4x8Majc29vp/iPSbqe5z5EUF9E7S4znaA2Wxg9PSjcCp/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVdJRQBzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUAc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFV0lFAHnd54+8Ht8SdGul8WaGbePSb+N5RqUOxGaazKqTuwCQjEDvtPoa52c6Be31y178VPCTWdzNdStFF5aSATxeWQHNyRwMEHb1r0K+/wCSp6F/2BdS/wDR9jXJ6t4v1w+I7TWNH0k3FotlfGK2bVHjF2sLxgs0YRlVx823hiQeSvSlpf7/APP9Bq72MyZ/Dly1w9x8UvCrSzxQoJVaJGheNCnmRsLjch2scYOQTyWHy1Z0rUdAsNas724+KHhS5it725umjDRq8gmXG3d9oIBHPODn0ro7rx3qUd/ElrpNg9jcSItvfTai8cc24JwD5JUNufAUtlgpxk/LWf8A8LR1NLTS55fDUKjVIoZoAupZwjzRwvn91wQ0qEDowJJKkYq1dy03f9foTZONlsdH/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVYzfEe7+yXbx6HHJcaWk02pwi+wIoo5HjJiYx/vCfLYgEJwOSOKr2vxXfUZLp9N8PXMlioYW19cebBBIyyCMh5HiCKCSSNjSMQpG0NhTO5TTTszof+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qrfhrXn8SeFYNWS0FvLMHBt2kOFdGZSNxUHGV6lQcdRniuctPiLfT6d9ouNDtreSSyW6gRtSGw5lETB2MY2gEgjAYkdFzhSbOwlqrmx/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVYdj8TLi9htZ20aG2ilt5ZG+0Xvks8ieZlIzJGqsAYjnLKygglQMmm6R4puPEfiTRZ3iksZIbu7s7iCC7keCXbCrhsMqbhyCCU45wcHJdne39dhNpJPub3/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVXSUUhnN/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FV0lFAHN/8LH8Ef9Dl4f8A/BpB/wDFVz/gvx94PtdBuY7rxZocLtq2pSBZNShUlXvp2VsFuhVgQe4IPevRK8yklubfwDHcWEkyXEfi64CLFcvCJN2ryoUYr1UhiCCCO+OBQtWl3sB1P/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVWE3xK1C3u7qK90G3hTT7eee9ddRZinksocIPK+fIdSpO3PIO3HL5/iBrVv4gj0STw5aC/dDIB/ajeXtMbvGd3k558pwePlIGNwOaOnN0FdXsbX/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVWDP4yvfFPhW+uNK0uWLTjYsZbyPUDDcW0pthMMKoBKjcq7g4OT93HNTaf431Ipb6QukwzawyRCBJb8iOZDD5hd5PLJVsKRtCtzjnGSG002n0/ULrTzNj/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iq52++KV5Dp8l9aaDCYY7Rrjyry/MEsrICZFjHlsrhdrLkNnI5AX5ql1v4l3uhW1+bzQYPtFgfMkiGo5Dw7N4ZMRlmfAOV27Rg5cDBJYe5u/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVY+pfEPULG9njj0S3kSO4hiSOW/MU7rJKkXmeWYsFcyKQQxGM5Knirmh+NrzU9Xt7K90eK0WWe5tGkjvDLtngJ3AAxrlCBw2Qc8be9CTauD0Vy5/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VXSUUgOb/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KrpKKAPO/Bfj7wfa6Dcx3XizQ4XbVtSkCyalCpKvfTsrYLdCrAg9wQe9dB/wsfwR/0OXh//AMGkH/xVJ4FG7w3dg5wdZ1UcHH/MQuK5HSfGusaH4d+zjS/7U8iK8uY5rrU5DK8MN0UfcTG7ZVWUjliwB6EDLWugjr/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqyNQ8f6pZ32orb6BbXVlZ2r3qXCakQZoY2AkIUxcNycDJB2nJXilvPiDqAAm0fQYr61muJLO1eS/8l5LhFZmVl8shFIRgGyeQMgA7qXS49/6+f5Gt/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVYtp49uNTh0fUG0mEWd5cTJC8OqMGDR27ud6GNFxlHXDkAEK302/Bvit/FVrftPZR2k1lciBhFOZo3zGkgZWKISMOO2OOCRg0+V7B5if8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FV0lFIDm/+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iq6SigDm/+Fj+CP+hy8P8A/g0g/wDiqyNT8WeHNe8W+D7XQ9f0vUrhNWlkaKzvY5nVRYXYLEKScZIGfcV3dc34o/5GLwZ/2GpP/TfeUAdJRRRQBzfij/kYvBn/AGGpP/TfeViX3gPw8t7f2useI7w3fiC7W7gjnnt4pUuIwNslvtjVtyqqjHzDA5Byc7fij/kYvBn/AGGpP/TfeV5JrmsyRePG/tTxI0M9v4pkWCG4eFfs8S2J2yKCucZYDJyvTjJOUnr/AF3X/D/IdtP67M9Z0rwRDpFvfQ2usaoUvZTPIHaLCyt9+QARgfMeSpBXOcKM4rkbT4bvJ44v7O6tdRh8OCxsoopRNb7LtoHZ9jgEuBudSNqp90jgYBxtO+JfiLULPRLpL2Jp7izsXgtYli26nLJMUuRyC2Y1GSEK7Ty2RxWhpnjDVLrwfPqVx4tkJOsy6UjW9nBIyk3O2NtwXap2d2UjBB2k8HRpxf4fdp+ugt4+v66/pqdRpPwysdI1211WLWtWmktbm5ukimNvsLXGPMB2xA4JGRgjFV4vhj4c1P7Vdpqd/fR3kF5au4ukkUpPJukAYL1Vhgc8Ywc4rm/C/jnXdf8A7Dh1jWxoplsjL9oa3ixfzJO6SxkMuAwjUNhdpBbOCBioPh/4w1HVjoVg+u29hBJFJNHLFbQbNRlFy4khIVQA3lhW+TactuORkUlHW3qvlr/kDla7+fz/AKZ3f/CutL/tCG7a7vGZGileM+VtmniTZHM3yZ3qvYEL6qaiXwbDpfg6x8HwW95q2lyOUluZ540ktl3eYH+ULuwwwNoyDj3NYni3xpqGl/EXT7DTtTlECXlnb3lm1sgj8ufzBu3kFiQVHIKgdDuzxxsHxV8QwrMtpr8GrztDqYiiaOAsPJmUROBGoLHyy7Y6MF6d6S1/H8NQatp6fjc9e8P/AGabxBrlzY6+uowmWOE2Ud2syWTouGXaB+7J7qSeRnvgdDXmXwqvLe68VeNjb6quqbry2kF1ujLTKbZMP8gC4ODyABxXptDVrei/ISd7hRRRSGc38OP+SWeFP+wLZ/8AohK6Sub+HH/JLPCn/YFs/wD0QldJQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6PsaZL4L0ywvf7X0LTVbVI3keFJdRnhgBlI8z5V3KAcbioTBYA8Hmn33/JU9C/7Aupf+j7GuPfxjebXmm8WfZjJdm31O1+zw7tETewEmSuVBwozKGU7twwBijqPpc7CHwVplvodjaC1WSTT4h5SLNJBE7g7huVTgrv+bBDAHBwSBWN4c+GVhD4Vs7PxLal7+HYZHtdUuWQFH3JsYlCi5AYoAF3AHBIBrkp/iBqdkbxr3xhDF9ktVnhV0tlF0oumjSQgrnbJHtJ246grtBpLvx54gl1TVZ9I8SW919iMwNis9n5ZXzlRZFRUe4CxxlncuPvAEblOC13/rQP7voeiR/DrwzGxYWdyS0skrl9QuG8wudzq2ZPmQnkocqTk45p0ngvwxNdXUBgdZbhxdSW8V9MgjfdkSpGrgRsWH30CknPPWuIs/E+uv8A2XHqHiu2uFuJvKhfRpobhrkOxCli0CLJtXOTEF27SxUjgY/hjxzcWOj2+njxi14BptlJdPIbaSTTC8pSdvlQfcGzPmbtuctkU0mLdN/1/wAE9a03wvZaTcSf2e9zDayROhthdTMgZ3LswDOQpyxwVAPPXpjOj+GfheJIlS1vcQwiGPOq3R2KJPMGMycEPyD1GOtefaj4/wBUsBfE+M4tlrptxdWjslsBeiOZRFJ9zkSBmU7cBtuU29a7bxnrFnrHwyvdQ0TX4xbK0e++0+eKRVAkXeCxDKAATnPbrS1SUv6/rcW7cf66f8AsWXgzwZqVnIbCNL20MsyuseoSyxeY2RINu8qGBLD1XJxjJq5a+A9AstVg1K3hvFuoJDKjNqVyylygQsymQqxKgAkgk968pvfHsWjaVqc+jeN7ZRcXGpGIrJauHkjUPHIMqcszYGB8pD8AHBrp5fFGqW+pRw2/iR7qdZLV7OzeKBv7Vt5ipkkXYgJCBmwUIACAtuzmhXsn3t+I2t/V/h/w56jRXiVp4q1HWrq2W98VzJaLqVjPHOPs0Z2SeapVgEKqokQAKSzA8FienttFtP67J/qK+tv66/5BRRRSGFch4W0uz1jwbe2Wow+bA+taoSAxRlI1GcqyspBVgQCCCCCMiuvrzOTU7rR/h419Z6odMCeKbtJptkbKYn1WZHDb1OBtYnIwQQOcZBOqQzpIfC/hKPXTbxhH1FLF4pLR7+R2e3kY7mkiLkPubq7AkkcnIpf+FdeG90DC3vfMgDiOT+1LreAy7CN3mZICkgZPygnGK8z1LxnNaXtzqB8VQm40/S7ySzvG8gNfRCeLy8jbtIchlyijdjK460tz8TLt5pZ4PGkMNldXFubSU/ZAMG68uVFBQ4URkN8zMwwGJUHFUlzKPn/m/wCvvJvq/J/ov69D0mL4beGILR7WC0u44JLcW8kaalchXQDaNw8z5mC8Bj8wAABwBR/wrjw1vZ/s975h8vEv9qXXmJ5a7FKP5mUO0kZUgkE5zk1zOvah4g0D+19Pn8V348q1Op2upzW9qNsKIweNsQhCfM8vqASHGOhzjXnxGuYbaaGPxjBL+8tZGmhlso5kWW3ZyqNKBCBuVT+85wSASStTd6v0/r77j7L+v6tY7TxZ4Csr7wxewaJZ28d61o9vbi4u5YreLcnllyqhl3BMjdtzjIyMk1Jp3gzwtrGhW0/kpexzxsXng1Oa4WbegR187dmRMAAA8fKMAYGOVsfFmtwixiuvFEV3qEf2Qx26i3ePVYpNvnyqyIMrHlwDGQFEeW3ZrFt/HbWek6SukeJ4rWyR83JQ2/liOS6lRpN7qxYr8p42quQWLbgtN6aedgv17L/I9NvPh34av8farW6cqVKkajcqVIYPkYkGCWAY46lVJyQMQS/DPw+cyWv9pW9ysss8cy6xegpLJ99+Jgee/P8AOuX0nW/EMnhfw74hHie91ODWLb7NNHHb2pSC6kTEbgpDkASAqQSQCwzwCKpDx3faVqUltL43t754tSu7ALdpb4IS18xWYRIrErKAuFxnOME4ptNNrtf9Px2/AOy/rr/kz2CJPKhSMuz7VC7nOS2O596jvb+00yze71K6htLaPG+aeQRouTgZY8DkgV4enjnxPOqvp/jCzNtdOVF1qN/YKlpIqKVR3t4ZUG9i+FbDFUwCrVJ4l8c3klpr1pq+t2/2KbSbyKSCTy4kiuUEQVIwVEnzB2xvbLjBCqOoleVgS2PcwcjI5FFQ2k0VxZQTW8iyxSRq6OjZVlIyCCOoqak9HYSd1c5rwKN3hu7Bzg6zqo4OP+YhcVAvgXTdGEV14dsXkvoI5IIVvtWujEI5X3SZBLhsk7sFeSByOCLHgP8A5F26/wCw1qv/AKcLiukpDODHw8Rtd0yCe1t30HT9KFkqx3s0UkjBgcNEgCvGQOVZiDnkVtX3gPw7qM9zLc2UubrJlWK8miTcRguFVwFYjgsoDEZBODiuiop3f5/i7iOVn+Gvhe51GS+uLS8kmlmad1bU7ny2dkKMfL8zZypK9OnHStfRvD2m6AJhpcUsfnlTKZLiSUuVUKCS7Ek7QBnqcDPStOilsrDCiiigAooooAK5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7ygDpKKKKAOb8Uf8jF4M/7DUn/pvvK6Sub8Uf8AIxeDP+w1J/6b7yvNbz4e6rdeJ5Z5fCfm2UviK5upQZLbEtq8AXlfM5DSKGKn0BIyKXX+u6/r5D6f12Z7dXNz+NbaDxLqGh/2Xqct3YwQ3B8mJHE0cj7AyAPng5zkDAUnmvNPC3w+8YefYy602oWFxaaWkFlNHPautrIqujJIcNJtYFWHltg4G7BAxlXfw+8TLtFv4LmZjY6fEzx3Np/x8QXBkmlJaUHLjJDdTu+bBJq0lzWvpf8Az1/D8Sdbf15H0JVDUtXg02GbMc11cR273C2lqm+aVVwDtXuckAe5ryxPBGu3viu/vbvw8bGy1K1uoLxLa7iZ5SbhGiZizHedgY4bKjlMKvFZniP4a6tqNjcSDwbZzzy+H2s7SKAWy/ZLjz2KnDvhDsYHKEgYIBxjKXR9/wDg/wCX4laXf9dv839x7ojb0VsFdwzhhgisfxH4mtfDK6c17b3MyahfRWKNAFPlvIcKW3MPlz6ZPtXlOn+EfElv4yTWIPB91aK2tLdtm6tFIhNp5T52THrJ8xxkkc8niqcXgTxdBqdrLD4YNtbS32mX09vbXcBSKSJpDMSWkBdsFfm+Yt3JNNJOS9V+lyfst+T/AFPe6KKKkYUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gtm21GG9kxZgzwhpEedCuxHRtpQ85znPQEfKckcZxr7n4p6Hn/oC6l/6Psa80m8J3mgXmqyp4Vayhnh1CBtQtpbSIXJnuke3X/WBj8o2YYDk44BzQt/vH9m/mj1651mO18QWWlSW05e9jkkjnXb5Y2Yyp+bdnB4+Uj3rP0XR7W31K4WLWr3UBZTkraXDRstpI6liAVQOxKyfxs3BrzGz8ISKHtIfAsjPtu5L2GOCxtoRJJEohVYxcuAPl4BY4JzxkU628C3x1+0vNS8BNcvJeR3F1ck2RLRfYfJeJiZctmXLEcqc5yTxTXX0EtVr5/h/me20m9ePmHJwOe/pXieieAfEcs9pca9Y61HPBbJHaiC7slW3VYvLaJ5PnlAY5I8tip3LuCkcauk+DtTsdVsJ08LQRJa3iiFnW2VYogQXlKo/7qQ7TzFkPld6DnBbWwS02PWKydS1K28Oi2drS4lW/vo4GkiKtseQ7VZ9zA7c4Hy5I44wOMfxJZHxb4Qtr+z0kS39ncR3tnbXQiLB45BlQ24oNyhl3BsYbOa41Ph/qWnW8dofD0V/Da6pCbVrb7Omy2eb7ROMMy4QN8gUcnaOCOaFvr3/DT+vxFK6i2v63PYKK8PtPh/4jvL6A3thq+lwW7ONMFnPYf8S4ieSRSd29kQo8a/ujkhCrKRjNjT/Amp6d4buor7w1qOtX100Ud3HdPp0kDSLuBuo0+QSNhm5mO8nbkHGQWKPZFkZp5IzC6qgBEhK7Xz2GDnj3A68ZqSvFLPwZPb6tDDafDS4s9LS+tpFRpbE4jSN45GcCblmDLnrkZznvSPhua6nsYfEHhiZrXSooftUUiWd01oizvIqoTcDygU2hgqyF1AGAQMis38/6ZP8AX47HvFFVNLv11KwW5S3ltwWZPLlKEjaxXOUZlIOMjBq3SGFcLougJ4j8HPayX93ZLD4j1C5D2nl7maPUp2UHejDG4A8AHjrjNd1XlOqW8M/w0DzWS3rw+L53ji+UMW/tiUYUsQASCVzkcEgnBoXxL1X5h0fzPVqjgkaWIPJC8DEkbJCpIwcZ+Ukc9evevHb/AMD60fssll4X2QW12t7Z20ctuXtEFwrNbjdJsjJQMf3fB3FSwAGakHg/Wl0+XHgC5huobFIrZhPZDbKt00iFSJuCqNweMYIHbItbX/r+thO6vb+v63PZLXTfs+pXN7Ld3FzLNhUE2zbAnXYgVRxnnLZJ9cAAY0rp4suryG0utV0W80S8MBlhMBLkxq2QGEiFSrjG5Qw56VQ8Vef4u+H0y2/hy6uLg3MYFjO9t5ilJVJYN5pj4APIfPbrmuUvPCd9b6zd3Fh4Dle3/tTdCkLWSg2hs/JZAplACs4BK8ZABI4xR38v+AXGz3PVdLgW302FFilhJG90nZWkDMdzbipK5yTnBx6cVbrw2w8H63BZQyy+ArkXkC6UpInsizGDKzsD538Ufyc4LA4PGasaf4Q120tLGG38GzQQrZRpqNubi1C3gS43eS22U7v3eQN3y4O0kAmqklzW8/6Znd2vY9M8UTRaVYyeILxr65tdKia4ewtvKw5H/LT5sElRkgbwPYnFal5axatpMttI0scV1CVLRttdQw7Hsa8b1X4fX9xHqCJ4JNxHPpV1FYxM9ofsbySAwxfNJwUwzArlV3YUmtVfDOpi7u0l8Fyz6Gb5LiTSnltdt0GtgjMF83YWWUbiHIzncCSKVly/13/r/hi+v9eX9ff1PR9J0dtMVmuNSvNTuGUIbm88sPtBJC4jRF7n+HJ7k1pV4jYfDjxPZ3dzPqaajqV9HC5sZY7y3S3ETRbBaySEC4wMkYVtjHDZU5I7LwBaXfhhZtHvNHns4r28kuLXZ9mWOFPLQldkTnb824fKCM9Scgl7kvTY7yiiipGc34D/AORduv8AsNar/wCnC4rpK5vwH/yLt1/2GtV/9OFxXSUAFFFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95QB0lFFFAHN+KP8AkYvBn/Yak/8ATfeVz3jD4mf2F4k0600ye2ltGluINQZ7GeQwvHC0g2unDYKjcqqxAPauh8Uf8jF4M/7DUn/pvvK5fWvhJd387f2b4ghs7db66vYoptPMxRriNklBYSrkfMSvAx0OaTv0KVuv9b/rY6TTfHmjT2CNeX6GaOyS6up4baYWy5RXOJGXAOGBCE78EcU+T4g+G4lt/NvZ0a4MqpG1jOHDRpvdGTZuRgvO1gCR0BrCPwsa50WPTdQ1hWRdOWyke1tDC020KI2f94wYLsBAPOSfmwcVJa/De6t/Een62+s273cOoy6heBbFlS4Z4RDtQeafLAQdy/PPtWj5XJ22/wCCZxuoq/8AWn+Y7VfiIkfjXQdN0e5tZ7C8uJbe+eS2lHllYTICkuQmRj5lwxGecVrj4heGStuft8v+kzNBCPsc2XcJvxjZnBT5lPRh93Nc9e/Cg3WqRumsqmnR6hc3wtTaFn/0iNklTzPMH94lTt475pdM+FI0i38PR6fe6bbPo14LmWSDSFia9Co0Y37ZB8+1zlznJwdo5BlWa18v+D9xT308/wBbffoddpHinSNeuZINKuJZzGgcv9mlSNhx912UKxGRkAkg8HFa9Yen+HpbLxReat9sXy7mMq1vFB5Ydt2Q8h3EOwUBQdoOM5J4xuUdEHUKKKKQBRRRQBzfw4/5JZ4U/wCwLZ/+iErpK5v4cf8AJLPCn/YFs/8A0QldJQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6PsaqXnjHTb6Ca0udA1C+tLomC2D28Tw6k2SCibnx2J/ebAQCRkDNW77/AJKnoX/YF1L/ANH2NQN4AtfJMMWsatFDHcfabKNJIsWEhJJMWYySPmIxIXABIAA4pdQ6aGbpnjvw/pul3UGkeHbyyttORHltbe2giEW6VonAUOBlHRt30yu7Iqr4q+Iz/wBn6ha6HaataXEMVxLDqQjtjC32dwsg2uxfG4hOY8nORx81a118NdNuYZUTUtTt2uIDDcyRSR7rgmQy+Y2UI3B2Y8ALzggjAHPWngC/1K81WC+fV9LXUXcX10F05hcxliVEcixGZsfKP3uMDIA6YtWvqJrR2+R3+ia5Frcd3stri1ms7g288NwF3KwVWB+VmGCrKRz35weK5PxH44urTxJpg0m01S6sorq4t7pLaKAx3bJBI7Ihdg+9GQd1B+YZYjA2tJ8KXWi6/cX1vr2oXNvezNPd210LfYz7FRSuyFWGAq/xY46EnNV7zwVBbaoNZs7zV5Gtbt9Qi0y3kg8t5mRlkC+Yo++GOQXABOQVyaWn4fj/AFca2f8AX9dBknxFtfOsY7fRtSuft0Ec8LRNblSHXcVB835mUYJVck5+XcMkVb74q2GnWzXF3oWtJEs81vvEcBBkiYh1GJeyqzZ6EA4O75asW/gK2ufCq6XdzXlnFLNLNLbxSI/yu+4RHcrD5VCoCuCoHykdaxbD4eT+IbDU4vEc2s6Wj6jdS2tuJbVlRZHJ8xMK/LIxUhicZOAM5p6c39eQP4dN/wDh/wDgHQN8QbPM8Mek6pLfW8kiTWKJEZUSMIzSf6zaV2yoeGLHdjGcgUYvi/4WutZGm2E0t7K8Rki+zGNzKwj8zYI9/mZ285KBeo3ZGKsL8OLdNUudSTX9ZW9uJXkeZWtwQrqiPGAIsbSI4+2RtBBByTJ/wrnTYrK80+x1DUbHS7uLY2n28kfko20LvXchbOAMqWKHupzS0/D8f8v18g16f1/X5eZseG/EVt4n0k39nFLAFmkgkimZGZHRirDMbMp5HUMRU9xoWk3eqQandaXZT39uMQ3clujSxD/ZcjI/A1FoOgw+H7WeC3ubi4Wedp2M+zIZgN2NqqACRnHbPGBgDUoEgooopDCvMpbi0s/hzLcX3h6HXwvie9SO2miicK76pMgcCQgbhuwORyeoGTXptcToOiw6/wCB7ywuJ5rcHXtRlWWArvR49TmdSNwI4ZR1BFC3XyGrdSwvxFsDf3lg2malHe2wj8u1ZYhJcl3ZFCDzPl5U/wCs2DHzdOaz7LxxcweJr5dRtNW+xzGzWK3nghRrGSVpI9rcgkM6qAQX5Oc7eatr8MtOSR5U1XVEmLF45leINE3m+arAiPkhi33s5DENu4wXHw4S5uZrm48T67JNNLbTOxNry0DFk/5YYA3HJHTsMDinG2l/6X+ZEr30B/iVax2djcPoOsAXVy1q8YWAvbSCZYcSAS93YY27uOeKjk+KNhC06z6JrEbWsMk1yGjh/cCNwsm7EvJXcrfLnII27jxWfr3h3U7vS72803RtQhvNT1azuGgjuLfzbeOF0LSfNIYwx2E4UtklcjrjQu/hfZ3i3Pma9rKNeWsltcupt8y+Y4aRzmE4Y7VHGAAMACnG2jf9aK3yv/W432X9K+vzLN98StD0wyy6gl1bWCmVItQkVPInkizvjU7twYbW+8qg4OCapW3xd0G806G9tra8lga7FpM8bwOlu5ZVG51lKPnzFIEbOcE8cHFr/hWmkyQSW15e6hd2pZ5YreV4wsEz53zIVQMHJLHqVBJ2gU+9+HsGpiFtS17V7qeKJovPkaDcwLKw4EQUEFF+6Bn+LdSVr6g7/wBf1/TNzXdai0DT0vLi3uJ4muIoG8gKShkcIGO5hwCwzjJ9jXOyfEu2j1G7sv8AhH9aeW1Wdn2JAQywsokI/e9hIrc4JB4yeK2Lnw/Lqvh240vWdRuJTLN5iXEZjEsWHDx4IQKSpA6r2wd3JPI3PgK9Xx3GLa61z+zLq2uWvL9ZrXiSUxZiwV37WERyQuQWG1gOiW9vX8tP1K0t/WxoR/FrQxpyajfWeo6fYSGZEu7lI/LaSLJMeVcnJCkg42npnPFO0P4qaX4k1C3s9G0y/u5JjIGaGW1dIjGyB9zrMVOBKjZUtkHAywK1neHvh4l/YXsHiO21K0to765exsJJoPLhV2O2aMxbmDbWx8zcEHA7npbPwe1tr9jq9z4h1e/uLKCSALc/Z9kiuQTuCRLz8ifdx93nOTmly3V/6/r+uotdUdJRRRUgc34D/wCRduv+w1qv/pwuK6Sub8B/8i7df9hrVf8A04XFdJQAUUUUAFFFFABRRRQAUUUUAFc34o/5GLwZ/wBhqT/033ldJXN+KP8AkYvBn/Yak/8ATfeUAdJRRRQBzfij/kYvBn/Yak/9N95XSVzfij/kYvBn/Yak/wDTfeV0lABRRRQAUUUUAFFFFABRRRQAUUUUAc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUAFFFFABRRRQAUUUUAFFFFAHN33/ACVPQ/8AsC6l/wCj7GuNHxA8a3iy39ho9lDpnmt5InRHlmCS7GhjVLnc0pGWG5EAI2kc7q7K+/5KnoX/AGBdS/8AR9jV1/CfhyTUm1CTQNLa9aQStctZRmQuBgMWxnIyeetHW4dDi5PH+s28mjOs+lajDcmD7WLS1lVlE0jquC0mEI24x85YhshAM0l1468URaPpNzaQaXfS+IGQ6fHbJ80GY3dkdZJkWQjaF3B0ySfl4APZQeDPC9qFFr4b0iEJ93y7GJdvzBuML/eAP1ANSN4U8OvbXdu+gaW0F7J5t1EbOMrO+c7nGMMc85OTT0t/X3Bre/8AXr/wDzXWNV8R+ILJDrMOj2kmm6tpjLbm3MrwTPJHn96JSvyksCVHIOOOc6Vz8QtftbqG2I0uaS31BLO8MVvIRKrzrCJVzIBEOTwTISysOAM13MXhfw/At2sOh6bGt6gjuglpGPtCgYCvx8wA7HNOfwzoUiQLJounOttF5MAa0QiKPIOxeOFyAcDjgU01dX2vf8v8vx8g6f1/XX+rnmWn+PfGdtGLSGxh1yaEzXlxIsccAMAuZIygMlwu0qI2O4BwAVUqPvHa8H6jNrfjuDW7kaeG1LQVnRbWMiSOMyjbHIxY7yvIzwM5GBjnsT4W8PtJHI2haaXina5jY2ceUlblpAccMcDLdTT7Xw5olhqBvrHRtPtrxi5NxDaokhLnLfMBnkgZ9aS0ab8/ya/r08xSV1b0/Bp/16+RpUUUUhhRRRQAUUUUAFed22rajovgGS60hrVZm8T3luwuoWkUrLqs0ZwFdSCN+c89MY549Erj/C2kabrXhO4ttZ0+11CBdc1RxFdwLKoYahcYbDAjPPWjqrjRgweOfGU91epFpFpJa28stkLt1iiX7RG23cEa5LsGwxEZCn7vznOaj0/x54lkW7kku9FvIrO8toHEdjNBJIJpTEV2tKdrqwyeCDgjj71egyeHdFlvpr2XR7B7q4jEc07WqF5EHRWbGSOBwfSsTTPAWn2Pim71WW00mWBoo4rC3TTFRrJVUqQr7jwQTkKq0Lz/AK/r+thPe6Oc03xfrwsi0U2g2tvBp73kirYShS4nkjIG2UkBmUN0Y5yOc5FFvHviWK6gvbyW0SKyt9R+1WwtWjWYwyRIrH963l8OCclsAN3Py+gWngfwnYGU2PhfRrYzxNDL5OnxJ5kbdUbC8qe4PFT/APCPeHrd4W/sfTImVz5R+yxqQzJtO3jqVGOOoGOlNaPXz/r5B/X4f56nInxP4sPia30FLrRPOadomvBYStG4MBmUhPPBBG0gruOQynI6Vr+FNd1rWbh7fUZbAT2Alg1GOG2dds4kIj25kbClBuwckhlORnFaVn4Y8OC3sptP0DTbc2haSyJ05YzbM3VlUqChJAzjBNW9H02XT4ZnvJori9upfOuZoYfKR22hRhSzEAKqjlj060af1/X9aC1POdG8V+LYIH+3ato00K219fNLcWMylRDclNhZZW4OeCF+UADDVc0Xxt4m1m9uNKRtItdQsnleWS7tpI0uI02cKglYxnD8sWfHGV5wOyj8H+Gob6e9h8O6THd3AcTTrYxiSUP98M23JznnPWj/AIRHw3tiX/hHtKxDIssQ+xR/I6gKrD5eCAAAR0AAojbS/wDWv6fiJp9/6sZ/gK81W/0a+n1m9hu3Gp3cUTRwmPaiTOgByzZ+7xjGBgc9T1FV7XT7OxadrK0gtmuJDLMYYgnmuerNgcngcnmrFDKe7YUUUUgOb8B/8i7df9hrVf8A04XFdJXN+A/+Rduv+w1qv/pwuK6SgAooooAKKKKACiiigAooooAK5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvKAOkooooA5vxR/yMXgz/sNSf8ApvvK6SuS8cWs17qnhG3tr+40+V9afbc2yxmRMWF2eBIrLzjHKng9jzWFCfEWqateweHvFGtX1nptwba8uJJNPiYyhQSkSfYmDkZAO5kGeMnmgD0qiuIht3kvI7Gb4latBqTQCdrCQ6YJ40xkkp9mzgeuMVQm1fSoDY7vi7eMl87pBKkullGKAlvm+z44xj6kCgD0aiuFJthZfbD8WL0WuUHnmXS9mX+5832bHzdvXtVQXfl61eWV78TLy1jt3iijle60rdJK6k+WU+zZVsDIB+8DkdKAPRaK4Bbq1k1Ww06H4p6nLcahC89qIzprCVF6lSLbnv064b0NSlrVba3uG+LN6IbmUwQSmXS9ssgOCin7Nhmzxgc0Ad1RXlkHiOxvNRWGy+Kd3Jbxic3cz3elRtbeWduTGbbcVJz83TAB7ito/Zxp898fivfCzt2CzXBk0vy4iQCAzfZsAkEHn1FHmHWx3NFeb2U2q33j2bw7D4y1t4F0yPUYb6I6e4lV3K42/Y8ds5DHNdJ/wi+r/wDQ9+IP+/Gn/wDyLR0v/XYOtv67h8OP+SWeFP8AsC2f/ohK6SvK/CUcen/DvwwdR+JN9pHm6LbTpbSPp0apH5Sfd8y3LFRkDJJPTJJrauXtbK8a0vPize29yqqzQyy6WrgMQFO022cEkAeuRQB3VFcM/wBnjZVf4rX4Zrk2gXfpmTOOsWPs33xnleoolFvBHeSTfFe+jSxcJds8mlgW7HoHP2b5SfQ4oA7miuUOiXosPtx+ImtC0Efm/aNmneXsxndu+y4xjnPTFUN1r9nE/wDwtm98k2/2oSebpe0w52+Zn7NjZnjd0zxQB3VFcJvtPMjT/hbN5vlEbRr5ul5cSfcI/wBG53Y49e1QXV3b20AuR8Vbt7ZUmklcT6YWCxD5yqi1O4qcAjIxn8KHpuB6FRXm+n6rY6hCLmH4tz/ZnCiNxdaWW3lSzIw+zYUgDOMnjPTFW7yex0+K2kv/AIuXVrHeJ5ls802loJ1/vITb/MOeop2d7CTurmzff8lT0L/sC6l/6Psa6SvO7zw7qg+JGjRf8JprjO+kX7rOYbHcgE1nlR/o23B3AnIJ+UYI5zDrGoSabPElr8R767Ed7Ha6h/pGmq1kHzhmUWh7joxXjPPFLrYfS56VRXm3iK9m0bQIdSsviNf3xuNrW0Rn01PtKZG4xkWjbyAc4A59R1rQn+z2011Dc/Fe+hlsyouUkk0tWgLEBd4Nt8uSQBnrmgVzuaK4QPasBs+LN4xKyMP32l8iP/WH/j26L/F6d6ZZSRXX2eFvitcm8lCDyILjTJMuybwqn7KC2V5HAyOcUDO+orzme4uXutMXRviFqeqwXl+bCea2l01vs7+Wz9FtCCfkwQSpGa0DFGupf2e3xU1AXvm+T9mL6Z5nmbd2zb9mzuxzjrjmgHp/X9djtqK4FpYnA+x/Fa5mIufsz5uNMG1+SycWp+cAE7eOnarenWn9sMy6R8UNTvmRFkYWp0yXarfdY7bY8Hse9AHZ0Vzf/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLQB0lFc3/wi+r/9D34g/wC/Gn//ACLR/wAIvq//AEPfiD/vxp//AMi0AdJXndu92nw+uDapevD/AMJFqAvBp+/7R5H9pT7/AC9nz5x/c+bGcc4roP8AhF9X/wCh78Qf9+NP/wDkWuZ8K6PeW3ha9vLnx3q+n20Oqan5rslgsa7b6cM7M9ucZILHnGScADACY0U9RXVA/k2UnitgsELaPMwucMN7eaLjAHO3AHnDdjG3581mWeo6xa6EUD+K1lm0lfNa7t70nzhcBQoZlJRihIJT5yDkBmxW14f1lNYtLlrz4m3dnc2rzmSFbrTJMQxuV87JtFOwgZ3YwM9afqcOga3ZS2F/8XLqSPcCwS802NkZRvBV1gDKwA3ZBBGM033/AK6/16i8v60ZzNha+JZNSgW11vXLO1aTzYw9rqd60U/mE+SxleNgnl7AGlTyzljwRmrd3pt1Ne2kuq2/iie1tNTWW4uoXv1kbdBOCViQl1IJjBMRKc4G35hXR2mm6boVlbxJ8VtSijuojcQyXN1p0j3CKuTJ5kkBaQBR97J4HWrBmshZT3f/AAtu8Ntb7POmEullY94ym4/ZsDcCMeueKeysC3v3/wAv+Ccxptx4ju9J04XC+J4tQSzthYM8d0iGRXInFyCME4A5l6jBQ5rU8B3Wox+IdOiuB4kaKezvBMdTgvDGrLcfuMtKMK3l7+cgkYznitFpI4Ybm5u/irdQ2kMqw+ebjTMByoO182oCtzwMnIwe9bH/AAjWq7N//Ce6/txnd5On4x6/8etPm1v/AFqv+DcTVzpqK8x0rWF1HxFeaU3xNukKSIlk8V1pkhvdwOQq/ZB8ykEFQW7c9quvf6XHt8z4w3Chk8wE3GlAFd23Ofs/Tdx9RipGeg0V5pd6k1tq1pGPiTevpkyzrNqH2jTQtvLFtyjD7Jt/i7sCD2rYSzMmpPp0fxP1N76OLzntVOmmVY/75T7NkLyOelAHZ0V53bX1nqOpQ2WkfFyS+ndm8yGK70tpAoUklUW1JYjAyOMDJzxg6mm6bLrNqbnR/iXq1/AHKGW1GmyqGHUZW2IyPSgC54D/AORduv8AsNar/wCnC4rpK878F+HNUm0G5aPxprkAGrakpSOGxIJF9OC3zWxOWILHtknAAwB0H/CL6v8A9D34g/78af8A/ItAHSUVzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLQB0lFc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i0AdJRXN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItAHSUVzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLQB0lc34o/wCRi8Gf9hqT/wBN95R/wi+r/wDQ9+IP+/Gn/wDyLWRqejX2neLfB8t54l1TVUbVpVEN5Haqin7BdncPKhRs8Y5OOTx0wAd3RRRQBzfij/kYvBn/AGGpP/TfeVi3XgvWbO31vTfD08KWGtXUl2bj7fNa3FhM4GWj8tT5g3DdtLJ3BJBra8Uf8jF4M/7DUn/pvvK4e/8AEPijSV8bavF4iuLuLw1eL5Vhc21v5U0JiSRkLJGrhvnIU7uwyDzS0v8AL8Lr/gDV+nf8dS1J8NNdbXrGd7vT7qzsrl3H2iSZpLmNrQxMZSdxdy55JY/LgAjAFXV8D6/HqWlXqy2Mg083kaQS3LkrFLEqRjzfLy5BQZLDODjLbcl/h34lR37ESWWrXE13qMkEVu8FvG1oqrGSpIlw4G/PBLkZ+XCmrV38WNDtLC7vGtb+SG3ikniMaxH7XFHIIpJIwZBwrHBDbSeoBFU02rPqv0/r8SU1pbp/wf6+4ybP4daxY+E/DMUK6Z/a+jQSW0yCd1huFaNowxk8rdlQxYAr3YZ5zWQPhZ4ps7hLe2OkXlnHNpbia5vpVlcWa4OUELDLc/xHHHWtn4hfEO4svCuqx6Cmp6frFnatd7zBCRDGr7Vdw5YFHIIG0E/7uDV65+L/AId0+W/tJnmurvTLVp50t3hLOUUNIqoZA2VBzyFBwQCSCKfM23L5/dr+DDlWi+X32/4Bh6P8LvEEMHlahc2EHm6ZqNhI9rcSO0f2ibzUdcxrnGSCOOmQTnA0tL+HmoabpdibaOzt9WR1N1dHUbm53fcVz+9B3KyxqPLIABC4b5Qa6Cx8dW9/4hi0eLR9WSWRBIZZoo0jVCMq4y+XU9MoG2nhttdRRqv682/1YN3/AK72/wAkeOXPwx8Wx2NvaWQ0WZILbVLbzJb6WMsLtyVbAgbBUdRnn1q1pXw88WWTzqRoUMU8lju2zSSsqQQeU+wmJdjE9COcEjjrXrNFT0t/W9ym7/j+J5r8P/AGu+FfEFnc6nLp8ttb6FHphaCd2cukrPu2mMDbhsdc8V6VRRTbb3/q7uTb+vlb9Dy7SNC1nVvAHge40m302WO38NiJjeXLxsHltUVcBY34455HWqr/AA38U3VvH9pbSI5YoGhRYrqQx8xRgEgQrk7ohljkkHqMBT2/w4/5JZ4U/wCwLZ/+iErpKS02/r+rjetrnnEngzxPNqeoXo/sq2nvLwTrNDdSMYkaOFXQo0W2QZh6EDOQQUIxVLTvhlqul28aW62klzAywm9m1W6kkuIAxJIV1Zbd+c/u85yQCmc16pRR5Ac34LsdR0bQbXQNTtoNmm2cMC3MMrusxCkHhkXHQHgt15rIHg3WLexhFtLYyzaZfLJp0MjMkb2yFykUhCkqQJMZAYDy0PNd3RTbbfM9w6WPJ7/4deJHt9Shs7bQ3W/s5I/3t5KnkSSXJmZVAhOUG7APBJGcDOBZfwZ4tutdvZp7bRILS7nuJcx38rugktVgA2mAA42Buo647ZPp9FLpb5ffqH2ubrueYw+E/GZ1i2ubnT/D/kxXFnKwGqTMwEEbJxm2Ayd2e2MY75rn00++0nxDZ6dqzaQt3CkMkmnwas0b3xSeSaPy1e2LS7C2QEMfOQxI6e3UU02nfzuLlSVl2sc3ff8AJU9C/wCwLqX/AKPsa5U+AfEX9tNqZOlySRyLJFEbh1jfy7hpUXaIsRghzkgMQRk785HVX3/JU9C/7Aupf+j7GsLWvH7vrMNhpcGp211aX8AmtzHBm9hkdo8AMxZMleN3lnofu0l8S7hL4HfbqZ918Odfht9TXTjpM51ePdPHcSyRrayfaHmAiwjblJkIJIU5UNg9KTVPh94kvtDlsAmjs8Ed0ltM1zIDOLh9zCX90doXJ6bt5APy1f8AEHxDF14duG8Px6nbX9uVa52wwk2JExjKTByQQWR1+Td0yCB81aOofEvTdOhnnl0vVJLZFkeG4jjiKXQjbbKY8yA/LycMFLAErup6g/id9+pgS+DvGA1O6vLaw8PgzauuoBDqUwwotfICZFv/AMC/T3qlF4A8aR6J9l+y+HTcJFpsSM1/MysLRixJ/wBH/i4GOcc8muvHxEtGuntjo+rJNHcPaOGSEbJhF5qpnzMZdOQeg6MVPFV9P+JNg8Fqr6frMkbR2ZN3NFCci5X907BH6lvlIVeD22801e33f8Ab6X8/+CY+l+CPFWn6nYXDx6TIq3tvd3ROoS5Ty4GhZY18gLjDbgBsAxtx3pb+0fxN8Q/EOkadLpTKjafLdySTbp4PKYyALGFOckY5Zdu7POcVpjxwda1TTE0v7Zp5i1dbO+tblISZEa3eRc7S5XopxlWHRgOlal746tdP1i5sLrStTCWs8EM12scbRJ53Eb8Pu2lvl+7kHqAOaW/9elv0Da3p+r/4JyNv4F8YWE0c9vFotxJ5tnLIsmoSxIDblxtRVgIVWDLhQAF5GD1N3QdB8WeGbrTLh9L0e4jgsvsUy2+oTb8tPvLKPs+DxjqVGSckDmtOP4iWd9ObeHT9Xt54b2C3kj224ceYCU3AudqttwQcOMjIXrWl4f8AGlr4ikVINN1C1eS0+1xLcrGPNTcVIG1zghhg5wOcgkc0J638/wBP8iWlqvT89PxOjoriJvihYQQ2Mr6JrGy9h81dqQEx4nWBlYebnId1zjPB4zzSn4nWgvriyPh7W/tVrHLJPCI4CYxGU3g4lwSFkR+MghuMnK0v6+7co7aivPJ/jX4WXUDZ2X2jUX4C/ZJIGLHIDDY0ocY3D7yjPO3OK720nkubSOaa1ltHdctBMULxn0OxmXP0Jo6XFdE1cBpulXmreB5U0xrf7VbeI7+6jjuiRFKY9SnbYxAJAOOuDg4ODXf1zfgP/kXbr/sNar/6cLijzGcra+Hrq21S00+7n0yHU5tQupprazmaUyafOzSOGUqpUbgFDcjI9TgUvENjf+G9b0d5ZdIRLjWIhp9lcXrBXfZOT87Rl0G6QAKPMAOCMZ2163RR28v6/rz1He7fnf8AH+v0PJB8MpNGuJtT1SS0ns/+P24Z9UubaOxkR3l+SJMRyoC/G/bjk85xTPCXhvUtd8G6HrFmmlB4NKgt7I297IpbapJdpFj+Rwx2ldrj74Oc4Hr1FO+jX9df8xf1+R5bP4C8WXcd9b3L6P5V2UVp4Z3jkI+yeQxAEP7vkA7UIyCV3ADnqhpuqav4L1Hw/fRRafL9j+xxXMEryqxMQBb5kQ8EnpkEd85A6iii97+YbNPseXaho2r2kt1dak+iadq15JaPpKWlw8jNcwgqVCMiFlKEg4OQpIPAzUfxF0G40fwzrF7HPY2ulJp0iTtNOS07eR5SDYylQ5Y/fVgSMKQ2cj1Wii7CNkzy5vCXiPUtX/t+0t9AZLyzkQRx38nljdAI43VhB82RyTgYBAGcZMDeD9f02zk1LXE0t4rSwuIXhguJXV0e3VCSgiXcd0YyT8xB6jGK9YopNLW3X+v1FHS3keM6Jo+ua6baXR5dC1GOGVpp9SOrfbEkJtnt1TCWsaHaCCV6kAAnJzXd+BvDmpeHxqjaq0DPfzx3A8q4aXawhSNlyyLxlMjAAwcYGK6uiq5twOb8B/8AIuXX/YZ1X/04XFTL4e1NWQnxhrTBZC5BhssODj5Ti36DHbB5PPTEPgP/AJF26/7DWq/+nC4rpKkZU0yynsLMQ3Wp3WpybiftF2sSuR6YiRFwPpmrdFFABRRRQAUUUUAFFFFABXN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033lAHSUUUUAc34o/5GLwZ/2GpP8A033lZ5+GVjNfanLfa1q15a6rcrc3tjK0CwzMoAUHZEr7QFUbd2DjnPOdDxR/yMXgz/sNSf8ApvvK6SjZ3A4+D4b2EK3sb6rqc0N7qH9oSwyGHb5m4NgYjBAyq8g7hjgjJzVu/hLod3Y3tobzUIobiF7eJY2i/wBEikkEsiRZjPDMBktuI6AgV3VFG39fIOtzkfEfw503xNHILy/1CB57D+z7qS2aJWuYgdw35QjIbJBUDqe3FNk+G+nvpWtaamqanFaa0mLqNHiwHKhHkXMfDMAMj7vcAHmuwooDa3kYR8K28k2lSXF9eTnS9hiDmPDsqlQzYQYOCc7doOeQRxW7RRTvcVrBRRRSGFFFFAHN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQBzd9/wAlT0L/ALAupf8Ao+xqiPhppyXDzxapqcc28yRSK0OYW80yqw/d/MVYtjduyD827jF6+/5KnoX/AGBdS/8AR9jXC6v4j1LXfEVrZzJpjC21K2n027Fq+IyZ5Ijyz7n4XqBGDkgZHNJfEl1FLSDb2Oru/hlplzFMsGpapZNdReXePbyx5uz5hkDvuRhuDsx+UAfMQQRxTbr4Y2F3p1xYvrOrLbyCQQorw/6L5jbpPLzEfvc/e3YBIXbXJeIPFWo+JfDuqaZfx6UjaZsa5d4mYXTC6aJXgBb5MGLOTv5YLn+KtPVviF4gtdLl1OyGlNBMt0beGSGQvbm3fawlIkG7cARkBdhI4eq1CWkmma83wxjmuZrj/hKdeSaa9+3M6C0/1oi8oH/UYxs4x+PWq6/CO0XTGsf+Eo1/yitsitutQyLbkmIAiDsTnPU4HNQHxl4jTU7iynbSMQ6m2ms4tpPnLWvno+DL0XhSv8XUFOlUNP8AHut22lWtx5eiQ6fHBpbmCK2kjCJdDYVBEhChCNwO0/Lxj+KnZ2+78dhvS1/P/gnQ2fwytLC5sZbbXdXUWc0UwjAtgsrRoY1LAQ8fISpC7c5z15qN/C91rXjzWJtUj1K10lvsrRqssHkXrRZIJA3Sja2CPuZxzkVh2niC+8RavozazDaGay1yH7PPBbtFmOWzkfgOzN3xk7SRg7V6Va8dalPqerR2Sf2ekGk61poC3ERedpZJUYSRncAoAYr0Jb5uRjks3JJ9/wA7f5hsrrtf8zQX4VWcKwiy8Q61aGEwlWi+zEkwljGTugPTeR74BOTknT8P+BovD1/a3MOtapefZrRrRIrryNpQvvydkSnOe+e1cvD471PTNHs72WDTo7JIZHmjs7RsTzb5RtXEh8nJjyNysGLEbgRg6zeIvEayWNgL7QTd6nG9za3awSGFYlQNsZPNyWOThg+CFZtvGKm+7/r+rfgK17ef/D/n+JneK/h3LBpCzaBLrN/dRS7IbWOe2URxPcxzOAZAo+Ux5UlickA5HSS58D3jeMrNYZdZFpPZ3P8AaOrrLah55JTENjjGQCkW3MaDHy4I5IrWXxB8SX6w3KRaXFBNc2UAheGQun2mMEZbfg7WOc4G4cYXrWNret32sXen6jro0y7ttOsr+Z7UW0igz29ykQmR/NzGehB+Yqu8ZbdkVFNO3qvwu1+vmxt6fj+On5fJHbXHw1s3sJtO0/W9X0vTZZRMLG0aDyo3DbiV3xM2CRkqSRnsK6aztryG+u3ubx57eTZ5EbhP3eFw3KqvU84JbnOCAcDiD4n8WHxLb6Cl3onnNO0TXq2ErRuDAZlITzwQRtIK7jkMpyOldD4BudTvfBdlda3eR3l3NvcyxwmPjccAgs3P4gdOBSFddDo65vwH/wAi7df9hrVf/ThcV0lc34D/AORduv8AsNar/wCnC4pDOkooooAKKKKACiiigAooooAKKKKACiiigDm/Af8AyLt1/wBhrVf/AE4XFdJXN+A/+Rduv+w1qv8A6cLiukoAKKKKACiiigAooooAKKKKACub8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8oA6SiiigDm/FH/ACMXgz/sNSf+m+8rpK5vxR/yMXgz/sNSf+m+8rpKACiiigAooooAKKKKACiiigAooooA5v4cf8ks8Kf9gWz/APRCV0lc38OP+SWeFP8AsC2f/ohK6SgAooooAKKKKACiiigAooooA5u+/wCSp6F/2BdS/wDR9jU91ofhWCTyLvSNJV9QkeEo1pGTcM/zupGPmzs3HPXbk1Bff8lT0L/sC6l/6Psa4O78AX8viSK7i8MwMkWoCc3Uy2zTlmSceZu3AOqNJGcsBJ8n8e1TR1GldM9MvPDGg6hFBFf6Jpt1HbxmKFJrSNxEhGCqgjgHA4HFRyeEPDcy3Qm8PaVILwKLkNZRnzwv3d/y/NjAxnpivMbrwTqsmkRmLwg8cqSWX2q2juLfN1PFMHku1YyAZKBl3MRI2/BAAzVabwprtsqjTvAM7f6ZeIVNxaKos5GBjjwJxlBkny8hcjnrTf8An+n53F0+7+vkenS+APB0iN5nhHQ5MsXKnTYTub15Xr71naB4X8D67oKXdt4J0i1gndg9tPpluGDxuyHcFDKSCGwQT1965fQfBupaa1tBrXhiTVLO3kl+wok1vGbB/tDyJIoDqEUo6L+75XYQFIPN7wToer6Z4osrq68M3GnrLbXq3ty01s2We58yENslZmwu4DAIG/600kKV09DcvNI8J6d4i07T08F2Ut0Ld7iylhsLYCPymX5VLEFWBcEcAe+a3NT8NaBrc5k1jRdN1CXyxGWurWOVtmc7csDxkZx6ivJ9f8Ga7PN5i+DG1C9Bulnvkubb/SmaaN4Zf3kin5VTAyMqQABjmte58KasdWu7hPC63OnzXQuL61na3M2oKWfMe4OFkC7lOJQuNgXcw5qd0h7bHf2fhXw9p7QNYaDplqbYsYDBZxp5W7723A4z3x1pP+ES8Of2e1h/wj+l/Y2l89rf7FH5Zk/vlcY3e/WuEu/B19LfKsPhtlRWtn065NxE7abChHm2xy+751DDC7kO/BOADXN/8IRrSaIYLfwJcxz/ANjSQAC4s8C7EuYXz53VFztbqoOB6U1q/wCvX+vMOn9f11PRP7O8I6p4uurJvBtpdTxyA3GpNpsDxidUVgrP9/eEcEEjHOAc8Ve/4RLwVoGdSTw5odgYgR9oj0+JGXd8uAQuec4x3ziuCt/Cd7JqepX118PW+x3Wp/abmwkay33kTQBBnEpVikoZ9rsB8+4EtUA+HF1NZ6zFqvhOK/ufstmba4n+zSmZ43JdVZn3bthVNzhd2zk4xRayXov+CK+p6jB4T8OWptDbaBpcJsWZ7Ux2Ua/Z2blimB8pOOSMZp9j4b0nTNTe+03T7a0mkjMbfZ4Ej3AtvJO0Akljnknkn1OZNGvY7yzdYrCWwS2kNuIZPLwAuB8vlsy4/HjGCARitCjqMK5vwH/yLt1/2GtV/wDThcV0lc34D/5F26/7DWq/+nC4pAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+A/+Rduv+w1qv8A6cLiukrm/Af/ACLt1/2GtV/9OFxXSUAFFFFABRRRQAUUUUAFFFFABXN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033lAHSUUUUAc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/klnhT/ALAtn/6ISukrm/hx/wAks8Kf9gWz/wDRCV0lABRRRQAUUUUAFFFFABRRRQBzd9/yVPQ/+wLqX/o+xrJ0v4lWFvpVy3im48u7tJ7pZGs9OuDG0cU5i3gAP0+UsAx27gTgGta+/wCSp6H/ANgXUv8A0fY1gp4MvNGaO91jVodQsYWvvtFra6NK8ky3cgZlULK5GDj+E8Zz6gKVrfP/ADN29+IPhzTtSuLC8ubqO5t4/NkX+zrhgEwhLBhHggCRC2CdoOTip5fG/h2G8a3l1JUKxtJ5pifyWCrvYLLt2MwX5ioYtjnFcSNA1ePXNA0mC4uoZn0W5ivb+4017hP3jRfIZF2osm1CASTjaMg5GdkfDaWG1On2WuPbadDJJc2SJb/v7ed42Td5u/5lG9mC7Qc/xY4p20/ru0T11/rQ1m+IPhtNPF5JezRxb3R1eynWSLbjczxlN6KAykswCgMCTyKg1X4jaNp6kQLe3b/ao7bdBYTuhLvsLKwTDgHOdueRt61z4+D0JvEu559HvJBM8jQ3uiieDEixiTCNLkNuj3Bt2RuIO7rWlP8AD28Mk0llrVvbHzoZ7eMWBEQeOUSbpI1kVWJxtyuw467jzRpdX+Yneztv/Vibw/8AEKyn0cHX7lY9RjMvmJb2UyrMFmaIeUvzF2JC/IpZgWA7ir0/j/w+lrHNFdzyLLCZleGwnmEYG4fOFTKtlGGxsMSpGODjk734QX2pppq6nrum3S6f57LHLopeOR5ZvNJdGnIK5AG30zyDgjWu/hzctZW0Ok6jpukNFC0bfYdJ8lMndkKqSr+7Jckoxf1BByaUvh8wjo9TfsPF+j3mo22lpfGa9miVwyWsqROTGHwGIKhtpDbC24A5x3ov/GehabqElld3UoniBLCO1lkXcF3lAyqVMm3nywdxHOKw9K+H1/Y65pepXuuQ3kmmhVjBsWU7PI8pkUmU7VPD4A65zuyMT6j4FvLy7vfs+sRRWVzcm+jt5bMyNFc7NobeJFzHkBtmAc/xAcU5b+6Eb21/r+mXbf4geHbya1htry4D3uzyGk0+4VDv/wBWSxQBQxyFJIDEEAkg1d8J6pdaz4Ytb7UfJ+0yF1kMCFEJV2XIUliPu9MmuZm+HOozQaOr6/bu+kw2yweZp7MiyQPkOq+d8u5flYZJ4GGAyDteFNH1nw/bx6bf3tpfWcUbsJorMwN5jSFscyvkYb0HQcnOA3bW39Ilc2jfb8ep0lFFFSWFc34D/wCRduv+w1qv/pwuK6Sub8B/8i7df9hrVf8A04XFAHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/AJF26/7DWq/+nC4rpK5vwH/yLt1/2GtV/wDThcV0lABRRRQAUUUUAFFFFABRRRQAVzfij/kYvBn/AGGpP/TfeV0lc34o/wCRi8Gf9hqT/wBN95QB0lFFFAHN+KP+Ri8Gf9hqT/033ldJXJeOJL6LVPCL6Vb29zdjWn8uK5uGhjb/AEC7zl1RyOMn7pyeOOogm8WeILe4uYLiz8IxTWkfm3Mb+J5FaFP7zg2nyjg8nigDtKK5H/hIfFH2GG9/svwv9kn2eVP/AMJHL5cm8gJtb7Jg7iRjHXIxVr7d43/6F7w//wCD6f8A+Q6AOkorm/t3jf8A6F7w/wD+D6f/AOQ6Q3/jdVJbw/4fAHJJ16bj/wAk6AOlorkNN8R+J9Zsxd6Rpnha/tixUTWviSWVCR1G5bQjIq39u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQB0lFc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHQAfDj/klnhT/sC2f/ohK6SvO/AN54xX4beGls9C0OW3Gk2oikl1qZHZfJXBZRasFJHUAnHqetdB9u8b/wDQveH/APwfT/8AyHQB0lFc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQB0lFc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQB0lFc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQB0lFc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQAX3/JU9C/7Aupf+j7GuO17xfqLa9Z6rBYS/2W9rdosa6tLD9oRJokLsirhHBLFcZJBwWXpWjeXnjE/EnRmbQtDFwNJvwkY1qYoy+dZ7iW+y5BBC4GDnJ5GADSv/h/eajK8lz4P0cF3kcrD4vv4VBchnAVLcABmUEgAAkZxnmhb3DpY0b/AOJV5Z6rqNlFodvMbQb42/tA/vFE6wtuIiKq2XBChmOPvbDxVPWPEviK/nEUmmW9hLpWuWls7WesysJmfy2CEeUgZCspB3ZwRwD1Ed14Bv7z/XeE9LHzM37vxlqEf3mDsPlgHBdQ2Om7nGSTUknhfUpNQmWTw7pJurm5TUXj/wCEzvwzSR4VZNv2foPlHHHC+gpxsmr/ANap/lcUtVLz2+7/ADLp+J0o025vBoyMulxNNq6i8ObdFlkjJi/d/veYXODs4x3OKi034pzatYXN7ZeHrhLYxxyWVzdma3hnV32jc7wgBuQdsfm5B4yeKr23gjUbRozD4Q0f5GZj5ni2+fzNzbyr7rc+Yu4ltrZAJJxkmp18J6wkMkSeFNHSJ5RMqJ4svVWFg2790BbfuhkchNoPel1/r+v6+5vy/r+v68+x8Na1/wAJF4ZsNW+zm2N3CJDCxJKHuMkA9fUA+wrUrkNMh8WaNp8djp3hnQIraMkpGfENw+3JJIBa0Jxk9Og6Cp5NW8YwyRRzaH4bjeZtkSt4gmBkbBOAPsfJwCcDsDTe+glex1FFc39u8b/9C94f/wDB9P8A/IdRzat4ytwpn0Pw5EHcIpfxBMNzE4AGbPkn0pDOoorm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorlrrWPGFjaS3V7ovhu3t4ULyzS+IZkRFHJJJtMAD1NLDqvjK5t457fQvDksMih0kj8QTMrqRkEEWfIPrQB1Fc34D/5F26/7DWq/wDpwuKPt3jf/oXvD/8A4Pp//kOuX8La34l03w5NJLpnh2GB9a1CMSXevSQ5la/mBQf6KQfnJVecsMHAJwAD0yiuXh1XxlcBjBofhyUI5RiniCY7WBwQcWfUHtUn27xv/wBC94f/APB9P/8AIdAHSUVyVlr3ivUonk07SfDF3HHI0TvB4jlcK6nDKSLTgg9R1FWft3jf/oXvD/8A4Pp//kOgDpKK5v7d43/6F7w//wCD6f8A+Q6jg1XxlcwJNbaH4cmicZWSPxBMysPUEWfNAHUUVydzrviyykgS80jwxbvcyCKBZfEUqmVyCdq5tOTgE4HPFWPt3jf/AKF7w/8A+D6f/wCQ6AOkorl4dV8ZXAYwaH4clCOUYp4gmO1gcEHFn1B7VJ9u8b/9C94f/wDB9P8A/IdAHSUVzf27xv8A9C94f/8AB9P/APIdH27xv/0L3h//AMH0/wD8h0AHgP8A5F26/wCw1qv/AKcLiukrzPwtrfiXTfDk0kumeHYYH1rUIxJd69JDmVr+YFB/opB+clV5ywwcAnA6j7d43/6F7w//AOD6f/5DoA6SiuSXxB4pfU301dK8LtfJGJntR4jl81UJwGKfZMhc8ZxirP27xv8A9C94f/8AB9P/APIdAHSUVzf27xv/ANC94f8A/B9P/wDIdH27xv8A9C94f/8AB9P/APIdAHSUVyl5rXi7T7OW7v8ARvDVrbQrukmn8QyoiD1LG0wBUy6h42dAyeH/AA8ysMgjX5iCP/AOgDpaK5efVfGVrA81zofhyGJBlpJPEEyqo9ybPipPt3jf/oXvD/8A4Pp//kOgDpK5vxR/yMXgz/sNSf8ApvvKPt3jf/oXvD//AIPp/wD5DrI1O58RzeLfB665pWl2dv8A2tKVks9TkuHLfYLvAKtBGAMZ5yeg45yADu6KKKAOb8Uf8jF4M/7DUn/pvvK4LXLptF1PUIbXU7LUdOunu7iXTruMR3emsUkD3CN3hLAjLDGGwG7V3vij/kYvBn/Yak/9N95XSVMldWKTsfOtp41jsvBWgw3PiqO1kt30oJpk7WUtu9sfLDSjdFvBUhyfmyhXPTFdR8P/AIh6hq/jPT9OvPE1vqlvdnUkCYgBPkzKIWBjUZJTcfQgZxxmvS5fEdtD4wt/Dj29x9pubN7yOYBfKKoyqy53bt2WH8OOeta9bc13zNb3/wAvwa+8ztaPL2t/X4nj/iDx/qVp42vLW016WHT1W+tpfMtoY0tJYrdZUZS6kk5J5Y7W5wvGTk6P8T9cutNkjl8QwTZg0qW5vVSANYJOCLiTAXbhTt++CFLZPHFe4XV3b2UIlu5VijLqgZjjLMwVR9SSB+NTVEdFr5fh/mU9fxPPfg1NFN4W1YRXC3BTXb4MwIJOZSQTjpkEH8a9Cooo7fIOr+YUUUUgCiiigDi/BWpXVj8M/Bsdtot9qKy6NaB5LV4FWH9yn3vMkQnr/CG6Vt2euahc3NvFP4W1azSXO+aeW0Kw4z97ZOxOf9kN15xVT4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQBzV/z8UtD5x/xJdS5/7bWNeZ3/jvV7HT1f8A4TjM8N5cW94kkNqDbol0Ujd/3YwWXjnAPVQME16Zf8/FLQ+cf8SXUuf+21jV/wAOaAnhvS2sYr67vlaeWfzLvy94aRy7D5EUY3MT07/SgHtY821fxhfaHNc2N741lha31Yw/aLiO0VjbSWfmRux8oIB5oIVsDJBHPSs+/wDFF3eaAkM/jqWZr7Q7fUZQhtFMB86MSFdsQ+TBfO7PQ9s17Vd3UFjZzXV5KsMECGSSRzgIoGST+FUNH16DWrjUoIbe4gfTrn7PJ5wXDkorhl2sflKup5wfUCmv6+6352YSTdn/AFvf/gfM81PjPU7d4LIeLVku1ur+0Y3UcC79oLW7MUi4YrgjAwwOdrAV2/gvXoNZ0GOH+12vL0CRi8rwGZo/MZVlAj+RlOOHAAbHQciunqL7PF9q+0lSZQmwMWPC5yQB0GcD64HpS6WDrfzPEdV+IGqWbaJHJ43a0lbdBerJFaKGlS9jibdui+VvKkZioxgKGwBnN618Q3fhzxvPYHxjPqN3PrE0LaZetahp1+xBo2wkSuMuEUbSFPAxk8+y0U09Lev42/IH/X3WPGNY8dahb+GRc6P42a+vp4JLhYRaW6+RNHHua3ZthA5/5ZFTLwfmABIs23jpnuDqC+O0ntV8QR2KW6m0aKSJ0VtuVj3nBLAEMDhecnJr16qs+oQ2s6x3YaFZJEihkcjEztn5VAOcjHOQP54Lq/8AXdf8N8xNe7b1/J/lucH8PvGr6lqV7b6zr8Fykwt5LAztDHI7SCTdGqoB0MZGzLsuCCxOcQa/4nuLTxL4kgj8Xy2sWnJZkW0Udq3kGZij7i6ZUD5TuYkKWyQwwtekT28U4TzxuEbiQDcQMjkE+uOvPcA9qlByMjkUOzYHjkHji+bTbGXXfEKKvlTwXEMTQAu6PMrPKCikqFVctGV29WQAjGp8NvGNgJrbQbvxNZXJOlWElnBJPCriR42DxIFwWwFQ4O5hu64Ir0+opreK42ecpYRuHUbiBuHQkd8Hnnvg007X8/8Ag/5icb2fb/gf5EteXX99aaf8KL2a/uobaIeJrr55pAg41iQnk+wJ+gNeo1zfgP8A5F26/wCw1qv/AKcLipLTszjdO8X315CmoW3iqS/spL690pPs0ds6+cWY2rllj/u4A7HKEg5Oc238aeL7Sa/Oo61p5itJTa3kLOrXdkgmVPtRhWBdi+XuclmZDkEYHy17RWbY63Dfa3qOlpbzxy2CxO0j7NkqyAlWQqxOPlIOQDx6c01/X9ff/SBvX+v6/rzPJbHxa1rJqlpZ+LkhX7XdTQ3/AJcLm+uAI/LhYbdvzqc4QKz9UIArrvEmvanDq3h+1h1Z9Ovr6xnnfTI/ILTSoiuEHmIzctleO2e/I76il9lL+tv6+4S0d/X8X/X3nhcfiTXNSi0m+17xrZ2Vj/aSebcWF1CzWbG3mLRzGS2VEwwUBHDMMnJJ2kbGgeMr7xJY6er+NBp93JYxNbrFb27nUnIYSlQUOXVhjCYCkZZSDivRf+Els28QW+lQpLM8/nL9oj2mNHi2lkPzbt3zDoCOozmtem2mtB/oeI/8J6t7eeHo9Y8RwS+bHplw0UvlJtufMdZ9uACSCo3Lk7Txx0pbHx/qF3qdtY3HjX7ML67tvs7kWayvHKsqyKEMZC7XRQBlypOGZicV7bUE97b21xbwTyqkt05SFD1chSxA/BSad1r63/L/ACsS1rddrfn/AJ3PK4fGt0dPt3/4Sw3aWuq3NrK8X2bz7nZMFjUjYEb5DkqmxyMEZwRXqtne2uoWcd1YXMN1byjMc0MgdHHqGHBqaooIIbSFYYRtXJIBYkkk5JyeScnOaXSw3u2S0UUUgPLr++tdP+FF7NfXMNtF/wAJNdfPNIEHGsSE8n2BP0BrHj8b+KnvJtQvPEGnWllbX0QvbCOZJJrSP7SqHzENuDFGY2JLM7EkBlYLkV6L4D/5F26/7DWq/wDpwuK6SnHR3/roN6qx4VH47X/hOQLnxEpkiju7Oe/BgE1nCLxdjmMrtPyhRkrwp3nIFbc/jnWo3mmtNVNzKHmTUtP8iMnR41lCrMAF3H5MthywbquACK9ZBBJAIJHX2qvqN4NO0y5vTDJOLeJpTFFt3uFGcDcQM8dyBSuoxSfT/hwteba6s4B9Q1iFrKfTPGVzrmn6msthb3UFrbMsdw3zRS7kiw2AGBI+TIHAOaxLbW73R7zUNNu/Gdzbq19eb7+6S2ZlnTy/JhI8oKPMViduMkKAmK9EW5tb6807Vrq4u4LaRIjZ28vlCKSWRTggKC5cKxBBO3uAcZG3DKZI1aSJ4GYkCOQru4J/ukjkDPXpTaaf3r8v6+4lNNL7/wA/w/4NjyO98V3moeGdcbxJrsWkX6aZMs/h6WONRta3ysoJHmcu33txT+HG7mlTxxfy615OkeIrc2T2bxRLJ5QjilEMbxldqM5yCx3MSCOQhCkn1+ii4+iXb/gf5Hhd/wCLprJxrEnji7tGXTyLb7U1lsvCt0VbbiMrICuDujwSMHjoPQPCWvS6zr12ZvESSzJJNHJogijzbqJMRSAgBwGQA5Ysrbxtx0PaUUJ2/H8RNat+gVzfij/kYvBn/Yak/wDTfeV0lc34o/5GLwZ/2GpP/TfeUhnSUUUUAc34o/5GLwZ/2GpP/TfeVw+veAb+bV573TvDsUxTVbXUTLI0P2iYrMWkVJCw3KEPAk2kZKglcY7jxR/yMXgz/sNSf+m+8rKm+JumN4oGkwzfZRb30ltdSXlncKkgSAyMI5AmwMOMhiPlBPcZF8Sa6f8AAHq4tHBW/wAN9fOi28Fx4cX9xZajZRwNNAfKknuBJDMvz4CoACSPmGBhSa3j8PdUuh4jttd09NWvruwMVhrMsqYANssZhYZ3Y8xS+NpXLbshq7eLx1oM32URzXm+6YrHGdNuQ45AyymPKKSy4ZgAcjBqGy+I3hbUBm31JgPssl3mW1miHlRyeW5y6DkPxt6+3NN3cWu6a/N/5/8ADApWd/P/AC/y/pnmcfw9126tbpL3wr+7kvdIuGgmktmEyQIqTjHmEZ4PXgjuelJr3gLxLfXGvT23hWONNS069tWghuYW86UzKbeRmdwThQWBJ+ToAuAK9fXxNpDeH5NaN35dhFkSPLE8bIQcFWRgHDZ42kZz2rhtF+J9xc63cWerXFhbRR6xNao72NzCZLdLfze+4JIMjIcrkK2Bmndtv5v70kKPupW8vwuzm38B+J7qC6tTo99ZaXJq8FzJaRzWbtNF9mEbFVdnj3LIN53jngg7hxr/APCv9dPijbNG93EZwzardvE7SWQtPKNo+MMxMnzEbNh+9nPFdw/j7w7HZw3U13PDHMW2iWxnR1VQCzshQMiAMpLsAo3Dnmlbx94ajnvIpdTEbWMjR3BkgkVY2VPMPzFcH5OQQcHtmhtu9/62X9evmEfd2/rc8v8AD3w+1u2t5bTV/DM/knRbS1do5rV1mmt3c4KM+HVgUwHABHUqRXsXh+3ntPDmnW95bw2s8NtGkkFucxxkKAVXrwPqa47QPiZFNf6+uvzRxWtjepDZtFYTxyvG0Ql+eI7nBUH5jhQACSAK3ZPiD4Ziluo31Ft9pKYZQLWY4fYHCjCfMSpBXbndnjNDbe/XX9f1Fpf8P0/Q6Siq+n38Gp2MV5aeZ5MoyvmxPEw5wQUcBlOR0IBqxUjOb+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiErpKACiiigAooooAKKKKACiiigDm77/kqeh/9gXUv/R9jXmUvw41T+2I7rUdB1PWbv+0ke6meXT/s08Qm3mQD5JWITKYkOQGKjKmvTb7/AJKnoX/YF1L/ANH2NZGp/FrR9IvHjvdO1GO1DSql85t0hdo5BEwG6UMv7xlXLKBznO3LULSSYNc0WjE134c2dx/wkWg6PommfYZbQ6ha26wogivXieFQBjCjC7gc8Gsqbwl4hdp5tE8I3GjXb3w+yXAls1NpAbIQHGyY4XzAGKrngA4JAFdRo3xL8Mvbz3OiaJdJbyn7VdT2sVvs3NKYndiknzkMOSN2RgruFPPxl8NvqU9lYxXV/NFKkQFrJbuX3SiLdt80MoDsowwUncCARk01f4e/6f1b0KUmnp0/X+r+pyNt8Prq0m095fCOqajH5kz3cV3Lpu1S0DIQixlFKuxQnPLFcsARylj4Q8QiztbG78GTNHcafZw6lLNPayCWeMuHkZPOIlOGTBcEYXoSqg9b4k+ILjStYsLO11LRNYttMlvoHuEt2/1e3cNoZ+7AZK7WGSrHrWjL45Fhpd5fNo+tXy293JBNGgtQ0RXaAFzIoYMWG0ZZyTjHYD1Xr+mn6kr3dO//AA5V0WOZvhdc+Hte0yVLjTdKW2uRdNFNHOfJ6gozZHHRgD0OMEVx2neDptSGh36+DC2nyCx+0QySWz+btjcSXBBkwQyui/32CnK8DPWXHxT8IaheXWg6nF5jGNo5rSfyJfMcYDQGMOzbsnb8yhSc4Y1o/D27nlt9Zs5LeWzt7DUTBa2UsMMRtYvJjcRYh+TALtggnjHJpq8pOXo/uf8Awf60E9req+//AIb+tTz/AFrwFq40pdPtPBQukt01G2haGW1VQktwssDKHkXCKM+hVhwMc1rXvgYXWuXIXwHCNL+3WVwIWjs9koEbrKdm/GRvGc4yFOM8Z9ZoqXqtf61uDV3f+tTxy38FastrZW114UkKW+lLYzNFJaOJzDKGUFHbDowHCtjqc7Dg16j4dt7i08NadbXsENtcQ2yJJDATsjIGMDJPA+p+prSop3drf11/zG9XcKKKKQBXl91pM2tfDd7a10Y6vIniq7m8lTECipqszOwMjKPuBl4OTux0Jr1CuF0XX4/Dngqa9nsrq8R/EWoW+y1CFlaTUp0UneyjG4gcEnnp1o6r1X5jV76HOTeA74eJr2W18NC006aCezaOya3RZY98LRH5mJZdqONjgKPuhQp3GpaeGfEMV0Ll/BMkM1vdWBtGt5bRRFFHNI0hUGc7CY32lQcZJA+Wu2m+JVhaX1xZ6jpOp2VzDatciKfyAXCsisoxKQMNIo3NhDyQxAJqnp/je4i8UXaanb6kLG4NksMUscGLB5mePDFSCysyrggv97OdvS43VreVvv8A8yJ26+f5FDxd4Mv9X8dnUrmz1LUbRYozaLZyWYSLaD5kUnnDzAsmcERnDA4bAGaoaZ4Bh0/QvDAbw/Z2Gp3dqdI1eGRIi8sTR/OxZNwcjysjnocHHSu01Tx1baTrF5YXGk6m4shA89zEkRiWOUsFk/1m7AZSCMZHXGOazLXxzpd1f/2l/wAInqUV4bK5aK5kitfMkSB8SQqwlJ4Y8A4U9QahPlXl/wAP+m/+Zerduv8AVv8AM5afwNNZahd2Vl4CElh5l/Ir2/2NIZhIg8kbTKrcEY+ZRtOMetZl78PfEWo2GpXGq6Pq17qk9i0cC/aNP8lg0IRYpGP7wlH+cDeUyoYHdxXff8LHgvQvkaNrkEK3ttbSXSC12o0vltGCGlJKsJFBwpIBP3TzUOk/EkXciyavpWp6afLuWij/ANHeK52XCwgKVdn8zcyrg7VJZuowQ4xcfut9yv8AfYV1dNd7/ezlLzwvrlvNe3Ok+ArrzvtsFxZr9rtI9i+QFnG4T5Uuw+Yjls5JNFn8PNXj8sr4djt3W/e4tWKWo+xGSzCBwquQuyZQx2lieGyxya9d0nUX1Sx+0S6feadIHZHt7xFEikHH8LMpHoVJB9a4vV/HjPf6ZNZPdafYx6uLO5lmEBiu0KyhgDlmUho+h2NzyORRtdd7foC2v2/S7Ma38F6hDqun6va+FBZpaTwGbTllgLSybJUmnUh9vzCRMkkMwTkZABXw/wCG9U8P3Wl6hN4X8o6ckqSFpLZhFEvmkCF/MVk3b1AU5QgZYIQDXTS+P4rO6uGvdH1yFk+xo1pIlsfL+0OyI/yyE/eG1gSSMDC9TXRaHrUWvaabuG3ntik0kEkFwF3xyIxVlO0sp5HUEinrv/X9f5hbv2t+pctZxdWkNwEeMSoHCSDDLkZwR61LRRUgefWugp4h+G+o2v2WC6uYdb1O5tEnUFRPHqM7J16ZIwfYmsnXPBmp3Wo6ff2PhuKK6+0RalPLC8PmRzfaFeWPczDDeWMbkHz4wWAwD2fgP/kXbr/sNar/AOnC4rpKFo7r+v60+5D6W/r+t/vZ5Ing7UIZnW68ILqGjm4D3Ngz2/nXjMj/ALxvnEcuxmGGfY5ySclVJgm8G6rpQgi0nwa7RWd/czQfZrm33LDPasm1TJIp4cjfkjOARu7exUUdGu6t+X+Qut/6/rU8Yi8IaheKJNW+H8k0cM1hJJbTtYyG5MULRSEDzSpPK/eIyB7YrT8NeFtVtLvw/PL4XNpJZkxN9oe2dbWLzJG/dmN9yEh14XcrYwwGAa9Uop31v53JUUlbysFFFFIoKKKKACub8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8oA6SiiigDm/FH/ACMXgz/sNSf+m+8rn7r4Y37+Kjqtnr9vDb/2pJqYt5dNMjh3g8ll3+aARjJGU69cjr0Hij/kYvBn/Yak/wDTfeV0lC0dw6WOMg8BXEC2qpq0cYtrzz4vJtCn2ePIJhhO8lFIVQwJZSN2FGRt5+T4LGeOe1n15XspLW6tVjFj86rNOJwS3mYJVx/dwRxgda9Too/r8LB/X6nJT+ArSfwC/hxPsVizMkvm6dYrbxLMjKyuIQf7ygkFjnnn059PhXrC+JP7VbxNZHdqb6k8Y0hsmR4PJZQTORt28gEHnrmvTaKd3e/9f1ohW0sedXvwpa7tysespA0kNzZOq2hMUdpNs3RRJ5n7sjYMElgCW+XGALSfDNTpnijTbjUw1nrrRtEI7Yq9qY41RcsXIf8A1aHovOfXju6KLu1v67jPLpvg49/r8usaxqunajPLeJdNBcaPvt2xCInUxtKcggAqc5Uj+Kuh0zwLJpz+Ika9s5rXWpo5Ftjp4CQqqLH5bDeQ6lUA4C45x2x2FFF/6+7/ACAz9B02XR9DtrG5vHvZIQQ0zAjOSTgAkkKM4AJJAAyT1rQooobu7iStoc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUhhRRRQAUUUUAFFFFABRRRQBzd9/yVPQv+wLqX/o+xrlbDwHdX+s6g+oQalp7XNyZ5rrNiQ7K5eJoZY089ijBceccAZGCOB1V9/yVPQv+wLqX/o+xrk5fH/iRvEBs7U6S1tJcwJDI1pLgpJcNCQGMoLEEBt21QeQAfvUL4kluwbtFt7I3tQ+Ha6o9w954n1x5Lm1S1lb/ReVV9+QPIwCT1wAOTxSy/DmGTTRp0fiLWobJLiO5hgRrcrCySCQBcwkkbwDhicYwMDisO58ceK59Ms00m3sZNQkNzGxXT57lJZIrgwgbEkBhVgC292Kj7ue9LbeMdbjtrm0tjokN9am/ubiU2rxw3Qgm2EKolJRmzkuWfHoc8Nafj+Gr/zC2vnovv2/yNbVPhfp2qTX0h1jVbZr0TpIYWg4SbYZEBaJjglBgnJHQEDACx/DgxbTH4u18Ot215vK2bZlZQu4qbfbwBxxwTmufufidrumWM2p3lpYz2qXNxCtrHC8c3y2v2hMszkAj7jcc9flxiprbxv4xSd4dZtNM04vYXVzbyTRqd/lqjI5WO5cBfmYEbsnbkEZwB3ite34b/8ABCPv2trv/kzok+Htmtjc2Lavqz2VyfNa3M0YCzk7jOGCBt5f58Z27udtWND8KXOg63cXcOu6hewXrGW7ivPIIeXYiBxsiUg4QfxbfReeOW0bxr4p1C2thdXOixzXt8LCGVbCURxubcT7mBnyeMoFBGTg5HSs5vGHiS+1G5uriTS/sMEdkk1hPZPIjs17JA0kbeaMZMe8EhuNo7ZNcsk/6/rt+HYSfPG6/rW3+f4nr9Fc14Y1rVNake+uJdNOmz+aLe3hVxcQtHIUKuSxD9OcBdp4561yOofE7W9PsrO9SytLyLWEP2KGBNslm4mSLbMXlCvzJ6xgMNuedwjdpIZ6nRXj3iHxHruu+GtQ0vxBp2m6ddafFDcXUNwqyNNunKxtEElcRMNityXILAZ/iq0fiL4wnQ31vpFla6ZNeRwW810EPW5WBkOy4LlsNu3FF2lSpU5BppXdg62PV6K80Hj3XrVWbUH0gKs17Z7hBKmZbfOJOHY7W6eWATn+LnFdV4K1u/13Q5ptXjiS7t7ya2fyojErbGwG2F32kjHG4/0pLX8wejt52OhrhNH8Pp4k8Ez2Ut9d2Kp4i1C4Elp5e4tHqU7qDvRhjcAenb0zXd1wOl6xNo3giWS1MCz3PiPULWKS5BMUTSalOoZgCCQM9ARk4GRnNHVW8vv6Btqaf/Cv7JdZm1OLU9SiuJXmb5HiwolKM6/6vJGY1PzE8ZH3eKzrb4T2Voki2/iHWkWSeC4Kj7LgNDI0i4HkYA3sWIHHYYHFc14c1XUdGkms9Pt9GlmzqbwNHb7Ski3qIwQmQDY28Hy8glkA39xtaX481e/s9RvoptMnt9DLR38JtpYZrhgpOYwzfIdw2bSGywYBuBl35YqX9b/5jcW5OPm0Xbvwxea38RNUlv49RtNHks7WMPFLb+VetG7sVYfNIAC69AucMDkdbcXw6s4tOtbQ6zqzm2NyBOXhWSRLg5kRtsYGCeQQAwI69q53UdcvdQvtLh1lNPvDBe2Go2l1ZRMoRZWkXy/mZvmAU/MCNwb7op3/AAsLX86LcAaW9pq/2a4ULBJut4pJ44midvMwX/egh8AZRht701Fy93zt/X4/d5k81nzeSf6f5ff5GvbfDC3ttOks18Sa26yXdveF2+y7g8CqqDiADGI48jHOwepyrfC6wkujJLresPCFmWK33wKkPmyiYlSIg+RIqsCWONo6jIOTb+OfEk15dhrzQktrSG+meRrSbBFvP5fUSnAYEchTgg8HOBSbxZ4u1OaNRd6baPaSX0dxHNpshjuBHCjqWjFxleHIwWPqRngS5O3N5X/T/gDslLl87frY9E0/S9QsbyIy6zd38Cwssv2oRbpJCRhsJGoXAGOMD/Zzk1z2q/CzS9a1L7Zf6nqUjGVJHjIt2WQKGARt0RLL+8fqSfm4IAGMeTx5rK6MbrSItLggtDa2bWjWzs2+aGN1kTbIAI1Mg+TGSqN8wxXQ+CvE2qa5cSw6utnu/s+zv4zaxsm0Tq+UO5mzgoTnjg4xxk1yvXy/4clT0Xmv+AVW+GEUjs03inX5WZbVSZGtmJFu++LJMGThiSSeT3rovD2gL4etbmCO/u70XF1JdFrry8q0jbmA2IvGSTzk89a4L4ravdPo3iDSr8WX9mPp8ywpJbmRpZlhMoPmBiEdSuQrIOBuDE8C3N4p1Oe10e6tW0rbPc3EMEV3YuZrJ47WRhvPmjD5Rg2AMq+Ae5Lvlbf9f1Yu2y/rRf8ABPSKK5HwV4m1TXLiWHV1s939n2d/GbWNk2idXyh3M2cFCc8cHGOMnrqJRcXZkRkpK6Ob8B/8i7df9hrVf/ThcV0lc34D/wCRduv+w1qv/pwuK6SpKCiiigAooooAKKKKACiiigArm/FH/IxeDP8AsNSf+m+8rpK5vxR/yMXgz/sNSf8ApvvKAOkooooA5vxR/wAjF4M/7DUn/pvvK6Sub8Uf8jF4M/7DUn/pvvK6SgAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKACiiigAooooAKKKKAObvv8Akqehf9gXUv8A0fY1am8GeF7idZrjw3pEsqStMsj2MTMsjHLOCV+8SASepNVb7/kqehf9gXUv/R9jXET2GsprF1fxJ4kujb3SeYq3d5ClwkpkQoIS23KB423xkqNucIQwo6j6O50mqfDHSbu+gaw07w/b2CIVezuNDimCknLSREFQjnjJIYHavHHLorL4f6XLFoa6JYRta3sMaRf2Qdq3LplH3eXt3EL/AKzOMjGc8Vx89h4yh8OwR3N3q8LWt0NOvrlFu7lpYYxIVuEjjlWU72aPLI275ecqCKGuruy1IQ6nb6/qUsdzprS30eg3Y89YlbfJ8iNg4IOAc5PqCA9tF3X57kyb362f5f5/1qekQeFfC08y30fhvTFn895hK+mokglJwz/Mobccfe78Gp4vCnh2C1itodA0uO3hkMsUSWcYSNyMFlGMAkHGRzXkkGoat9gllRPGouLaxQxrJa6j80y3TbeGX5z5bLkHII65xx0HhKW5vviLLd397rKxq90sCXDX8cNyS/y5jZFt12IrABWYt94gMDgSv+P4Bf8AT8Tpbew8CwX1x4UtdE0uNpwJJ7OPSwsEpUBsMQnls4BB2k7gCDjFal/4Q8N6qYTqnh7Sr0wII4ftNlHJ5ajoq7lOB7CvJNZttSTUfFK+HrXxZDeXF9PNbzL/AGgsLMtumwjoGzIsgHITAAORsWt2+l8RXFjqk9k3iCHX97AKYZzaNaF1IZEJVPMEeflRll3ZB7YOifz/AK/ruU1Z287HpNpoul2F9cXthptnbXV1j7RPDAqSTY6bmAy2Peox4d0Rftu3R7Af2gMXmLVP9J/66cfP+OawvAtxNa6XHpuo6jf39xIZJ4JbvTrm2PlZHyZnZ3ypOPnbcRzyOTwN7DrknhK4bSx4uGoyXV+sDyzX42BGdrcFCQcFWGCSEOMNuIC0WCKur+f+ep6PrWk+DtM06yTWND037Gsi2Vsh0wSpEZWChAFQhFY4BPC5IzVqbwX4WuGla48NaPK0zK0pewiYyFRhS2V5IHTPSvN9eOpS3NwHtPEV4t1dWsrSrbXZEKrdRNtEW1kGEVyGTaQB867iCe88BXFxLod1DcrqQ+zX9xFCdSimWVofMJjO6UbnG0jDZP1yKaXu36/8N+rFpYsf8IF4PLbj4U0TOWOf7Oh6sMMfu9x19as2fhjRtO1b+0tO020s7nyfJLW9ukZZeOCVAJ+6MAnA9K1qKkArlPB9la6j4Qv7TULaG6tptY1VZIZ4w6OP7QuOCp4Irq687gkvY/h5dGyS9eP/AISHUBdiwDG4+z/2lP5nl7Pmzj+782M45xSA19H0bwLqNw15pPhvTRM7TRvP/YwiYMjbJFZmjBBzxg9cEjIBrah8NaFb3FrcQaLp0U1nH5VtIlqgaBP7qEDKjk8DivJtK/tGLULmwtI/FdpFKt+Gkks70p812jxMT8oLGPzPnVg+Ced2BWloz67LHP51t4js9RijY6JG0lxJbyx7GAE5dQoO7LYmAkC7ADnOa+yn/XX+vS47Lma8z0IeEfDYhSEeHtKEST/aVT7FHtWb/noBt4f/AGutFzofhux03UnutJ0yGzuA01/utYwk2OS0gx83rk5rzWQ6kL2wkibxiumSXNsLlXW9aVJSsguOgLeXjy+R8gPKY5NYuoXGqXfhaeyu7bxldPeaReQyRtZagcyrMBbA/LwSgbJ43D7+c0W1tf8Aq1/+G7iT1X9dfzXXseq6HpHgzVhNq+j6DpolmMkE8zaWIJjnh0cOivz3BHINWp/CHhO4jWxufD2jSpxItvJZREfKoQMFK9lwuewwK4C5/tMmYWw8VJJG37of6b5b6f5Hvz527PX9/ux2rS8E6S8HibSdSvF15ri50GMSyX0t4yicN+8V1kO1D3CkDuVHU0W1t/Wzf6fJ6E81v680v67rU7M+EfDZCA+H9KIjtzbJmyj+WE9Yx8vCcn5elQDwP4ZjljltdB020ljeNhJb2USP+7IKDcFyAMDGMYxxW9RS63K6WMvUfDOg6xM0uraJp19Iy7Ge5tI5CVyDglgeMqOPYelVZ/AvhK6RUufC2izKpyqyafEwHyheMr/dVR9FA7VvUUAZmneG9D0e5a40jRdPsJ2jETS2tqkTFBjCkqAcDA46cVp0UUAc34D/AORduv8AsNar/wCnC4rpK5vwH/yLt1/2GtV/9OFxXSUAFFFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95QB0lFFFAHN+KP8AkYvBn/Yak/8ATfeV0lcl441Kx0jVPCN9qt5b2NpFrT+ZcXMqxxpmwuwMsxAGSQPqas/8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQB0lFc3/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFUAdJRXN/8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVAHSUVzf/Cx/BH/AEOXh/8A8GkH/wAVR/wsfwR/0OXh/wD8GkH/AMVQAfDj/klnhT/sC2f/AKISukrzvwD4+8H2fw28NWt54s0OC4h0m1jlil1KFXjYQqCrAtkEEYINdB/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVABff8lT0P/sC6l/6PsatDxl4YaF5R4k0gxxpvdxfRYVd2zJO7gbvlz68Vyt74+8Ht8SNGuk8V6G1vHpN/G8o1KHYrtNZlVJ3YBIRiB32n0NcVHf2kc6S/8JJ4AZkfVHz/AMJIBk3bblP+p/h6H1H5UiklbU9pXxBoz3lxapq9i1zax+bcQi5QvCnXcy5yo56niqqeMvDElu88fiPSXhjjWV5FvoiqozbQxO7ABbgHueK8Xs0s3jtpNQ8ceCIbi2gkhRLfXFaFv3kMiZTYvUw7X6khicn7tbWvavpOr2969r4n8B2U+o6ZcWdxEmtoUjd2DB9wUGQkg5JVSMj72Obsrr+u/wDXkRrb+vI9Hs/F1l9lvZtdnstJS21B7FXmvF2SkYKkMwXkgj5eee560iaf4Z8KXK3Ut3HYfaZCIVvNRfygxBJEUcjlEONxIQDjNeZ2usWSX8+oXHinwI0k8l0j2beIleLyp1iBbcYwdymLptwwYjK1Y1fXfD2k6Do1tYfEHS9ca0u7JIrS81G0WCPy8DeWjQyKOMlmL4zmpWy76L79/wDP/hhXdn839239f5nqI8VeHi1uo17TC11EZrcC8jzNGASXXn5lABORxxTIPF/hq5uIoLbxDpU00xURxx3sbM5YblAAbJyASPUV5JZSaNa61Bev408GCNdQGovFBrUcYV2eUvHwv7wAS/KzHsflXOapaHqGk3mleHNSk8TeD7K60eGNbe2l1hUaceart5vy5jYbSAAH5JOeaa1fz/r/AC/EqWidtf1/r/gHrUfi/SpNcZxPpraYNON0usJeIU2rJsdScbQoOOdx5zwMVoweKvD1zcwW1tr2mTT3Kq0EUd5GzShgSpUA5IODjHXBrxy3v4IJpR/wl3gIoDKY5P7fQs++8+0D5WiIjOMgEFipwRWt4J1rRvD2ubtR8XeDmsYrWS3imi8QrLM264eUFlZR2fB+cnIzzngVrL5/r/wBO93b+tv+CexUVzf/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FUhnSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lc34D/wCRduv+w1qv/pwuKP8AhY/gj/ocvD//AINIP/iq5/wX4+8H2ug3Md14s0OF21bUpAsmpQqSr307K2C3QqwIPcEHvQB6JRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAHgP8A5F26/wCw1qv/AKcLiukrzvwX4+8H2ug3Md14s0OF21bUpAsmpQqSr307K2C3QqwIPcEHvXQf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lFc3/AMLH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUAdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSUVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQB0lc34o/wCRi8Gf9hqT/wBN95R/wsfwR/0OXh//AMGkH/xVZGp+LPDmveLfB9roev6XqVwmrSyNFZ3sczqosLsFiFJOMkDPuKAO7ooooA5vxR/yMXgz/sNSf+m+8rndE8U6vpnxM1zw/wCIL2W+s5YDd6Q8kUathDtkiyiruILLjIJx3NdF4o/5GLwZ/wBhqT/033lQTeALO61S21K91PULm9s7ma4tZ38lTAZF2lQFjAZRwwDBuVGSelC312swexyHhb4nXVho81x4tOoaldTzajJGLaG3WKGO1c7o15Rs7QCN2c/3q6v/AIWTpKx3U0tpfRWlpZx3Uty6xhVDqrKm3fv3EMADt2k5AbINZsfwe0lNPW0fW9ZlCvdMJGe3DAXIImXiEDDE56ZB6EDitGf4aaRe6fDZaneX99DDZGyQTOisqkKN25EU5+RePu5GcZ5p+vl+v/ADr83+en6kGpfFGy0dD/amga3ayLZT3rRSRw7gkLBXH+twT8wYEEqQeCTxWVpfxEmtvFviK01B7rUY/tltFpNjFHCsvz23nMoJKDAAY5Zu2Mk4B29b+G9j4hs7eHU9X1WSaGzmsnug8QkmilADBv3e3PyqcqoOR7nNWL4T6bDeXF8Na1dr+WWKZLsm33wvHEYcoPJ28xkgggjuMHmjT+vX/IO39dP8yPV/iLb6j4b1R/DH2wSx6Q9/DqKxxbIj5bOmUclj90jOwrkEZzxRb/FGx0/wjbanrkM4QpDCLsz2qx3dw0e51QmUBCMHO/YBjFX7j4aaRPpcOmxXd/bWlvZyWkMUTp+7V4/LYgshOdueCSuSSQTgisnwr0+JYhHrmsJ5DwzQFTbr5U0SBBKMQ8sVG1s5BBPHTBpd9tPzf6A+nz/JW/H9bGDafFqzsvEOvXuo6o1zojRWEmlwnyIiGmjdiodyg/hz87cYxntW3pvxSttWutTfTdG1C9sLOG2kjuLcRHzmmXcBgyDaNpBy2AMNkjirF78MdNvtfu9Zk1XVUv7iW3mSVHizbyQghGTMZ6hmBDbgQx46YsXvw80691K7vX1DUonvLi1uZljmQK0lv9w8rnBwMjOOBgA80aW/r+u4Pf8Arf8Ar9TI0DxvL4k+I2nDTLyb+w7/AEF7xbSWKMFJVnCEkgFsjkEbiOOK9DrjvDnw00vwvrFnqGnX+oubOzks4oJnjaPy3lMhzhAxO49c9AK7Gh2sref5v9LC6v8Arojm/hx/ySzwp/2BbP8A9EJXSVxfgrQNH1j4Z+DZtX0mxv5bbRrQwSXVskrREwpnaWB29B09K27Pwd4Y065t7jT/AA5pNrPbZ8iWCxiRos5ztIXK5yenrSGbNFFFABRRRQAUUUUAFFFFAHNX/HxS0PjP/El1Lj/ttY1Ri+JdnJCjtoWtRmUzJCpiiPmyxSFJIwVkIBBBO5iExk7uDi9f8fFLQ+M/8SXUuP8AttY1zWhfD6XV9HlbxM2rafOl/cT2lq8ts622+4ModNgcMSMAhyw+8AADyIOhor8TdOlgh1GGx1aS2ktVlEca27LgziEniTJZW64JUg5G6tO88XQf8Ifq2r/ZNStv7OMkVxFGsJuISn3mXcxjOAQw5PHYnisib4UWkhIi8S67bxbWQRRm1KhTN5xHzQE/f5654xV248Kad/ZmqeG7vxLeibxDJLOVeW3W4IOPMEQ8sZXGAcqxAPUdaa8/P8/8hK99fL8v8yzY+ObS81xdLfTdRt3a7lshPMsXlmVI/Mx8rk/MnzA4xxg4PFZmr/FvQNK1+50aKC81K/t9wMFi0DyO6rudBG0gfIXJyVCnBAJPFTW3gO10zU7K8ufFGrSzJqLXiC5a1UTzNF5ZUhYVz8gIwuD1P0vXfgpJ7i+az13VtPgvpPNmtbV4fLMhxuYb42YbgMEZ2nJOM80aaen46fhv+AK63/rf/gfiZN58THiayuLLw1ql1p9wk8vnxyW37yKJA3mR5mAKnOcnqBwDkU69+LWhabeWVnqNvdWt1eCNkt5ZLcSKsjbY2K+bkhiP4clerBRzUcXgHSNQivLPS/FWoqILmdHis5LVvsfnL+8gC+SQikEHBG4dQeTnZTwXHBcwXFpreq206WiWk8kTQ5u0TOwuDGQGG48oF688Uv8Agf1+Q/8Ag/1+f4GYvxT042Run0XWI4xa/bDvjhyIVbbI/EnRD1HU5+UNVaf4lyWl5GsGgaxqMBW+ln2/ZvNi+zyKjKq+YoZRu9SxG3qc4hs/hxo+raZLb6f4z1a8t47WXSpGgms5Nil90iEiDhs8HuB6Vq2XgePw4yalb32taxdWrXMghdrUNcCcq0icoi4LKGHK4ORnHFPT8/8AgfoNW/r0/wAzf0nW01iSYQWlxHFEkTid2jKSb0D4Uq5OQCM5AHIwSOa065jRNGbw9p2i2EN6LJBLIZLZ5VbziyswiUspY7AONpGFTuBiunodr6Eq9tQooopDCuF0XX4vDfgua9ubS6uon8RahbkWqqzKZNSnRSQzDI3EDjJ56V3VcJo/h9PEvgiexlv7uxVPEOoXAktPL3lo9SndR86MMbgD07emaOqGrdR8/wAU7C2hSSbQ9YVTLJA/yQfu5Y22yIf3vJX72RkEdCTxV1vH9oNWk01NK1FrqO8e1eP9yMBVjYyD958y4lQ4GX5OVGDjOuPhTZ3alLjxHrjxtcXFyUzbKN833zxCD15HpVx/hxZTG6+1azqtxHeXKXVxHK0JWR1VFz/qvlz5anK4I52lQSKF5/09Pw3Jd7u39LX8diWPx9byXFoF0XVvsl7PHDbX3lxeRKHyFcHzM7SR0IDcg4xzWbbePBNrf21/tsOnyWbIumzRxeYLlbryMAqTlmb5eXK9DxzWmvgK3j05bGLWdVS2gnSayjDxEWRVtwEeY/mHbEm/A4GKoR/CvT0mlZ9c1mWNt5iieSDEDNP5+9WEQYsJBuBZm9DkcU1a6v8A0rfnf5BK+tvL89fwLQ8fWt5cRabb6fqcOoSyPBPDiES2TDaCzAuQ2PMRvk8wYIJ4rK0L4lW9p8P7PVfEUstwywRrNfboI45Z2YqIslkVX4BOQqgHkiti5+H1nd2oim1XUjI1wt1PPmEvPMuNsjAx7VYbUwUC8KB0yDT0z4V6ZpOmmztNX1ZVHlvHJvhVo5o2JWYbYgDJg7SSCGUAMDil0/r52/T5XH0/r+v60M6D4qaWLm51uTUXbQ5dPgeC3doE2ztNLGyiQkLklMZaTZxkHHNS6V8W7bWGvrrT9Ev7rTLeCJ0nhe3O52ZwysTKFUDYfmJ2/Kfm5XOrdfDyG+1E3934g1mW68mONJd0CmN43LrKuIh82Wbj7mGI24wKdc/D62vL0XdzreqyTnyTIzGAiVoi21mHlYyQ7DAAUcEAEAh9P6/r+l5g99Nv+B/X4+Qzw54ml1vXdRubWae60yXSrK/s7ZkjVk80S5UHjk7F+8xAOeQKZbfEuxurSOdNF1hTPaC7to3iiBuI9wVsHzNq7Sy7i5Uc5BI5q14f8FQeE5p7qx1HU78fYo7SO0nMG1Y4t3lqpCIc/Mwyzc7ue2MDwx8O3ufCenf8JHNqlrqVtGiRxSyWz/Ywsgcqm1WRlYop+fecY5GOHKzlpt/w/wDwA6Mvr8TdOdYL6Gx1ea2uILR0REtyoE8rRq339xIcbW5I6EAjJrqND1qLXtNN3Dbz2xSaSCSC4C745EYqynaWU8jqCRXJt8KLTzUMfiXXYooxCqQKbUqFilMsa5MBYgOSck5PQk10/h7QF8PWtzBHf3d6Li6kui115eVaRtzAbEXjJJ5yeetLS33/APA/Ubt08vy1/Eo+A/8AkXbr/sNar/6cLiukrm/Af/IuXX/YZ1X/ANOFxUy+BfCSMjJ4W0VWjkMqEafECrnGWHy8E4HPsKQjeoqppmkabotmLTRtPtdPtgxYQ2kKxJk9TtUAZq3QAUUUUAFFFFABRRRQAVzfij/kYvBn/Yak/wDTfeV0lc34o/5GLwZ/2GpP/TfeUAdJRRRQBzfij/kYvBn/AGGpP/TfeVxHib4p6zpOq6tb6Y+j3UVvaXs1uywyP5cltsLJI3mLuJDEHaF2nu2DXb+KP+Ri8Gf9hqT/ANN95S6rpHg57uC01fR9Jnmv7hkRJbFJPMlK+Y2flOCQmST1wPal1Gv69Dj0+IOr6jO+h3dpppmudUTTzO0DtAsT2gnYMhfLE8oPmAOc44wavgnxBJ4W/Z90W8tI4vMe5FrG0qkxQ+ZdFN7AEZVd2cZGcYyOteiReD/DMEM0UPh3SY452RpUSxjAkKfcLDbyV7Z6dqtQ6DpFvpL6Vb6VZRadIGD2aW6LC2772UAwc9+Oau67dvw/z1Eul/63/wCB9xw2qePfEGi6o1neW9hM1glmbz7PDIftRuJ2hHkkv8m3buIIfJJXIxuOPD8UPE/k3gni0kyR2uqSxOltKF32cgUFlMvRgTkA8HnPavUD4f0Yy2cp0ixMlgu20f7MmbYYxiM4+QY9MVyVlbfDHUbw2ltoGjmdb2TTzFJogjIn2F3TDRjqoJz0PqaW+i8/+B9z/wAh6aO3b8N/vOf/AOFq+IVtJYDp1pPqEt1Y29sbeL5FNxb+b8yyTIGIIKj50zkenOxaeNfEupTaqq2mnaY+j2qm9tLrMsvmNAZAyOj7Sof5cY5wTuBGK6uPwX4Whgngh8N6RHFcKqzRrYRBZQv3Qw28gds9KvHR9Ma+S9bTrQ3aRGBZzAvmLGeqBsZC+3SlLVO3X8NP6/pCjpa/9f1/W54to3jLxNZ2N9rcz6TcXdvoumXt3dNZTb5LaQyF1KifbuQFm3AAHkEDjHZXXjbxFH4zs9F0/TrfUo5IlvpZY0WEfZXlKAgyTj5lXDEhX3EgbVzmtfw7YeB7m91e28O6JpsFxasbLUUTShbk5GdjZRd6kYPGVIxXQzaVp1xd211cWFrLcWmfs0zwqzw5GDsYjK8elW5JyTtp/X/AFrZrr/lb/g/h2LdFFFQM5v4cf8ks8Kf9gWz/APRCV0lc38OP+SWeFP8AsC2f/ohK6SgAooooAKKKKACiiigAooooA5q//wCSp6H2/wCJLqX/AKPsa82i+IV0T5cnxAgCyf2mpkIsw0f2eTMJHyYyy9cggr0APzV6Vff8lT0L/sC6l/6Psa6SkUmktjyrT/EmuyaTPNN4iupgtmNZjvIrOCRGtmhI8kBUAO2UHjcGIH3hzWVZ+NnlvrNdQ8QWc+o2dxffZJJ5YnZ4zaB43ZYlUOPm6qvPQE9T67ZaZ9kvLq6ku7i6muCPmm2DykBJWNQqr8o3Hk5Y55J4qS/s4tT024s5XkWOeNo2aF9rAHg4PY1Une/p/X9epCWyfR/f/T/Q8e0rx3eLcWF/deOvPt7nUVtfsMk2nTnaYHY7vs65z5gG0BwSCARk11Hw78ZNqkt5b6xr0F280sTaeZpIFklV4txVVjABwVfgbiNpBZiDW/4LZLzSP7RN1qV3MzyWzyamIRMvlSOhXEICY3BuRyeMmt6aCGZ4jMMmN9yDcQN2PTv68/Wns2Gr+R5drur6hoHi3X59N1OSG7e8t5V0wWyS/abfyI1lmCkB2CAMcqwGVwc5qlpPjnU7vfZ6n4tXT7RrlvJ1pxatgGCKSJGOwRYZml5xzs2hiea9jpMjdjIzjOKmOisym76nlXgPxRb3njnVdPTV0WKTU55IzCYyt9IIowyMCC0ZXG4AEE88/IQVvfFuq2HiTVrZPErzzWWpsiaYbWGR/sht0kZ9qqrsIyTg5GfusSSDXqtZGi6DHo99qt3HqF1dnU7r7TIk/l7YmChMJsRTjaqjkk/L1znL6Jdlb8v0JStfzf53PJoviTeQeXDqXjWK2V7yVI5pHs90kDWPmpJkRhfllIAKjGTtJfrXT+AvHsF/qw07V/FVje3F1p1lcwRPLAjmaRHMkaKgG7G1Tjkjd1wQB6TUU1vFcbPOUsI3DqNxA3DoSO+Dzz3wafMu3b+vmDVyWiiipGFc34D/AORduv8AsNar/wCnC4rpK5vwH/yLt1/2GtV/9OFxQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34D/AORduv8AsNar/wCnC4rpK5vwH/yLt1/2GtV/9OFxXSUAFFFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95QB0lFFFAHN+KP8AkYvBn/Yak/8ATfeV5lPa63pvxGunhTxTF9p12dpZLWO7lga1a0CxtjmE4kwBnkYGcAcem+KP+Ri8Gf8AYak/9N95XSULR3+X5f5D6WPKrO11iNdLDjxFMLa+8gobi8QXILLmfczFlUBX+SbKEZ2typPNWz+PLKKeCyXxHJfRaXfQqboXMsbSrd7o8M52s/kk7WzzwM5r3qinf+vlYX9fieeSQeJbT4RTiwvr2/vyyvHIbWaC5WAupdFSV3l3hN4BZixOPY1wunxatp/jOYada+LLW2uNdnlaVLO8IktnswiO5ddrkSBceZkgjJxya99oovq33/4H+X5htG39f1r+R4vqC+LLfS4obNdfaKGG7jtpo5Lt5J74eWIHYMTIsRPmfLKTHwckrtq0IPF89n40ltp9cj1S1mV7CNjMIZA0CCUQ7xtYBxIVC8BgMYB59eoovp/X9f8AA0Dt/X9f8P3PAEsfEy+ItUi0Jde0zSr7U4We+nsL2WYJ9lVY3PzJK4Egw2WODjeCMiur0/Ttcv7jxZFe6n4jtpILtBaSrHcLHIrworlFJ5TeHOI2yvVSMgn1Sii/5W/L/IFp/XqY3hJp38K2RuoLq3k2kbLyWSSXG44JaT5+Rg/P8wBAPOa2aKKG7u4krKxzfw4/5JZ4U/7Atn/6ISukrm/hx/ySzwp/2BbP/wBEJXSUhhRRRQAUUUUAFFFFABRRRQBzV/8A8lT0Pv8A8SXUv/R9jXm0XgnUYzg+AJzE39prLEJbLa6yyeZbKR52MKeg6K3I9a9Kvv8Akqehf9gXUv8A0fY0yf4ieGre5eCS8uTIkqw/Jp9w4ZmYqNpEZDAspXK5G7jOSBStfQpSaX4nnmn+C9cj0/TrebwlNA8F5PJJLHd2yOiT2hjfawc4/eYLdexAbnGtpfhO+gu7b+1fB8dzYJkWMFu0EDadIshYTMqybULAgExEkbPu/MRWpH8T7efWYnWK5t9JRrmK4FxpVys+6IKQyjaDjlsrsJGMkjpW03xD8OCSdBcXkjW7+W/l6ZcvliFYKpEZ3EqwYBc5GSMgEiua9n5Gajpy/wBb6nnsXgfxDqOoWs2radq9rbx3E8lvDaz2G+1ka6kmErM+8qGV0UmI7xtYYIIrpPH/AIbk1LVvtp0WHUIFs2jmmu1ikjijCuW2gkOjHI+6GVsAMBgGtW28dW39rX8lzcwyaOLOzubGS3tpHll88yDbtG5nJKAgKoPOMHFM/wCE68La7a3Uc8r3Gm/Zz51teaNcqZwZBHhRIg8z5js2KrEkj6VM4trl66l395y72OFt/Bt/q+g28ln4YENje2lpFNBLLC5lkWKQG72GQxt96MZfLcZ2ZVaW58Fa7N4du45PCT3V7c6UsMrXEtq0xmHlKoSXzBwDGXw+dvGxskqPWdBudKn8P203h+OOLTQhEEUNuYggUkFfLwCpBBG3AII6VjL8S/CrwNKL+42rG0pzp9wDtRtjnBjz8h+9/c6tgVo5e82iErxV+hwF14R1j7ddPZeCb6GOTVWkgaG7s4mhtXtfLkVW807d0pLkAHPUgniu98ErPpFqmi3Wi/2dnzZ4VhSFEWMMAAyRyMFc5z8vyfQ/KLUfj7w5LDDKl7N5c/neWzWcy5MJxIvKcMD0U8nsDTh440Jvsq/ap4pLshUWWymUxsXMa+aCo8rLgqN+3JGBU3f9f15FPX5f1+p0NFcjonjqzfStNHiC6ii1G7Yo32e3k8pT5rRoWPzCIMVwN7cngE111IAooooAK5vwH/yLt1/2GtV/9OFxXSVzfgP/AJF26/7DWq/+nC4oA6SiiigAooooAKKKKACiiigAooooAKKKKAOb8B/8i7df9hrVf/ThcV0lc34D/wCRduv+w1qv/pwuK6SgAooooAKKKKACiiigAooooAK5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7ygDpKKKKAOb8Uf8jF4M/7DUn/pvvK6Sub8Uf8AIxeDP+w1J/6b7yukoAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohK6SgAooooAKKKKACiiigAooooA5u+/5KnoX/YF1L/0fY1z83wz1R9bTUovENr532hJZWn01pHlWOcyxqW84cjJXPTGMKvfoL7/kqeh4/wCgLqX/AKPsa5fTfH2rrc3s2taRFIbaLUZLdrO/kO9ILhYyrxGMKOoIfLHAbgZIoXxJrpr9wNXg09np95o3fgLWZNWuLiz8QWUNtI128cMmlvI6G4UBsuJwGwQCPlHp71Fp3w61e00q6srnxFazC5uYJnEemvGjpHCsRjdfPJYFUU9RhhyGB21lp401nU9VstXtrC0aOFLyNI7TW5JbS9SNEcybvKCnBJAYIxzkZHNWrL4h+ILjXZIYtFsLizur5LWzZtQaJ4y1mLhd48k8EZyQcjOADjJIrRpdl919P6+Q1rqvP/gmfqPgXVPDujBP7V+2Wvk2Viv2PRZ5JbdLcsUkIhn8xjliMxbSCVIwAc6Nh4J1y+top4tYttOhW0+yxRJpc8bSL5wlLuHuDIN2CGVjuOSSQTgOsvi02pXVvHpvhnUbyNo0+0tbwzSeTI8QkC7hF5ZHKglnU/MPlIq9p3j6+vL2xgn0ywhS4n8qWUagxVSSAEXdEuZBnJjfY390Nmq1ctd/6RMrLV/11/r0NTwtoOo+GbddJS4tZtMiSR4WS1MTI7ys4X/WEEANjG1eg55wOZPwx11rcRN4n0/Isr2z3DR36XUgd2/4+OowAP1zXpdFT/X9feNaO6PPbb4banFBbQ3Gv2dxDDPPK0T6TlZBOuJFIaU9ycdcA4IJ5q/o/gvV9DvPtNl4ijZriPy7xZ7N5FYB3ZPJ3S5jC7yuGLjGBxiuzop3YrHnGm/CcWupWt/qF1o+pXEa7JXudEVyAJHkVoS0jGJgXIJ+YHC8Ajn0eiii+lgsFFFFIYVzfgP/AJF26/7DWq/+nC4rpK5vwH/yLt1/2GtV/wDThcUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+A/8AkXbr/sNar/6cLiukrm/Af/Iu3X/Ya1X/ANOFxXSUAFFFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf8AYak/9N95XSVzfij/AJGLwZ/2GpP/AE33lAHSUUUUAc34o/5GLwZ/2GpP/TfeV0lc34o/5GLwZ/2GpP8A033ldJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCV0lABRRRQAUUUUAFFFFABRRRQBzd9/wAlT0L/ALAupf8Ao+xrP1r4b6XNHe3mj27pqc4k2ibUrpYT5jh5VCq+I9xGdyrw2GwSKv3/APyVPQ/+wLqX/o+xrzaKfU1OyRvG3lP/AGmsg8nUSQqybrTB25HHQg5P3SSOKTdtSkrr5o7mw+HtpcoJ/EK3v2jY8aQx+IL65WFXXa4EjurNuGP4RjAxzzVtPhr4ZiuoLiK3vkktyrRldVugAyx+WGx5uC2z5dx5xxmvP9PuPEL6fpysPF0Vz9sn82V4Lt9sctoSu5XwGAlxjPCEYyuRnU0xb+a4t7bVovFNrYAEWEtnLeMzzCQ7jKXG9VZduBP8o+b5uhq2tbf16Gal7tzo5/CHg7wnpf2uW2u7ezhRYJAt1dTKyk7V8xAzbwN2AzA7RjBAHGnF4G0CG4E6WkxlEwnZ3vJn8x1OVL5f59vG0NkLgYxgY8x1KbWINMitbiz8U3RGn3NnMrW15dLJKt1G0ROAwJ8vdiToRxuOMDWux4ivrqUxS+ILW8a5nW+IiuDbmzLN5BiUFQGx5YPlESAb88gUul/63/pj1v8Ad/X6ep3+j3dlZ3beHFvLi4v7OATyfaFlYmN2O0iR87xkEfeYjHNXdT1az0iOCTUJHjS4uI7aNlidx5jnaoO0HaCcDJwMkc15Fb3OrL4ns3fR/EEdidPhguXWO8M2BcyFNs2wMR80ZZWIfYSDkgio4k8Tx2Xn67caxfXT6hZtc2CaNeNHBJHcq7Ojl3Vl2BuYlVMAZAYgFpXav3/W35fiN6X/AK6X/P8AA9rklSJQ0rqilgoLHAyTgD6kkCqup6tZ6RHBJqEjxpcXEdtGyxO48xztUHaDtBOBk4GSOa8cTSfEd/ZifxLe65dSR39rJe2NvZXsIhdZxueOQSsHG0n/AFICgAMQpFP+0a2tzN9tsvEk1rcXunTxQz2l3ctE8d2xmJO0hcIqn5QqEY256kirtX7/AOX+bE9L+S/zPbKKKKkYUUUUAFc34D/5F26/7DWq/wDpwuK6Sub8B/8AIu3X/Ya1X/04XFAHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/kXbr/sNar/AOnC4rpK5vwH/wAi7df9hrVf/ThcV0lABRRRQAUUUUAFFFFABRRRQAVzfij/AJGLwZ/2GpP/AE33ldJXN+KP+Ri8Gf8AYak/9N95QB0lFFFAHN+KP+Ri8Gf9hqT/ANN95XSVzfij/kYvBn/Yak/9N95XSUAFFFFABRRRQAUUUUAFFFFABRRRQBzfw4/5JZ4U/wCwLZ/+iErpK5v4cf8AJLPCn/YFs/8A0QldJQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6PsaNS+IfhHSbtba+8RabFMbj7O6tdxjyX2lsPk/Jwp698DvRff8AJU9C/wCwLqX/AKPsa56bwb4kg1mC/wBPGmNFZXguLezlu5Ar5SZW/eeUzRjM3CfOo2nG3OAD0syTxL8W9K8OpbYm0m8ke0+2zJHrESZiyAPJLACVj1C/LkA4PQHY8LeO9M8RW6+bfaRFdSzNHDBaarFdebhQ3ykYOcHlSoIweowTykHgzxpFogsDa6CT/YMmkl/7Sm+8zffx9n6Y7U668FeL9RS5Fxa6HbNc3NpI0kGpTMyJFEUJBNuMt0IHuee5Nl3/AOH/AMhPy/rRfrf7ju38W+HEtJLp9f0wW8c/2Z5ftke1Zf8AnmTnhv8AZ61btNY02/vrmzsdQtbm5tCBcQwzK7wk9AwByp+tecWXw01Sw0lhaW9jBqYjW3F2dYu596qhRXxKrKowzfudrKem7oR1nhzQdU0rXLya6e1WykQ+XFC7OS7OXZ8MuYwcnKhmUnkBelVZX/r+v69Ra2v/AF/X9djp6KKKkYUUUUAFFFFABRRRQAVzfgP/AJF26/7DWq/+nC4rpK5vwH/yLt1/2GtV/wDThcUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+A/8AkXbr/sNar/6cLiukrm/Af/Iu3X/Ya1X/ANOFxXSUAFFFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf8AYak/9N95XSVzfij/AJGLwZ/2GpP/AE33lAHSUUUUAcl4402x1fVPCNjqtnb31pLrT+Zb3MSyRviwuyMqwIOCAfqK5vTfDPh/xLqeovoHg/wjDp2l3j2Ti60VHe7kQDdtZcCNQx25KvnBOBXW+KP+Ri8Gf9hqT/033lZurfDoXsOr2NleWsWk63K09/Z3Vj9oIkYAGSFt6hG+UN8yuA3IFLr/AFvp/wAEen9dv6sZ1zYfC7TPOh1fwvoMF1aW/nXaRaGsqxkIHZQyxEMwU7toy235sY5pIIPhHc2M93b+HdCljgeNGVNBBkYyIHQLH5W58qcjaDwD6GmRfBfStPGtJov9m2qalbGGGSXSkkmtHMXlOySBlO1l5KgD5iTnBIqs3wZluY5f7S1mwvG86zmiSXSd0Ia3i8rEkbSkOrKTkZGDyDVdfu/PX8Bf8H/gFxIPhDJdSW6aB4fLRJHI7f2IuwJIhdG3+XtKlVPOcZGOvFY2qHwFJdaD/wAIz4T8M3EN5rMem3qXWgiOWINGXBCsqlTgAglSCDkV19j4EudM1XXLrTNVt7CLUrCKztorSwEf2IxqwV1+faQC5O3aO3PHOLD8I7m31S3vU8Qo7R6pbalJ5liWMjxQ+URnzRjdy2eeT3oVuby0/PX8BO9nbs/y0/H8jqP+FceCP+hN8P8A/grg/wDiaP8AhXHgj/oTfD//AIK4P/ia6SikM5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia6SigDm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrpKKAPIvDui+CrH4eeFGufAdjrOoXei29zKttpVvLMyiKPzJW343csOASzE8A1SFr4M0jTNWj1jwZbXRhuLwQ30GjWAZUjOdoDKoLKpzyuCFPJPB67wf4eTVPh54Jv4dQvNOvLXRLZFmtCmXjaGMtGwdWBUlVPQEY4Io1D4U2uo2slvN4l11Y5JbiVgrW2T54w4yYCcYyB35PNC3u/61X6fqN9LdzkG8P8Ahyy8TsLnQdHlsIdbngeE6JaEtALAXAX5Yg2VYHGDk5wSa7TQPCXgbXtLW+XwBo9mrMQqT6basWGAQwaPcpBB6hj3HaiH4ZpHqS3snivX5pBdG7IY2qhpTD5JbKQAj93xwR69ea19G8MvoN+z2Wo3ElvPJLPdJMIv30jbQpwka4wFxkEZ5yGJ3CtLW8l9/wDwSdf6+ZwtxP8AD22heR/hZGwWW4hUJo9kTJLAW8xF+fkhUZh2IBAO75asXEPgGHULe1j+GFpcLcqDFcQ6bp5iYmLziuTIDkJyTjHoTkZ0vDvh6+tn1DV9X07VpJrfUru5sdKaa1KnzWb94hDfeKORh5MDnAGcnR0zwHBBZaGJLu7tv7MeWX7LG6PG5kBUoxZCxVUYoNpXAHsMT087Ict3buzh7XxD8JL5ZZLDwNpd3DBJEJpodOsGSGKQkLM53/ImRghsOvGVGRWqNP8AAyzTvP8ADSKGWOyhuPsMmkWGSsjsoOQcKflO7eyqBj3rpo/AEEenwac+uatNp1uSIrKZoHiEe0hYiDFl1XgjcScgc1Rg+FlvGyGfxPr135cMMMf2hrZtqxSb0/5YfNgk/ez19QCHp0Am0Lwj8PvEOg2erWHgzQhb3kQljD6Xb7gD2OAR+RI960P+FceCP+hN8P8A/grg/wDias6BoE3h/wD0SDULifTY4gkEE/lko25mJBVFPQgcls4HQ5J26Ha+gked3ngHwevxJ0a1XwnoYt5NJv5HiGmw7HZZrMKxG3BIDsAe24+prkfK8L6br2p6hrfgK2h0m2unsxB/YunGFApQCTzNwfdluUyxYMNq5Vq9Ovv+Sp6F/wBgXUv/AEfY1lXPwssbye8ku9e1mb7W07OjG3wnmhd23EOR9xMd/lxyCQVH4rvb/hv+CD20/rf/AIBzVpD4Jl1SePVPhxZadb29xdok66XYyRTLAhLBgpaTOAWGFHYZNTWLeAb3WI9Ob4VQ28kr+Wjy6Xp5Rn8kzKvyyE/MgyDjHYkV0Gp/D+RXuNQ0zWtWe5X7RNBZeZBHEZZYyrfN5W8Z6/e4PTFVPDXgVxY26zHVNIitLgXNtHJHYRTJJtdJOLaPyyrK2MnLc5ypAoW2vZfeP/N/8AxLDVvhDqGsaZpsfhHRIrnUVj2xy6dZhoXkXciOgJfJHdVZRkAsM10uueFfAuixwhfh/pWo3NwxENpZ6VbGR9oyxG/aoAHqR2AySBVrRfh9B4ci2aLrerRL5YWSNpIds7KNqMx8okFQFGRjIUbg3OdK+8OSapYab9q1W8ttTsMMmoWnliTcV2vlWQoQw6gpjoQBgYbt0Drpsec6Pa+BbK61GPxD4Q077L9tm8i8udEtI1gRbdZ/KcBVbcF3/wAJ+7gtnq7S9X+FWuXS2ui+A9KvrrzNrQwWFg5VOP3mQ5Vh8w+VSXHOVGDjqpPhfY3Eh+265rF3E93LdSwzNAVlaSLyWViIg23y8jgg85znBq7N4Diu7GG01DXtYvYYmUhZ3hIKqQVUgRAcED5xiT/ao009F/wf6/UnVL7/APgf1+hkeEPDHhDxLobX938PNE09vtM0SxyabatuVJGUEFd3pg5xyDxjBO7/AMK48Ef9Cb4f/wDBXB/8TWnoeixaDYyWlvcTzxNPLMon2kx73LlRtUfKCxxnJ56mtGgav1Ob/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukopDOb/AOFceCP+hN8P/wDgrg/+Jo/4Vx4I/wChN8P/APgrg/8Aia6SigDm/wDhXHgj/oTfD/8A4K4P/ia4BvDXhrSvhjq+q2/grSL+8h1TUYoj/Z1szIov5o0/1mBtVQABnoAAMV7HXDaNoSeJPAGo6XLe3VlHPrWp75bTZ5mBqM5x86sO3pSYHD2OsfCbRfM0rxFo+hzXtt5gee603To3Z1bmFliOBIuQpbaqNgkHANEMngDVbq41LTfC+myaWtiRLbW2l6dI9vMs6oXDYKtw4Jw7AjGBmvRj8P7N7a6tZNW1R7S5k882/mRKqXG4OZ1Kxhg28b8Z2budtVNT+G39ryNJeeLvEDPJb/ZpGH2Qb03Bv+ffA5Ufdx09zmlum/60f9fc9yZJuLUf61X9fetjFhh+HLXEsd18O7GzSJrlGlm0e1ZS0Ay6gIWYnaNw4wRxnPFQnSPB2ueH/EBsPh/Z6Lc6daGRLi40qwb5jH5iFQpkB4wfmHf16bdz8PJ7WzkuLHxBrN7exNdTxJNJbRiWWZNrZZYQR6jGME/keFvCVxF4W1HSJhqOlWV7EYxHLFYRzxM2Q7L9mj8vkEctuOc9KhpuLXW34lppSTe1/wADFsbbwG9jFBJ8ObG41XbGos00mzElxui8zzFyQoXAY/MVPGMZIBn8Oab4H8Sa/eWtp8PNHSwhtIbiO7fS7Ybi5bKlfvAjaRjb1VsnpnaT4bQR3ovU8Ra0t4giENwDbBofLjMfA8nadyk5DAjnIAIGNfSPCVjol9LcafPcok1qltJAzKUbYWIkzt3b/nbJ3YOema0la7aM48ySTODhm+HU901tH8M7Y3C3MdsYTpNkHVpEZoyw3fLuCEYbDKcbgvWqOqweCdRtdMk8O+C7CDOo2kV5J/Y1kUi8yZUaCXcGO4hicx5xgfMMjPXW3wts7O6tJrPX9Zh+ytEwRfsxWQxb9m7MJPAkYcEZ6nJ5plr8KLKzt/Jg8Q64FaeO5f57f95LHIHRyPJxkEY4ABHUEgEEbKSb2uvu0/4P4FO+tuz+8jv9B8AWGsfYf+FfabcrGFN1dW+j2zRWm7O0yZw2CBnKq2By2BzXParZeCruC0Gm+C9O0qc3tlIoudGs8XlrNOsZZflfCkN0O1wcZA7+i3fhaC61yTUUv763FxGsV5awunk3YXIXeCpYEAkZRlyODkVkP8NLN7OGA65rGbZ4fs8peBnhiicPHCCYjlAwU5OXO0ZYjilHdN91/X9dL9RvZ2/r+vzt5nM6ZoXhDWPiFbQ2fg7TI9IuNNnljE2j2YiuGSWNRLGwUvjDsMMRnAIXue1/4Vx4I/6E3w//AOCuD/4ms8fDxtPure70PxDq1rLaJJDbQs0DxRQu6s0eGhYlQUGOd3bcBjHaUacq/rqD+JnnfgvwD4PutBuZLrwnoczrq2pRhpNNhYhUvp1VclegVQAOwAHaug/4Vx4I/wChN8P/APgrg/8AiaPAf/IuXX/YZ1X/ANOFxUy+BfCSMjJ4W0VWjkMqEafECrnGWHy8E4HPsKQEP/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTWzpmkabotmLTRtPtdPtgxYQ2kKxJk9TtUAZq3QBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNZGp+E/Dmg+LfB91oegaXptw+rSxtLZ2UcLspsLslSVAOMgHHsK7uub8Uf8jF4M/wCw1J/6b7ygDpKKKKAOb8Uf8jF4M/7DUn/pvvK8q8da7eax4j0zVFt9PibT9R1Oyt45rdmk2xW0m7zGDglXxkBduBg5Neq+KP8AkYvBn/Yak/8ATfeVc1Dwf4a1a4kn1Xw7pN7NKwaSS5sY5GcgYBJZTkgcUmrlJ2/r1/r5Hn8Hj7VdC8MQXT2ditjHo8UtjaQxSOZG8qMn975h2hC/KMu7aAwY84tr488Sy+IrTQ4U0w3Lahc6dNcyWsixyulsJkkRfMJUZO1lJb2IrqNAXwje3V/Z6DptnFLphNjdRLp3keUD83l4ZBlCDnjKnOanvdG8K6HpkV/daPplta6MrzwOlih+yDqzRhVyp4z8vJrRyTld9f6v935+SM4xaSiun+VvzPLtd8SXWoeN/Dut31lahtL1XULSOGGI+efJtnLZcnkMQCFwMDHXPG3pvxD8Wahb+HZZdNsbRNcvBFDJMgYPE8DSKyiOdyNrIQd2Nw5whyB37+HtAub5dVl0bT5bssswu3tEMu4DAbcRnIHGetVdM0bwpqumWN7pujaZLapIbq0cWKL5chPMigqCrEjrwalbWfl/wfvKeruvP9bfd+JU8Pa5rNz4kutO19tPjKRF4IrWJzvClVdxKXIYbiQVKoynA+Yc1w2q/FvXLW51NNPbRrxIYUubWWOGUoV+1/Z3Qt5gLHvuAUZBGGGCfWLax0+O6kvrO1tlnuFAkuIo1DSgEkZYckZJ/M1nXfhDwrPAft/h7R5IlyT51jEVGW3E8r3bk+/NHVXDoziJ/HGp6xYnRbu000y3eqX+mTTSwM0DRQIzEeWX+8y8ctjqcH7tb/wf/wCSP+G/+vJf5mtPTdE8I31jcwaboultapet58S2CKhuEOCxUqAWB/i/I1safp1jpNilnpVnb2VrHnZBbRLGi5OThVAA5JNCdo+tvwX63E73+/8AP9NizRRRSGeNXkc1x8LvhtbSfZJ9Nl0+FruyuLVpvtISwZwow6/3Tjg4ba38ODNa/ETxqtnp9lb+GIxNqSK+mTb7d1aMRlihU3mWPAAcuuRk7MrtPWeB9C0jVfht4LudU0uyvbi00ize2luLdJHhbyUOULAlTkA8egrbPhDw21lPZt4e0o2tzL508Bso9ksn99l24Le55oW39f1/XmD1a/r+v67Hm+mazqFpf3M1vY6XZXN7rMzyQ3EIn+zXH9mLKWVkcD7wYMR94MeR31oPHniBtLleaOwa4e10+6jeC0lk8pbncGHkhy8xXYSApUkHGOMnqJfh74MnmeWfwjoMkjkszvpkJLE9ySvNU9a+HWiXtiI9H0nQ9Pm3JvMukRTRTRp0jkQbSyjggBhgqvpiqcrrbt+H+YrXe/chi8QeIofCulSar9ht9W1W9+zRyPZSRwwA7yheJpN+SEHy7lOXA4qpP4v1yG6ljmXSpV0+4tbTULeJHZrhp2VS8LFvlVS33WVslWGRjNdJp3hXTLTw2dFurGwuLOQlpbVbNEtiSckLDyFXPOOfXJPNWf8AhHdE+0W0/wDY+n+daReTbyfZU3Qx4xsQ4yq44wOKWl/6/r/h/IFseST35m+Hkmg20Wmw2enQJculxFuZ915IqCLBAQoUHOG5IAx1r22sT/hCvCxtYrY+GtH+zwhxHF9gi2IH+8ANuBnv61soiRRrHEqoigKqqMAAdABQJKzHUUUUijm77/kqehf9gXUv/R9jXnniDxBeXeuWXiAJojr9kvoo7ea1MjiKOeFGjlO8biTkjgBScYbrXod9/wAlT0L/ALAupf8Ao+xqze+C/C2pTyTaj4a0e7lkcyPJPYROzsQBuJK8nAAz7ULSVw6WOZn8aazFrr6W8unW897d/Z7EyWrtHCu5x5jOsm2XOwDaDGQzBSO5W58YeIIJ5kB0lm06e2tL2FI5Had5iq+ZEd42qpb7pDElWG4YzW/rGm+FNG0m7uNU0axWyuPLju9unCUSjICb1VDkAkckYHtV8+HNDaa3mbRtPMtrEYYHNqm6GMjGxTj5VxxgcULb+v6/4e/YOp55/wALB8UR6Ob2X+xmI0mTVPkt5QCIpNjp/rerZBB/h7h6htJdRHxC1K5FxpB1W41N7GyvZ7OT/R4xapKY2xMPMBGMLkANvfvtHdf8K/8ABuzZ/wAIloW3bs2/2bDjbnOPu9M849aki8DeEoLSa1h8L6LHb3BUzQpp8QSQryu5duDjJxnpmqTS/H8/8tA1/r0/z1PP5fGfjDWtEuLqzvdK01Yb6xh2rZSSswmljU/P5wG3knOBuU4+U8123xDmvrb4a65NYXUdtdR2MjecYyQML82AGBBIzg5ODg89K0v+EW8Pn7XnQtN/00KLr/Q4/wDSAv3Q/HzY7ZziopPD2hpYy6Zd6XBdWmoXLSyW8lmskLSH5ssoXaPu9Wxk45LHlaWt/XQadrM80t/GGteDLTUItI8L2sui6bM8ExtfKtkWcqD5iq9yWVCxz5ewYHzbzzUuo6zrr3Mep69pNjaarZ6Vqfl+fFG8dxEqwuu+OOaTaDkjb5h9e+K7+407wrouoWLSaPY29zdgafbyxacCdu04iLqvypgEAEgdqdJ4C8HzQRQy+FNDeKAERRtp0JWME5O0beMnnii9/wAvw/r5O3YUfdev9f1+aucvbeNddi1RopV0l7KPURYpHHC8TFWsxcId5kKjaflPGCOflxzo+FNV17xLZ6k3iOC0OmPbqscZ0ua3LsykyIfNdhIqjA3BdrZyDjitGf4e+FG0+W3svDmj2Ttlo5oNNhDQyYwJFG3G4djWb4C8OaOmjz3VpDpMsF2r2sq2GinT45QjFGEsTFizZDA7uOuBycqVpJry/QNuVo5rwl4s1bS/DmgaGh09TdadYCyuGgcrbeYsi/vRvG//AFXGCmSwHvW94V1/X9a8aMl/c2kdrb2csctvDA22WVLh4jKjF+AdgOCGwMjPc9EngnwrGrrH4Z0dVeHyGC2EQDR5zsPy8rnnHSi/8M+H9Q8myuNItcwwbYHFkpEMYZTsRypCcgHAIPGR0yLcry5vN/r+X9bBKzWmm39fP+tzcrzy3v5dN+Hdzcwx2kuPEt4jx3cJkRlbVpVOBuGGG7IPOCOleh1xfh3TtL1PwXdwa7p0Go2n9uamTBPa/aF3f2jOAdmD0z1xx1qBo5y/8ZeJ59A1GOS50uKR7PVRFNBayAxtaS7N3Mp+8p6fwkZyw+WqvhFrrwnr8un6cdJgh1K/VLopaOiCQ6eJVkRfNwo3J8wJO7JORXe3HgTwRHZ5ufCmgLb26s/z6bDtjHVj93jpzUHh7RfA2o2Msvh/w9pUcKzr5qDSltyJU+ZSUZFORuypx0bI60K2vp+o5NPp3/r5HH6Z8SvF2twxyabpNmYobeI3l06oIkeSIOJFDXCvsBYDaFbdzhwRitCDxt4mu7Fgk2kRXj2dldwKLGWXzDcJJ+4CecuW3JnfuACk5HGa66Twn4W86CCTw3pjHypI4v8AiWoyohOXXO3Chix4OM5PXmo5Ph94MmYNN4R0KQqoUFtMhOABgD7vQDindakve6/rb/gnOWvjjWrXxRaafq7adeW+JIbxtLs5naOdIPNYL87Fj1HlqjHGCWBO2qetavCvii+1bT7SErcWOnJLHqenyRtIpvHjO6N9jBhnKlhxgcEV3dr4W8P2U0c1noWm28sO3y3is40ZNoKrggcYDED0BPrVXUPDHhPXNRa41jw9pV7eFvK82+09GkfaM4VnXLADuMjr6Gi6umC0TXf/AIH+R514a8Wy+GfCerRaVaQCHTb+7WOy8nY0pkvmSN42LqgiTJDZxyMZUcnqZ9f14eBTea/pllbX0WowQSwXEaSJLG0yAPsSZxG2HBALtgjPPFdHaeEPDVghSw8PaVbKVdCsNlGgKvgOOF6NtGR3wM9Ke/hfw/LoyaRJoemvpiNuWya0jMKnrkJjaDz6UX6jerv5s8yt2/sfUmvtIis4Lu1/t9oWkhyg2zowUhSpx14BHXNXbz4i+LI9YTQ9O0q01DU54EuoWhiCxhDGrGIiSdMtk/eDdOdhxXX2/gLwQzS+T4O0RChMbE6REmeOcZQbgQcZGQeRVn/hBvCW1l/4RfRcNs3D+z4udgwmfl/hHT07Ulsl6fr/AMD+mEnd39fx/wAjlj4z8RyTTxqlhBPMga0tvJ89kUOqu4dZgk5G7lAUYHAAbqe30K//ALU8P2N8ZY5TcQJIXiRkViRyQrfMBnseRUcvhrQpmuGm0XT5GukCXBe1Q+coz8rcfMOTwfU1LYaNY6ZdXM9jbxwNchBIIo1QYRdqjCgZwOMnJxgdAAHpaxPUyfAf/Iu3X/Ya1X/04XFdJXN+A/8AkXbr/sNar/6cLiukpDCiiigAooooAKKKKACiiigArm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8oA6SiiigDm/FH/IxeDP8AsNSf+m+8rzrxBceOG8S6nN4atvEEKTQ30JW5MjoShjMbxL/q0yPM2YGT3JPT0XxR/wAjF4M/7DUn/pvvKfqXjTR7O/i0+21PS7m/N3HbTWjalFHJFuPJ2k5LAZO3GT2oXxf110BvT+uh5Pa22p2via6bTrTxTBaXXiGycy/Z70PLa/ZdrmRyNzAMADuOQeuKy2uPGVv4aYEeNHvLzSbtTiK/dkuEuALbBA+QmNTk8bh97OefcNP8beGtTtxNaa3YMjXbWSFrlBvmU42DnknqB1IwRwa0r3VtO02W3i1G/tbSS6k8u3SeZUMz/wB1QT8x9hVJtf15W/4PqG39ebf9eh4pHqevp4kkugvjI6dJq/zI1nqBAtWsyHwhTcB53TAyp5XA5rQ8PR+JLvQdHe8/4Saa+k02W2miuWu7cwyLHJ+8YthXJLIPn+bIBUkAivUpvFGgWy3bXGuabELJ1jujJdxr5DHor5Pyk5GAcVFf+KNLt9DuNRtdS02ZY2aKNpL1UieYcCIuM4YnjGCfaplZxd/60t+o43uv663/AK9DzP4c6ZqdtqENpcnxTbWtvodlOIp2uhH9qQt5sa+d8gyCo2DAx0HGRkz23irUtG1WGe08UfYZjpl4kVy9y065mP2hQRzkKASiAAdVUcV3egfFzSNT8P8A9saq9jplqtrBNIDqUcjxySswETJwy9FIZgAd3sa39O8aaPe6ddajPqelwafFdm2hvF1KKSKbgYO4HCsScbCc8e9aSb5ndf1f/htCNEvX/L/h/vPKYZ/F7aRMtsvij7PHNqIsPNjvROZy6mz8wuN5i2Fv9ZmPrv5q/LdeKLX4hM7f8JI0Q1mxDrHBdyWvlG3YXBX5Snl+YR7DgjHWvVf+El0L+0TYf21p32wSLGbb7UnmB2G5V25zkgEgdxU+navpurpM+k6ha3ywSGKU206yCNx1VtpOCPQ81Ke3l/mv+G9LFS1TXe/4/wCXT5lyiiipA5v4cf8AJLPCn/YFs/8A0QldJXN/Dj/klnhT/sC2f/ohK6SgAooooAKKKKACiiigAooooA5u+/5KnoX/AGBdS/8AR9jXnutnxo6u+itrcN+LiVdbEsVxJD9m835GtVDKGbZ2gYNjdk78V6Fff8lT0L/sC6l/6PsaV/H3h5JLmIXVxJLbsFMcVjO7Sklh+7AT96MowJTcBtOcYpdRo821G215dBns9Un8R6xCLVJNMlt9Puot7ecxkSaMs7nahQL52SQCRluTDOPFeJr3UNS8Sm4a+h86ysdLv0CL9oU71cOyMvk7wVRADkbxuArsrr4nQv4gtrfTopvsMd8LW7aXTp2eVWtWnRoSAMngDbtYkEHAyCd2bx/4bhSF2v5HSeETRvFaTSKQU3hcqhAcqCQh+Y9gau9mpP8ArqK1n6nnK6jrFpu+zxeMp2E+oW6q0F7/AMe4yYDudGG7phyC56ZPArZLapbfCLWhe3Orw3Nndu9tM0lzHOI/MVo9rSMZHGDjDE56EdVHVR+O9Cvmt1sNQYNNNAgMthPh1lBZCCVXAYKQHPy5BHJGKcLzw58Q9KvNNWW4ubVSnnIvn2hZT8yMrDYzIccMpKtjqaVml+H5a/13Jdm/XX776en+R5zqcHiy61F003U/EGm+HJ55DZ3Mtje3N1HLsjxuRXSYJu83b5m5OxXbtqG3Gopoun3E8njJbmS81CK5aZtRjCW+yYxMyk4QZaIh+o/vfKcen6n4nsLGSbR7K8CaokLCAzW8s0QkEZcK7jClto3bC4Yjn3rJh8c+H9Z8HKNcnnSS5s4vtdva29ysh8yPcTGEG9kwG+dCQAp54NJ3cGl/V/6/I05rNKX9f1e5xttJfXx0eVh4nudNmksWnkmgu3dZwkgmdDt3ImDH8y4TJypzk1DZSeKtRuLR7/UPEdhaW8QEEf8AZV+8txGrOJFdlkXa5XGGkUt0KHdmu5fxx4Z8M+Hxb6V9tvLaxgjEAgguLhXQlVULMVbfjeucFiAR9K2NU8a6Ho1wkGpT3MMslt9rVfsE7fugQGY4Q42lhuB5UHJAHNVKzbt3/T+vkZxvZelv6/rc8zhGvwaL4auLdfFf2xYrW5vWuHvpNzCZEnQxHvsBOHyCOUUklq7f4e6lE2jtYTW2oWtzJd3twiXdhPb7o2uXYEF0A5V1OOvPTg1bv/iBoEEV8kWplJba3aYzfYJ5ogqlQWBVQJApddwRuM8461Ys/Fvh/UNaFjBM/wBvMklrl7OWL50G5o97KBnHzAZ5HIyBmndtWtvd/wBeSKl3/r+t2eb2Vxqp0+Z9Nl8UXhtpb6C9PnXLqYRcssQjdg251HUx5k2gjOdtUvtXiCDStTs7geL2u47KeOGSG31BgXW7LQFW5yfLIyckleGJwRXfazc2vw80ey0zw7FcRy6pfMkT3EV1qCRyMGd3fDFuSCcbh1Ldmq9YeP8ARJ9I+0XF2zTxeWksdvZ3DGR2UkGFCm+VCFYhlBBCk9jUp/a7f1+v3hJXXL31/r7vwKXg3WhHrGraTdDWgr37GwfUrO62tH5SFgJpVwfnEhClug4GMVlST3Ft8NLmayXUmnTxLeMo02OZ5Co1WUvlYssV2bsg8H8q6y28XeHL/VbO3trxJrm4TNtIIH2ncm/YJNu0OUw2wkNjnGKyfD2qw6P4NuLi5n+zq/iDUIRIbd5gGfU51AITkZJxk4AJGaHfT5fgC0Z5/dzX8mg3cEsPjO4jvbbVYPKktdRckebm0BBXK5Unk4yOGOOK0LVtWs4IbezTxckSamrwu0d5KUtpLLbgiT7wEwPyt9w4J2g5rt7v4l+H49JvruzluriS1t55hD9guFZzE2x1GUHKtgMOqg5OBzVfw78QbS40sS6/fRJK929ujR6ddWyqREJdsiyrlGCEnJOGAyDzgC6+i/P+kXJvqur++36I5FbnxFZyRwaTa+IzOLa9jR5BeSRTNiIq/wC+B2MSJQvmE89GKsuXzC9/te18h/GX9hyPN5YYah5yp9nO8P8A8tB+9CbC/wA2d235a72Hxvo1xcx7byS1j8maWRLzT54W2x7cnc4ULgMDgjJDAimH4ieGxsBursSOzqITptz5oZF3lTH5e5TtO4AgFhyMih6r5EHPalNq9/8ADLQLiVdaN8tujXVvHFcwTSzCPbtcxgOh385Ksndht5HO6hBrd5dSXml23iJdQtbrUEsGuVu9qM0SGP7xCsm4OAW+ToM4wK9SvfFOkWGk2upS3EklrdqHga3gkmLqV3btqKSFA5LEYA64rJf4haTbapFazyzuk09xG04sJ40tRCoLCQsp9c7vlXBz9SWsm/X9BLaP9X3OZWLVbT4P+JZ7jWtWmkWCS5tZZbe6sZ7ZlTO1TNK0rAMueW2nJAyvFZOtt4idrt9C/wCEr+xkNcWLy/a9wmVUMilMCQg/NtDny/vYVsqK7/V9b8LeIfBWrSapLdPpEAMeoIsNzDNGBgkMihZQMEHpgqc9KfH458MWEENvJfXFvGke0Pd21woUKpIDvIvDFVJG45ccjOc0763HbRL1OAmvr251S6QL40SESagy7bbUkUqUVocHb/fDbQOR06EA+meE9aXWdBtzIt4l5DDGt0l5Zy2ziTYMnbIqkjOeQMdearN8QPDaaeLx7ydY/MdGRrGcSxlAC5ePZvRQGUlmAUBgc8iqWmePdFvdWuLaIy6f5dxOJWutOmjS4ES/M4mKqgIxnksdo7dpWit5fl/w+orbPzf4/wDDHY0VzJ+InhtWjQ3V0JZJGiWH+zrnzCwQvjZ5e7lQSvHzYO3OK3rC/ttU06C+sJRNbXEYkikAI3KRkHB5oGYfgP8A5F26/wCw1qv/AKcLiukrm/Af/Iu3X/Ya1X/04XFdJQAUUUUAFFFFABRRRQAUUUUAFc34o/5GLwZ/2GpP/TfeV0lc34o/5GLwZ/2GpP8A033lAHSUUUUAc34o/wCRi8Gf9hqT/wBN95XM614F8Q3Ot202lDS47CHVIb9oJLqQZZZGd2X9020tu5XJUnLcEkV03ij/AJGLwZ/2GpP/AE33ldJRs0+wPVOPc8mg+E+pE6VHqMtvc2tpJexzwRahcW4khnm81XzGASwIAMZ+U/3uBXX6v4ZvbrxvY6zbizu7RbNrK6tb1mwo8xZFlT5WDMGUcHGcA7hiuqop328v1/4cHrfz/wCHPINS+FPiG50S80+3u7F9tlcWVq811IPPWe4EzPLiM7SoGABuyecr0q1a/DvxLDqsmpP/AGSJBqs15HbC7kMZjltxCcnyhh1xkcEHJGR1r1Wil0t8vxv+Ydf67WPEdH+Eniyz0l7S7fRgyW+nxxNFeSsHa1nMvzZhG0MGI4zgjvnjcj+H/iVLu61DOmfaTq13eQ24vZPKeO4h8o7m8nIZeowpByRkda9Sopt3vfrf8bX/ACFb+vRW/U8Zl+FXie1uEFg2kXccA0tY5bu8lR5BaZLbgIWxuJxgE4A/CvRvCeiXmhQXcFyYFtjIv2SCFzIIYwoG3cyg4z0U52jgEjGOgop8zd79QstAoooqRnN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQldJQAUUUUAFFFFABRRRQAUUUUAc3ff8lT0L/sC6l/6PsawpPhrevqF1etrVpNPcKys9zpzSMRvZ4yW84NuQv1Ur0GNvOd2+/5KnoX/YF1L/0fY1gat8Vv7Gjt7i50V3s9Sne20uSCV5ZLiZX2FZI1jLIDgkbfMOAeM4UrS4+liRPh5q9vrFveWviSF44bqO8YXmntLLLKtr9mJaQTKMFfm+7nPes7S/g62lr5gvtFur1oVU3lzoIkljdE2I0bGXKDaFyuTk5IK54ZrXjnUte8K3aWmjX2lXdmkU94ZLma0kgBmKoYwUR5FbyycME+U8gn5asn4sXc0rvY+FrqayNxHFDdSmaFJA06w/eaDZu3MGCq7ArnLKRir1k+V7sOZ7drD4vhtrsN3ZSJ4nsRHaxWUZX+yH3MLbdtwftGBuLtng9vTnR0Dwfq/hjUXurfU7a/e9MEd60lmyvIse/MhczE7yGHOG5XoAflhi+It7hjeaHBCqtdwMw1EY8+3zuGWRQIyBw5IP8As966Dwl4hfxNor3k9otpLHcS28kaSM65RsZVmRGIPUZUUczevzIslp8vuKs3hnVY77V30vWYLe01TMjwT2JlaOYxhNyuJF+QhVJUjPXDDNcnP8Hrm71CyvL/AFbR79rGygs4YL3Q/OhYRKy5dGm5J3E8EEHHPUGTQvFWt6Xp1zY22mHV5Fm1KSza61NzJKILkqYiWRyMIwCkk5IwQBzWmfH2q3GoW8OkaFZXsF1ZNdW8/wDabIHKxxuykGHgYlAB5yRyF5wtl934X/4JpKD5rev5q/6f1cLj4cSutwllqltYxSW6xpDbaf5ce9WQqzojhXCiNVUAKwGRuxjDfE9nqepeP9Ls7KaS28zSLqC5vTpcs0ADvF8ocEIjkIxGWOMDIORnKb4zvdWVxfaL4YvbyxhtXm+0SLNGiskQkZWcQtGoxlQQ5JYAFQDupuseIvFN1r/k3NpbWUVpd6a8CWWqS5fzpWUrJ+7UMrLnIOQuBgMTkPld1f8Aq+n6kOXLFy/rSzLWo/Ci8uRdfY/EMURltJrCN7iwaZ47eTy/kJ81clfLwpAAweQTybH/AAgvia3uI7+LxFpst3DqEmohf7Gfa7tB5OzBuhgbcn73Uj0qJPivcT31vZWfhq6u7pX8u9W2E8qW7ec8PDpCVKho2Yl/L+XkAnig/ErXEs4LqXwxZeVPp1xqCbNWYsEgKiQEGAYPzfLgnOBnbnILv8/83/mNRu0kv62Ok1zQtX1tNDli1K1sJ9PuFupwbRphI+woVX94u0fO3Xd29OefsfhpqOnXw1K28QwHU0aJxcSaeziR0WRC0o87L7kkwfmByoIIHyixF44ubrxFYWN1owhDzZSSPUm4V7aSWMsuxVYkIwKk7VO0gt1Gt4O8WyeKVvxPYx2j2cqKPJuDMkiugdSHKKD1wduVyOGNGqv94rppf13KNh8PYbPxlN4glbTLqe4kWeWWbSkNykoQKfKn3ZRCFHykMRk/NzVPT9Eu/EPw/u7CwvobCU+IL+XzprYzj93qczgbQ6dSo79M139cDp2pvpPgG5ultvtC/wDCR3sTqLloCA+qypuDKCTgsDt4BGQTU9kNb3Kc3w01+WxMA8UacrOl+kj/ANjOQRdvvfA+0cEHpyffNW/+Fd6sWVm8RWuftkd66/2XlWkFv5DcGU/KVwQDnBzncDgVr34j3/8AY16954fiRVgviBDqrqzG1l8uQB1iDLkHKsOc8YH3qmf4qqNWuLaDQL6azjma0ivRFMI2uBII9jOYvLVS5wGDseDlRT1+/wDR/wCZUuZb93973GzfDG+uWSObxDGtosdxGIIrFh5SyhNoiLSsECmJWxggktwAQBam8Ca1Pq8GrSeILE6grO07/wBlt5ch8lok2r5+VADMTkncT/COKoeI/GPirTZ5Y73QLGO2i0q5urqCPWHR2COq7o5Uh3fdPH3DknOMDNnxB8S7rRbG51C20OO70+GWa2jla+MbvPCrM6svlnauI3AbJJIGQAd1Fm0vP/OxKV3Zf11NCTwRdyeCNK0E6rAJ9OhWFL1bNgRhdgdAJN0bhc/MH6nkEfLWbdfDK71GG6g1PXYZorqa6aTZYFW8ueNUK5MhG4bFO4gg85Xnje0/xRdXdjrTz6SVu9Kbi2t5jN54MSyJg7QdxDAEYOD0JrldW+IGrLps9zZafYC9j0y6nikh1SSSFGjljRlZPKGWG9SCyhgQwwoJy3eUnfd/8P8AoLRRT6L+v1NqHwC1v4D1Xw/aTaPYT6lC0L3GnaOLeIAjaWMSyfM20nndjpx2NK++Fwu9VudSS802O+u4U829OkK9xDMkYQSW8rPmIfKDt+YjnDAnNXfD3j+41zxM2lNoVzHChlhkvoo53hWaI4dd7QqhXIYKwYk45Va7Sk77jTt7vY4PSfh5qOhaj/aGla3aQ3Lyu0inTWMTJIsfmDb52Q26IMG3HGSCG61HqHw2v9SvJo59eg/suaW6kaAaefPP2iMo/wC983bkZyPk+oNegUUX/wAgsv1OFk8BaxNrVjrE2v2b6jbSo0kn9mMElVI5I0Xb53yn99IScnJxgADFa3g3R9Z8PaYmkape2l9a2cKR208FobdmxnO4GV89ufl+hrpKKLsDm/Af/Iu3X/Ya1X/04XFdJXN+A/8AkXbr/sNar/6cLiukpAFFFFABRRRQAUUUUAFFFFABXN+KP+Ri8Gf9hqT/ANN95XSVzfij/kYvBn/Yak/9N95QB0lFFFAHN+KP+Ri8Gf8AYak/9N95XSVzfij/AJGLwZ/2GpP/AE33ldJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJXSUAFFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7GnSeAfDUzXZl04uLoszobiXbGxYMWiXdiJiwDFowpJAOc02+/5KnoX/YF1L/0fY10lAHNXnw98N6hGq3lpcykReS0h1C4Ekq5yBI4fdIQRkFiSD0xTJvhz4anheF7W8ELzLP5SancoiyK24MqiQBTu+Y7cZIBOSM11FFAHIyfC/wAKzf621v3/AHss2G1a7I3yffbHm9TWnpnhWy0bVHu9NkuokkRhJA13NIjuSCXKu5Xdx1AySTkmtuigNzlovA2l6PJHqGg2U0mo2pme2S61e6ERaU5k3ZZxhjycq3POKy5/h+8mo6BALe2GlWUVz9r+z301tIZJmDtsWMDK7gQQXAIbkHHPe0UDv1Oau/h94avVuo5bGaOG7iEU8FvezwROAAufLRwu7aAu7GccZxTrvwF4fvry3urmG9M1usKoyancpu8okxlwsgDspJ+ZsnnrXR0UXYuljl7T4c+GrFw9pa3kT/PuddTud0gZixDnzMuNzM2GyAWJGCTUbfDPwu1tBbm2vvKt7aS1jX+1rviKQ5dP9byD7+g9BXWUUDu9zk4/hl4Xj1GK+FrfPcQ7djS6rdOPlQoMq0pB+UleR0J9TWvovhrS/D/mf2VDLGZURHMlzLKWCDC53seQOM9cADoBWrRTuybIK4rQNC0/xH4Ju7DV0mktjrupyFYbmSA7l1Gcqd0bKeCAevUCu1ryzUpJIfhTdzR6nNpiR+J7oy3MTIuyP+2JAxYupUKASTkY454yKW7SKWr0Lt34A0DV/D6f8Iey3Uc32iD7Y2u3MqRLNkTMo3OsrbhyrYGRnIIrqJfBOgTy3jzWTuL0Hz4jcS+UzEYLiPdsV/8AbADe9ePnx4ui6JctpXjW3gS6l1SaEB7Zh5iXe6NgWU53h2yOhGCoGM11Z8UajDq0tt/wljvLFcGNrWWO2BNkYt/20ERjhc5D/wCrwu0gnkt7BL4mv6/r+up1eo/D7w1f2KxajFePFHC8TyNqt0rvG2CyySCTc4+Vfvk4AFQp4I8Ha/pz3EEZvrK+iwZINTmaKUbdpcFZMbio2lx8zDIJOTXnFr8Tb1dHjurnx1avKNItNQZWFqN0xkKSQkBc7SMEj7wJ4Kjirum+J9U0fSYl0rVjdWi+aNRjEMbf2QDdKBLkLkExyO+H3AhQwG0HLs07C+1Y9OsfCOj6d/aH2aG4YakqrdCe9mmEm1do++5wdoAyME4GelZsfgDwnfbrmOGe6EkMts0o1O4kEiucSAnzDuOVHzHkbV5G0Y5T/hLdTjuLXzvErTaat95NteQC38zUYyY8PgoEdRmUExFT8m7DAEUaB46mvJtBuLrxQt1bS7o5BCbfMpDyhpJRsGVCqhJjI29WXBBpdmLbQ9A0/wALaTpeove2MM6TPywa7ldC2MF9jMV3kdXxuOTknJrXrh/G/iRLKfwy1l4oi0q11S6eJ5laBlliMDsHUyKw4YJgjj5hkHIFcJbfFC5uLfS4H8aQfbNWskYLCLUGGYOV2qSpCbgMneH54VRkClcq1lf5/jY9riv7O4vbizgu4Jbq22meBJAXi3DK7lHK5HIz1qRbiFrl7dZozPGqu8QYblU5AJHUA7Tg+x9K8TsPHRu5Zbka/DbazeaXpcVw9uYdyTEzl1O8FYzuZQcqcbgAuWFT6f8AEO/1KwmWXxZbw3C6dYXNyqvbxvbuyyeeqs0ZVDlUJ8wYGcZXcMU42v5Ae00V5R4f8ca1d+LBJq+sabYaXBHunstQnWC4MHlBluPK8rK5Y5LeaUAJGARmvVlZXQMjBlYZBByCKTTSuSnc5zwH/wAi7df9hrVf/ThcV0lc34D/AORduv8AsNar/wCnC4rpKQwooooAKKKKACiiigAooooAK5vxR/yMXgz/ALDUn/pvvK6Sub8Uf8jF4M/7DUn/AKb7ygDpKKKKAOb8Uf8AIxeDP+w1J/6b7yukrm/FH/IxeDP+w1J/6b7yukoAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP8A9EJXSVzfw4/5JZ4U/wCwLZ/+iErpKACiiigAooooAKKKKACiiigDm77/AJKnoX/YF1L/ANH2NdJXN33/ACVPQv8AsC6l/wCj7GukoAKKKKACiiigAooooAKKKKACiiigAooooAK5vwH/AMi7df8AYa1X/wBOFxXSV53b6feal8PLqGxtRfBfEOoST2JdV+1wrqU5eLLELyOzEA9CcGgD0Ss5dZjPiZtFa2nWUWoulnOzy3XdtIGG3ZBx1UDngmvKbn4da5c6hC7Q6na6bln02ysZrMNo7+YWXc0obaMY5hJIAK4YYqvc+B/Ek0UEcfh24tn+xpDqtxb3Fozak6Sgu2JCyt5gGR5i842ttGKFuv66P+vyuEtE7f1qe30V4ZJ4A1OyN0un+EtUuSLey+yXVxc2InR47hnfJSRApEb+WCo4A2g462rvwfrt1JJBaeDpLG2tb+S708+baHyR5sThUUSlYtwV+VG7JxlQSS7K9glotP60/pHtNIyh0KnOCMHBIP5ilByoJGPY9qKQDIIY7eBIYV2xxqFVfQCn0UUAFFFFADJolnheKTdscbTtYqcfUcinIixxqkahVUYVQMAD0paKAOb8B/8AIu3X/Ya1X/04XFdJXN+A/wDkXbr/ALDWq/8ApwuK6SgAooooAKKKKACiiigAooooAK5vxR/yMXgz/sNSf+m+8rpK5vxR/wAjF4M/7DUn/pvvKAOkooooA5Lxxptjq+qeEbHVbO3vrSXWn8y3uYlkjfFhdkZVgQcEA/UVwenQ+EbLxRr1p4t8NeEorCx1GLT7RrTwz88kkqK6b2BcDrt+6ATzkdK9F8Uf8jF4M/7DUn/pvvK5i7+F+t3WtX97/wAJLYJHe6tb6o8X9kOSrQ4CIG+0dMKM8cnOMdKF8Wu3/BX6XB7f12f62Fgi+El08C23hnR5mntpbqIR+HC26OIkSdIfvKRgp97OBjkVLLZ/CaCS4SXw3oavbgFk/sEFmO4LtQeVmRwzKpRcsCwBAJq1o3w3k02x0OK61gTTaRf3F2JYLUxCZJt5eIqXbjL5znooGO9Fl8MLHT77W7iEaZIdTnedZLjSkkmTzDueN5d2XjLcgDaR69MPT+v6/qw/6/r+uvkczr158MtP8+2s/CGix3K2cd0s914ZkMMYkfaol2Qlkzg/exg8dc41pk+ENvqz6dN4d0MXEays7L4f3QqIhmT96Itny5APzcEgHk4p+rfCm81Czu4YfEgV73TbewnlurNp2PlSmQMD5qnncRgknpye/P6foPimf4gavbQ29lYpcC5jj1WKxvY5rQuP9dGHJtjuYLkRtvbILHIODS9vX/gC835f8E1Ly4+EtvZWtxD4R0u4FzemyEcfhsmWOQLvYNF5O8ELzjbkjkcc0/Rbf4Y3emaU1/4f8LvdahEkge10PEIDsVQktH+7DMNq+ZtLEEDNWY/hRcW0jXFlrsa3Q1X+04nlsS6Kxt/JKsokUsOrZDD8etQab8HDZWFpZz63HPCsVtDe7bIo1wtvM0sWw+afLOWwx+bIHG2mlHr5flr+If1+P+Q6Nvg7LNNCNB0FJITOrrLoITDQ48xfmiGWG4fKOTngGt7TfBXw/wBWsEvLPwbovlSEgCbREhcEEggo8YZTkHggVhwfCvUotej1CTxBYyxi9vLl7d9JJDrc7Q8ZzMRwFxnB69K7jw7pMuiaJFY3F4bx0Zm8zaVUBmJCqCzEKucAFjgADNSvhV9/6uD3dtr/AIdDO/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JrpKKAPO/APgHwfefDbw1dXnhPQ57ibSbWSWWXTYWeRjCpLMSuSSTkk10H/AArjwR/0Jvh//wAFcH/xNHw4/wCSWeFP+wLZ/wDohK6SgDm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mukooA5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJrpKKAOb/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDia6SigDm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mukooA87vPAPg9fiTo1qvhPQxbyaTfyPENNh2MyzWYViNuCQHYA9tx9TXQf8K48Ef8AQm+H/wDwVwf/ABNF9/yVPQv+wLqX/o+xrpKAOb/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDia6SigDm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mukooA5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJrpKKAOb/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDia6SigDm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mukooA5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJrpKKAOb/4Vx4I/wChN8P/APgrg/8Aia5/wX4B8H3Wg3Ml14T0OZ11bUow0mmwsQqX06quSvQKoAHYADtXolc34D/5F26/7DWq/wDpwuKAD/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJrpKKAOb/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDia6SigDm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mukooA5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJrpKKAOb/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDia6SigDm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mukooA8x8OeE/Aln4TvL/WfDGiMker6jEHbSo5XIF/MkaKoQs3AVVUAngAClY/CFWRf+EZ0lmeJplRPDTM2FcIy4EOQ4YgFPvDIyK09F0aTW/BU8Ntd/Y7qDxDqNzbzmPzFSRNSnI3LkblPQjI4PUdaZefDzVLkCWPxBbRXiT/bYpxpzfurtmG+RVEw+UoNgQk4BJJbJoXn/X9f1vdD8v6/r+ttasVr8J5bH7YfC2kwwCaSB3uPDZh8t403uHDwgqAoPLYHbOeKgRvhC8NxJ/wi2mp9mfZKkvhZ0dTt3H5WgDYCkMTjCggnAIq9eaTLcReKNStorqT7TZ/Z/JbT2USXO0pLKkL4ZlKrGOpBCnaTnJxtL+Hi69bQXM6WFwbWRmil1jQrlln3gLIJIbuZpSwEce2QsMDgAgUx6f1/XyNfSdN+FOt3kdrpvhnQ5ZZDIqb9BEasYz86hmiAJGc4zkjkcc0lxpvwstbi6hm8KaPutTtYp4e3iRtwUrGREfNYMQCE3EE461a0LwHquj6hp8z63YS29nd3FwYIdKMO4SqF2AiYhdvOMLjpxxUuo+Bb+81S7urXXEtI7lgzW8dowSb94GPnBZFEnyrtBG04J3Fs4pdidbM5+Ob4Ty63Dp6+D9L8u4ht5Ibr/hHcxOZnZEUsIsIcrj5iOTjqDiwB8ITM0R8MaSGRZGct4aYBFjcpIWJhwArDBJ6cE8EVZh+F9zaWscNnrcEYhgtoos6eSFa3uGmiOBIOPmKsoxnggr0qWz+Hus2up31yPE8QS5hvI4zFp5SaFriTzC2/zcEqwGMKOPfmq0/P/gDfl5f8Ex7uf4VwNbCHwXYSLcGZXdfCzsbcxqCd8Yh3j7ynBA4Oc4xWgdP+Flv9niuvDmgySywq/mQ+HwY2LJvC5EZCuw5WMnecjANPj+Guo2kMn9m65Y280ks8jFtLdkHnQpHJhfPBzlNwJY9Tnd1qa2+HN9b2n2Q67BJbu1vcyobAgtcwoio6nzflT90hKck4OGANT/wP+D/X/DiV/wA/+AGhaJ8L/Emf7H8L6FNiGOcb9DWLdG4O113xjcDgjIzggg8jFO1Pwn4c0Hxb4PutD0DS9NuH1aWNpbOyjhdlNhdkqSoBxkA49hVvwj4M1Hw1e20lzrFtewQaVDpwjjsGhY+UzFX3GVh/EcjHpyKueKP+Ri8Gf9hqT/033lVK19B9TpKKKKkDm/FH/IxeDP8AsNSf+m+8rpK5vxdZaxcXfh260Cyt7yaw1Np5EubnyIwhtLiLJcK5+9IowFY5PYZIPt3jf/oXvD//AIPp/wD5DoA6Siub+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOgDpKK5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6AOkorm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DoA6Siub+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOgDpKK5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6AD4cf8ks8Kf8AYFs//RCV0lcJ4Tj8daN4L0TS5fDuhh7LT4LdhLrkqvlI1U7gtqyg8cgMw9Ceta/27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAHSUVzf27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdABff8lT0L/sC6l/6Psa6SuEuY/HUvjTTdUHh3Q9ltp93bkjXJdmZJLdhk/ZdwP7o4AUjrkrgBtf7d43/wChe8P/APg+n/8AkOgDpKK5v7d43/6F7w//AOD6f/5Do+3eN/8AoXvD/wD4Pp//AJDoA6Siub+3eN/+he8P/wDg+n/+Q6Pt3jf/AKF7w/8A+D6f/wCQ6AOkorm/t3jf/oXvD/8A4Pp//kOj7d43/wChe8P/APg+n/8AkOgDpKK5v7d43/6F7w//AOD6f/5Do+3eN/8AoXvD/wD4Pp//AJDoA6Siub+3eN/+he8P/wDg+n/+Q6Pt3jf/AKF7w/8A+D6f/wCQ6AOkorm/t3jf/oXvD/8A4Pp//kOj7d43/wChe8P/APg+n/8AkOgDpK5vwH/yLt1/2GtV/wDThcUfbvG//QveH/8AwfT/APyHWR4aj8daVpM1vJ4d0MF9QvbgeZrkoOJbqWUfdtWGMOMHOSMEhTlQAd3RXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AdJRXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AdJRXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AdJRXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AdJRXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AdJRXN/bvG//AEL3h/8A8H0//wAh0fbvG/8A0L3h/wD8H0//AMh0AZmhau2jeDZ5YbcXNzP4g1G3t4Wk8tXkfUZwNzYO1e5ODwOh6Vzui/ES80USaTLpGp6rdxX1w90sTXN41vCbl0UK4jfdja2A5QbV4OeK0bDRPFs/hm50nWPC+hywzajd3WH1+aJ1Ml3JMjK0dsSuNwKsGDYwSFOVDbbwVqdncCa18J6RFJ5jyMy+Lr/5y5yyt/o/zITklDlcknGSci31/rYb+G39dTSk8c60dOtNStPDltLp+oTwR2cz6mUZ1lbapdfKJVslTt5GCecjbVCx+Kl7fR3Dp4ZljjVQYLmaSaK2kbzBGVMrwKOpyvl+YWHYH5aa/gzVX2j/AIRXSkRLkXUccfi+/RIpA27KKtuAg3c7VAUkAkcCnt4S1dmmI8J6OglmE+yPxZfIsUgbdujUWwERJ5OwLnnOaP6/L/gku9/68/8AgD2+Kvkabaane6SLaxlsTdSeZcMJWYK7GOFTGBIQUwRuDDIO3HNV5/H2o67ot9p0fh29sdRa2uJP3s1xZjyEVcyxSPEkhbMigDavIPzAYJkXwhqaxpEfBugSQIHAgl8TXbxEMCDmNrUqeGIGR8oJAxmmyeDdVltIbebwnpEqwBlSSTxdfNIEYYaMyG33FCP4CdvtRJJpoqLs0zuPDssk/hfSpZnaSSSzhZ3c5LEoCST3NaNclpw8YaXptvYWXhzQlt7eMRxLJ4juZGCjgAs1oWP4k1Z+3eN/+he8P/8Ag+n/APkOqk05NoiCcYpM6Siub+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DqSjpK5vxR/yMXgz/sNSf8ApvvKPt3jf/oXvD//AIPp/wD5Dqjc2/izU/EnhuXU9F0u2s7DUJLiaWz1V53UG0uIxlHgj43SKMgk8jjGSADsqKKKACuZsPGU2o6rPZxeF9aSO2u/sk90xtTHG+AckLOXK4ZTkKcA89Djpq82g8K6rfzeLL1LXVNH1O5nmfTpJtRBgffAI1byo5XVSCCdxUNgjnqALfXt+qB9Eu/+Z6TWRrniWz0GMmdJbiRdjPDb7S6IzhA53MBtDEd89cA4rzc+Bp7nxDpNy3ghYNJ+2I1xpzm1dbf9zKkspXzCCHZ4iQuSwiywzgHU8feF7u78QSX+l+Fjqkk9hFbLcW7W8bwlJw7AtI6MAU4G3PocU2rNf10Dp/Xe35anpdFeK3fgPWdS1V45tF1aw0eO8mNnb2E2nq1uzOrLOu8uEHB5TEi5OAcmtrx1oS6r4xe1ttCGo395obxJOHjQ28glHlzMzFT8jHIKgsM8Dk0lry+f+Vw6v+utj1CivEtd8Bax/Ycum23hBdQaGTUUhmjltgGW4BaNlDupChyCQcEFQQD1q3pvhcTeKb+30Xw2umXFtqVndC9TyUFj+4iaZCFfJZxuB2BlbJyeBTDo/n+H+Z7ESFBLHAHJJ7UV47/wguqy2cRuPDrrLDb+XqMavbSLq9ypBW4ZHbbIOG/1hRvn4xtBrR8KeC9YsvHEWra5Bex3Ma5Sa1mtjaCIxBfs5JX7QQp6KSUyA2c5oSuxPQ9QZgilmOFUZJPasLS/F1nqenfbmtbyyt3kjS2e6RVF0JMeW0ZViCGyODgjuBXIah4T1G4167uLjw/9smFzcSyX4eE/b7R43CWZDOCcFlG1wEG3dnNC+EJG+EPh/S5vCMbXOmz2stxpZW2Jco481gd/lksNxyWGQeeSRRGzV35fjv8AcOWm3n+G33ncaRrqa14fXVLSxul3F1+yyeWJQyOUZeHKZyp/ix71qZGSMjI5I9K8PufCfiD7CBF4FumnuLe5E/7+yyZGvFmhLEzc7FDYIzgtx3rvfC+hXVn4m1i4uNFW1tb5S7zT+U0szs5O0tGx3qFOPnUFcbQWHND8vMlX6+R1H9qQS6PJqNiGvYlR3RYCuZdueFLEDkjAJIHvis1/FtovhzSdaW1untdUe2SMKE3ReeQELgt0BYA7Sx56GvM4PAGrW/8AY6WfhRLJ9Okibz4WtgWxO3m4PmfKGRg3ygMwGGPAWrFr4M1vTNL09bDwzLDJbHT4buKCe3H2t4Jkd7nmQAjam0FsOdwBUAU4JPfuvu6jldbdv6+49iorzDwpoGoeFPEl1qmr22rz3d1KbaacS2X2e5EkuUkAXbM5UcfvMsoJC7h03PEOueH7TWpba+8S6FoV4oBd5NQWO5YFRjcm5Pw3bxwOKnoh9Walz4y061u9ZtpYbwSaPFFJNmAqJPMyEEZbAblcZ+7nvwcWNK8R2ur2lnNbwzo900imGQLvhMbFX34JHDDbkEgkjGRzWRYWNxd+N9Ze+0qS50i9022gS8naCSK62GQsNgYnBEo6oAcN2xmlqel+JdNh09/CVpHa75QstrbrAqW8K4EcRDcCMDeW8v5tx+XinbWwvT+tDtzIwuBH5L7NhbzcrtBz93rnPfpjjrSyS7Ld5Y0abapZUQjL8dBkgc+5ArgfFvh+71TxZcyReHp7q0n0tIJbmJ7YCZlnDiNlkbLjAPysNpyRkZJD7zQtTm8L+HLe70CG9gtZD9t0iF40TBVgjBXcodhKtt3ED+EnaKnXlv1/4LH9q39bI6/RNXh13QrPVbaOWKG7iWVEmADqD2OCRn6E1S0LxOviC6mW20nUYLRI1khv51jEFypJAMZVyx6E4IGBjPUV5d4d8Aa5Fc2M/iLSNVlNpbxpBbwzWDRIiR7JIHZ8yFXO44Vtrbhu2kEilb+CNUttHt7W3+Gs0Ev2CGG4eGSwTzJ0nSTzMicE/Kpwx5yfxqtOb+vMJKydvI96rOn1qK38R2mjyW8/mXcEk8c42+X+7KhlPzbs/OD93HvXk114D1nUdVdJdF1aw0eO8mazt7CawVrZmZWWdRIXCDg8piRcnAOTW/4c8O6xp3jfT7298PuJYxexX2rrcQt9q8xkaKRhuDkbV28rlTgAbeaI6pP+tg6tHpdAIYAg5B5BHevJJ/Bmqz+I9XupvD0n2e+SZJlgktiLnbcJJGzeY5MoZNw2yYAwUARcE7GqeG7u/wDCvhWyvvDEF29reI1zbxLD5dtFtZT8skmMYYZVS3ccjGV9lMPtNep6HSO6xozuwVVGSxOABXi2n/DnVrPTpYLrSby/nneOG+E72JtpwCcTRxqFMhGf+W+SB0DkAVpaD4L1AWVvaeKPDP8AaNytjFDbX8s8LC0Cw+XJE3z7irEM2FDK28bsY4H8LaHbWx6fZ30d+iTWqO9rLCk0VzxslDZOAM7sgYPIA+YYzzizXiujeDNWsYzFF4GNpYi1sFvrLfZqupNEJRMpCykMSZEb58BthBIon8EavbfbGg8IzXEhtF+wsk9tm2YXTSRxgtKCGjjYAEcDBCnGM00uay2Iu+W/XQ9pyCSARkdR6UtcN4T0LUbG61xxpf8AZX26IOk8/kmdpmLsdzRMQ4XeAGYBuCMsADXNweDdXSKCb/hGBHaxrCmr6T58DDWZF3B5h8+xuSGzIVZ8YYDAqSj12ivMJPBIu7i6tb7wgJ7ea3CabPNcRMNOj8rYYHy5bGcnCB1JbBOFBrH/AOEN1O51/TptR8CGa3ZNPW6dpLN8GFJY5S4MmTkOnTdlRg8/LTX+X9fIX+X+R7G8jJLGiwu6uSGdSuI+M5OTnnpwDUleHt4GvLbTFW0+HJ855NTjcRGxUiGYv5C580fKN4+X+HaeOmbF7oWo29pLYDwrJAl7PZtFaTtaTR3UqQN52+H7Qok6DO51yVDZJABXp5Dejt6/h/meyTSNGFKQvNucKQhUbQT945I4Htz6A1JXmP8AYKQfD/w3aaH4Vmvf7N1FXmtQtpHJHsLCU8y+Xk8j5XbOcE9ak+HmgaloWq2XneGJ9Ki/sowXMvm25VpVlJQHZIxOE4BwQAccU+rX9bX/AOAJt/162/4J2OneJIb/AFqbS5bG9sblIhPELqNVFxFnG9NrHocAq21hkZAzWzXNaNLf33ia6vNT8PX2nssRhgnuJbdo/LDZwvlys25j8xyqgAAdufP9d8D6ze6dqCDwwbjUCLhbi7Wa3/4mu+TMJ+Zwcx8HL7Sm3CZzSXQb3Z7LRXA+LfDMV0vhaOw8ILeWdldPJcWsS2yCCJ4XVkIZ1B3M6khSQdpznjPI6b4T8SQWljE3hG4QCxij1RJbm1xf+XMD5TESnd+7yBu+XHykgE0+tgekb/1ue2UV4wvw91SW71b7L4c/s4z2Lf2bOz2xNmfMJEKkMxVgjMoIUqu4gHA50rrwxHo3wZ1m1uLC+SNpBcx2eom13QvuT7gtwIoxkZG3oSTwTS6Xf9aibsz1WqsOoQ3MxS0DXCpK0MskZG2JlGSDkgn04B5645ryLW/Aus39tdnTfC/2S3nmlubO0M0BexlCRYIHmGNC7I53JuYbhyu5iC98Eawmq3f/AAj/AIUOm3txNfsNaha0jws0Z8sFlcycMeflODyM0f5f5f8ABG/I9nqCG+tZ5riGGdHktXCTAH/VsVDAH3wwP414zD8Prm18nZ4Q1S9je2u/NivZNNHlSPGoVFSJkQKWQNwPvHccHJqWPwJqb2d/LP4Q339xJBOrTfZJFlYWyRlZR5mTtkDvuVgRncpJJFNJa3/rUD2iioLOSWS3/f27W7odpVipDY/iGCeD2zg+oFT0hIKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFc7qPiK4svGGn6esUZ0+Y+TPMQdyTOrNGAc4AxGQcjq6dK6KuH1H4df2nFe3lzLpLeIZbxbi11g6TmS1VGUog/e7jgLjhlBzyvXItw6D9c+Idjo/iS2gNyG06NZ/t7Lp88rIY1zlHUbW2nhlUMR321q3njjQdPaRbu4uY2jRHYfYJydrLu3ABOQByxHCfxYrIsvAWo22oWjXGt21xY289zMbU6eQX+0BvNXf5vA3MxXg4Bwd3WoL34Xx31jpYvrux1O908uvm6tpi3UM0bBVw0RcYYLGgDBuoJxzigOv8AXyNf/hYnhw+d5c97N5MpibytMuXy4GcAiPDfKd3HG35vu81Ja6l4UvvF4e2htpNb8got2bIh3QYLRrOVw2MjKBiRnkCsiP4fXyaPf2J1ax/0i8+0wMmmFBbjyxGAoWUEEKowyFMHtg4qbw18ObXw3r8uoxNp9yXd5Rcy6an24yPnfuud2WUkk42g9t2OKel/67C1t/XcvL8QvDj2clytxe+VHI0R/wCJZc7i6lgyqvl5YrsbcADtAycDmq9n4k8EWWrXk2nm0gu7qP7RcXdvYsouQADzMqbZGAkU7Qxb5hxzWXP8MJL3SYINSvtK1C5ttRub2I3mj+dbkTsWdHhaU5ILHDBlIwPfMd58KZLq9jnXWYYfsx/0QR2ABtlAQqigPtCK8SsFCgYyDkncDQp2vptcv6h8UtDt5fJie+iDWk05u5NIupEtijBSJIwgYYJJOduABkjcK1r7xz4f025mt729kWSBGd2S0mdDtXcyqyqVZwvJRSWABOMVj+IfA+u+ILdjJ4isYbqewmsLmQaUzRmOQocxp54KkbP4mfqenSo7v4d391Zz2h12AW7yy3USnTyTFcyxsjtnzeY/3jsE4IJGWIGKX2fPX/gf1/w4lvr/AFp/n/XQ6S18V6TfaffXllLNOlinmTILaRX2ldwKqVBYEdCAQe1Zdn8SvD9xpdldzyXVu11bibymsZ2KEqW2EhPvEAlV6uOVBBFSaF4U1DTZtRbUdVtrtL20htgsFk0Jj8uMpuyZXznJOMDHqa561+En2OQTpd6NPeG2jiN3daGJZY5I4xGjxOZcoNqrlcnJyQVzwPS9vl+P/AFG7Sv/AFt/wTfX4l+FmAJvbqNDGkweXTrmNDE5wsgZowNmSMvnaM8kU+fx/oUbBxfTJHEZvPRtMuS/7pAzD7oKkBlbBB3LyBjmsK8+G+tXWlixXxJYpH/ZEWlsTpLkkI27eP34wSOMUy8+HHiS71C9uh4p01Ptc00pT+xXO3zIFgIB+09lUEe+e3FN21t5/np+ARu7X8v+CdP/AMJ34fNrJOt3O4jdU8tLKdpXLLvUpGE3uCuTuUEYBOeDVGDx1bDW9QFxdQzaULW1uLF7S3klmlMvm5UKu4yH91kBVBAzkcZqhD8P9cg1dNVi8R2S3kCQrAf7KbyxsiMTB18/LBgxPBUggcnkGKH4ZX1lrMWo6br8EUlqsX2VZdPL7XUShjJiUbw32iXgbcfLg8HL01BXtqb178QfDVha29zLfTSxXEYlQ2tlPcEKW2gsI0Yplsr82OQR1Bq5pfizSNa+yf2dLcv9sExi32U0f+qYK+7cg2YY4+bGT0zXBav4Zn07XrK1tPOlMMJmUvpNzPDdzNM8rhmglREG8ghZtyjgjoc9h4U09Vv9V1WJLmK3vZ98EFzA0Rjyo8wqjKGUM+T8w5xnoRSVvz/4AMkt/Gmku0SPdyzPcXUlugj0+dfLKyeXiTIOzDfLubaCelVZfGSaX421DSdbniis1htZLWWO1l+QymRSJZAWUDcgwx2D5scmqNt4A1KOZZJ9dti66jJeLLBp7RSokkvmNGriUkAkAHOVK8Fc81paz4OfVtauLpNREFpfQQwX1uYNzSLE7Mmx9w2ZLkHKtkdNp5oVrK45bu3y+8kHj/w6yXJiuriVrdlUxx2M7PJu3bTGoTMinY/zJkfKTng1L/wnHh0XXkPqIRvKM3mPDIseAm8jzCu3eFIYpncBziudi+Gd5HNeTvrVrc3F3EiSS3Gns5Zo2kZHY+aG3DzOqleVGNo4qBfg9aCS7827s52uk3G/n0uOTUEm2gFxck/dJGdpXPJG7HFC8wlv7praX48t5LfxFqGqylNM0q5RUkTT545EjaNH/eRkF8gvydoGOcAc1fufH3h6zvnsp7m6+0JM1uY00+4cmRY/M2jbGdxKHcMZ3c4zg1Ri8FajPp3iS11nW4bo69EqvJb2Jh8lvKERIBkbIwoOOxzyc8c/q/h/XtL8VaTPDqQuru/1JZ2uI9EmkhtStm0BLhJCAjEpgMykZPzEA4dlt/V/6uPS1/U64ePvDbeT5eoNKsyBkeK1ldCSu4IWVSBIR0jJ3nsKs6N4u0XxBG7aRcyThIEucNbSxlo3BKsoZQWBwRxnkEdRiuXsPha2k2s1jp+sKLC4ul1GWKe0LubxSG8wMJBhCyqxTHbAYA1peEfBeo+Gr23kudZtr2CDSodOEcdg0THy2Yq+4ysP4jkY9ORS0s/66f56fj6L+v6+X9d6Ok/E22v9TWa6ElrpVxapJAJNPnWaNzMY8ucY2H5fm2hQTjca6ix8TaVqup3Gnafd77uFSxDQuqsAdpZGICyANwShODwcGuOb4a659kubVPEtgsElmLOEHSHLIgm8wFj9o+Y8kZAA6HA763hH4fweE764uIBpTs4cRzw6UsNz8zbiJJgxMgz0GFPAyWPNJba+f/AE73dvL/gjdE8YX0uhaudait21XTbh4VS3QxpcguVhZVLsVDEbeWPIajwz48t7nQNEfxLeW8eqanbxzMLa1lWCIyDKIzEsqE9BuYbiDgdqdb+Cb1JIby51a3k1GFZwrxWTJBIzuXQvEZSW2MzkDePvdqxNP+D0FubT+0bjSNRMdpHazyz6KrS4jBVGhdpGMTbcZ+8CRkBafR/L9fz0K0saVv8AEO3u/GT6dDeRiwlS3NtK2mXGXd3kUqXJC7WCZWTAXnq1a48e+HWgnlS8mdYCgKpZTs0u/O1o1CZlU7WwyBh8p54rnH+GmtyXtjLJ4otZIrSO3gKPpR3PHA7sg3CYAMQ5BOMZGQB0rUHgzVz4ct9Fm8QxSWto8awj7AR5kCjHlzYl+c4xyNgyBlTyKT20/r+v6819rysvv/r+u1/QPEMuvalqqWlxay2SQ289hOkLAlJYywLgt83Izxt4OPeuZj8ZeKNL8Mx+JtcfSr7S0u2t7qCysZYZolE5h8xCZZN/Izs2g88Ekc7PgvwZqPhKO4ik1i1vYmtYLa3VLBojGIlKqWPmtu4POAvTjFVLTwDq7aXDpOteIbW50yK5a7MFpprQNNJ5plAdjM+UDnO0BScAZ65bsnp/X9f0yVfr5mrB470MWlm8+oPK15zG0WnzqAC5RN67SYyWG0b8bmBx6VV0X4jaRrMJuvNuLKJLczNBdadcRuR5mxWR2UB8nA2oGOSBn1h8OeCNZ8PTxyxeIbaUyR+VeD+zSolUSO6mP96fLYeYwJO8EY4GKoL8M9ULRrN4jtvJtYRHZiLTGV42SdZ42djMQ+GUAgKuRnp1pdV/X9f1sPW33f8AB/r8zcf4keF4wPMvbhT5Tysp0+43IqMFfcvl5UruBYNggEEgDmoNe8V+CLyG6sPEKxX9vbL50sc+mS3ERCsoLL+7KvtLru25255xWbffDbU7y8u7tdftI7i/tLqC6b+zGKs86xoXQed8oCwoApJ7kk54qXvwr1i9WWWTxPaNeS28to876U7fuZPLJUDz+Npj+XnAB5BPzFq2l/6f9WKe2h1Vh4x8PvFJb2S3kK2csNs0J0q5i8tpDiMBTGOD6gYAwSQKztR8bTW/jifSYTHb2WmwRTX0lzY3BMokLACKRRt3AhcDDbySBgqatw6b9s8ex3489WsrTyb1jatFFcSjBiKlh8wUPL90sBuwTkVW1bwRqGra/qd+2tQQw3Udr9niSxJe3kt5DJG5cyYcbmbK7RkYAIxkmmjf9f1v93qLo0aFl488P6jqUNhZz3cl1KCRF/Z1wCmG2nfmP5CCRkNjbkE4BFczqvjbX9N8XX+mw3ejXrW1zbrDpMdpIt5cQylcsG84gbN3LeXtOOdtbGi+Cr/S/GUniC51e2uHuYZFu4o7Fo98jbPmQmVtoAiQbSGPB554dN4P1SXV9V1Aa1axTXM0c9k8ensGtHRdo3EykSKUyrABc5OCOxpeL+/+v6+QlfVfcaNx4z0C1vri0ub/AMqW2R3kLQyBDtxuCvt2uwyMqpLDPIqlbfEjw1dS3EUc9+sltFJLKkuk3cbBYwC+A0QyQGXKjJ5HFcxqHw6OjabrGoLFpl9dXYkkea20APdiSU/vSH8wu0Y3MRGPnwMBjxU+i+EL/ULGKWHURaiNbiIXEul3Mclwk6KHLJczNKHBRcO5OQMbcYNTrb5fiVpzeV/wNi38f2dtLq02sXKfYYLiMWb2tnM8jxPbpNlkXcxwGJLYAAHIFMvfGHhTW11XTdbsJLy0s7iOIxT6XLcpcsYxKCiCNt+Ac8AkAbuBg1lp8L9Wlsbiz1DxJaT21zsWWKPS3jV1W38jBBnbJwFYZyAwPB4xeg+H+p2V6L6x162jvEmjmiZ9OZ0DC3WCQMvmglWVFIAIKnuw4q9Lv5WEtlffqXv+Fk+FLe3PkXN29vAEUvbaVdSRRhgNnzJGVAIIwc47djXRWmp2t7JdpA0mbOXypjJC8YDbQ3BYAMMEcjIrj7HwfH4X0jXIdTun1TTdTRIvs1tp0jTAldhzsZt2S2chVC/Qca8Wgap/wr9NHj1JIdTltglxezwebl2/1h2qycnJAwRjj0xU7pv+v6X6oF0ItD8XfabfVZtbENolm6zRFAfmtZFDRMRySx+ZcDqRgCqmo/E/Q7R4UQ34Se3uJjcf2VcuLfyiobzIwm8YLZIO3AHJGRmtffDC3F4G8NSaZ4ftZIES4hstLCmWWOQSRy5VwPlZRwVOQWGeQRY1/wAF63r1vE8niCyivvsVzYzS/wBls0TRz7AdiecCpHljks3JPHQB6f1/X9fgONr6l6Tx9ocelzXZuLxlhnNq7JpN0+JQm8/IE3FdvzZHGO9Vbb4h6bc6smliW4jlD26C7fS7jyJzIgfCtjbHkEYLN36HHLx4MvQLt11eES3VgsDD7GfLFyI/LNxt8zPKYXbu7day2+HOrlbeJfENl5CtaPcK2luWlaBNnynzxtDKOmGIPftSe+nl/wAH+vMjW3yf/A/ryN3/AIWD4bMcrR3k0rRlR5cVlMzyBgSrooTLoQrHeoK4UnPBq3q2r3PnWVhojQfbb+N5YpbhGeOKNQNzlAVLcso25X73UYrlLD4UR6XorWFhPo9u64SK6h0RYpmUAhWkdJAzSAHIdSnPODkiuj1LR7+G60zUNMcXN7ZWz2bvccl0kCZcjK7iGjViMjI3DIOKHb+v67ldf6/r8DFtvHl+/wANbzVpra3Ou2qtH9mUFY3l270bG4kIUKuecgZ54rV0vxpprRW1pq+owDUTbedO6W8kVvuCB3VXbcoYKclN5YDkjFZ3/Cvro6cQdYh+3tpv2EyizbyCeVEvlebneI2ZM7++fQVnWvwgtU+2LfzaXcG9gdJbqPR0S7SRo9jGOcuxVMc7SCeSN2OKfV3/AK3/AOHB9Lf1t/wxHL448Ral4vWw8P3ulxWE15HbRte6NcCVN0EkuWDTRk/6rj5QCGBHuat471/SrqTTdQvtB0u5sryCG6vrm2draSGZGKSgGZDGQUZSrM3bmrcvgHxM+uwat/wlOmtcwyxTESaK5VnSKSIcC4GAVkJI9e+OKtTeAtSku47/APt22k1CS9ju72a409nSURqVSKNBKPLQBm4Jc5bOfU00t/Wq/S4dPO346/8AAL2ieJdRu/BdxqWo20K3kc0kEDIjRxXZD7I5FViWVXJGASevU9aS08U3h8N6fq15Fb7Vm+yamiAqYZfM8osmSflD5yDztOc8YMM3gvULnydNvNT0688NxXAkGmXelmR2jGSsRk83aVU4IzHxtXOcc1l8E3dg15pGmfYYvD+o3aXBtbe08lbJFKF0GHIYvt6BFAyx9ARWv/X9d9gfl/X/AA2h3VFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==" alt="" width="501" height="808" vspace="0" hspace="0" border="0" style="width:501px;height:808px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em><u>Description of selected adverse reactions</u></em><br />Infusion associated reactions<br />Infusion associated reactions consisted most often of fever and chills. Additional symptoms included mild or moderate dyspnoea, hypoxia (oxygen saturation decreased), throat tightness, chest discomfort, flushing, pruritus, urticaria, face oedema, angioneurotic oedema, rhinitis, bronchospasm, tachypnoea, wheezing, hypertension, hypotension, tachycardia, palpitations, abdominal pain, nausea, vomiting, infusion-related pain including pain at the extremities, myalgia, and headache.<br />The infusion-associated reactions were managed by a reduction in the infusion rate together with the administration of non-steroidal anti-inflammatory medicinal products, antihistamines and/or corticosteroids. Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction. The frequency of these reactions decreased over time. The majority of these reactions can be attributed to the formation of IgG antibodies and/or complement activation. In a limited number of patients IgE antibodies were demonstrated (see section 4.4).<br /><em><u>Paediatric population</u></em><br />Limited information from clinical trials suggests that the safety profile of Fabrazyme treatment in paediatric patients ages 5-7, treated with either 0.5 mg/kg every 2 weeks or 1.0 mg/kg every 4 weeks is similar to that of patients (above the age of 7) treated at 1.0 mg/kg every 2 weeks.<br /><em><u>Reporting of suspected adverse reactions Saudi Arabia:</u></em></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2340. reporting hotline : 19999E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials doses up to 3 mg/kg body weight were used.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other alimentary tract and metabolism products, enzymes. ATC code: A16AB04.<br /><em><u>Fabry disease</u></em><br />Fabry disease is an inherited heterogeneous and multisystemic progressive disease, that affects both males and females. It is characterised by the deficiency of &alpha;-galactosidase. Reduced or absent &alpha;-galactosidase activity results in the accumulation of GL-3 in the lysosomes of many cell types including the endothelial and parenchymal cells, ultimately leading to life-threatening clinical deteriorations as a result of renal, cardiac and cerebrovascular complications.<br /><em><u>Mechanism of action</u></em><br />The rationale for enzyme replacement therapy is to restore a level of enzymatic activity sufficient to clear the accumulating substrate in the organ tissues; thereby, preventing, stabilizing or reversing the progressive decline in function of these organs before irreversible damage has occurred.<br />After intravenous infusion, agalsidase beta is rapidly removed from the circulation and taken up by vascular endothelial and parenchymal cells into lysosomes, likely through the mannose-6 phosphate, mannose and asialoglycoprotein receptors.</p><p><em><u>Clinical efficacy and safety</u></em><br />Efficacy and safety of Fabrazyme was evaluated in two studies with children, one dose-finding study, two double-blind placebo-controlled studies, and one open-label extension study in both male and female patients.<br />In the dose finding study, the effects of 0.3, 1.0 and 3.0 mg/kg once every 2 weeks and 1.0 and 3.0 mg/kg once every 2 days were evaluated. A reduction in GL-3 was observed in kidney, heart, skin and plasma at all doses. Plasma GL-3 was cleared in a dose dependent manner, but was less consistent at the dose of 0.3 mg/kg. In addition, infusion-associated reactions were dose dependent.<br />In the first placebo-controlled clinical trial, Fabrazyme was effective in clearing GL-3 from the vascular endothelium of the kidney after 20 weeks of treatment. This clearance was achieved in 69% (20/29) of the Fabrazyme treated patients, but in none of the placebo patients (p&lt;0.001). This finding was further supported by a statistically significant decrease in GL-3 inclusions in kidney, heart and skin combined and in the individual organs in patients treated with agalsidase beta compared to placebo patients (p&lt;0.001). Sustained clearance of GL-3 from kidney vascular endothelium upon agalsidase beta treatment was demonstrated further in the open label extension of this trial. This was achieved in 47 of the 49 patients (96%) with available information at month 6, and in 8 of the 8 patients (100%) with available information at the end of the study (up to a total of 5 years of treatment). Clearance of GL-3 was also achieved in several other cell types from the kidney. Plasma GL-3 levels rapidly normalised with treatment and remained normal through 5 years.<br />Renal function, as measured by glomerular filtration rate and serum creatinine, as well as proteinuria, remained stable in the majority of the patients. However, the effect of Fabrazyme treatment on the kidney function was limited in some patients with advanced renal disease.<br />Although no specific study has been conducted to assess the effect on the neurological signs and symptoms, the results also indicate that patients may achieve reduced pain and enhanced quality of life upon enzyme replacement therapy.<br />Another double-blind, placebo-controlled study of 82 patients was performed to determine whether Fabrazyme would reduce the rate of occurrence of renal, cardiac, or cerebrovascular disease or death. The rate of clinical events was substantially lower among Fabrazyme-treated patients compared to placebo-treated patients (risk reduction = 53% intent-to-treat population (p=0.0577); risk reduction = 61 % per-protocol population (p=0.0341)). This result was consistent across renal, cardiac and cerebrovascular events.<br />The results of these studies indicate that Fabrazyme treatment at 1 mg/kg every other week provides clinical benefit on key clinical outcomes in patients with early and advanced Fabry disease. Because this condition is slowly progressive, early detection and treatment is critical to achieve the best outcomes.<br />In an additional study, 21 male patients were enrolled to follow GL3 clearance in kidney and skin tissues at an alternative dosing regimen. Following treatment with 1 mg/kg every other week for 24 weeks, a dose regimen of 0.3 mg/kg every 2 weeks for 18 months was able to maintain the clearance of cellular GL-3 in the capillary endothelium of the kidney, other kidney cell types and skin (superficial skin capillary endothelium) in the majority of patients. However, at the lower dose, IgG antibodies may play a role with respect to GL-3 clearance in some patients. Due to the limitations of the study design (small number of patients), no definitive conclusion regarding the dose maintenance regimen can be drawn, but these findings suggest that, after an initial debulking dose of 1.0 mg/kg every 2 weeks, 0.3 mg/kg every 2 weeks may be sufficient in some patients to maintain clearance of GL-3.<br />In the postmarketing setting, experience was gained in patients who initiated treatment at a dose of 1 mg/kg every 2 weeks and subsequently received a reduced dose for an extended period. In some of these patients, an increase of some of the following symptoms was spontaneously reported: pain, paraesthesia and diarrhoea, as well as cardiac, central nervous system and renal manifestations. These reported symptoms resemble the natural course of Fabry disease.</p><p><em><u>Paediatric population</u></em><br />In one open-label paediatric study, sixteen patients with Fabry disease (8-16 years old; 14 males, 2 females) had been treated for one year at 1.0 mg/kg every 2 weeks. Clearance of GL-3 in the superficial skin vascular endothelium was achieved in all patients who had accumulated GL-3 at baseline. The 2 female patients had little or no GL-3 accumulation in the superficial skin vascular endothelium at baseline, making this conclusion applicable in male patients only.<br />In an additional 5-year open-label paediatric study, 31 male patients aged 5 to 18 years were randomized prior to the onset of clinical symptoms involving major organs and treated with two lower dose regimens of agalsidase beta, 0.5 mg/kg every 2 weeks or 1.0 mg/kg every 4 weeks. Results were similar between the two treatment groups. Superficial skin capillary endothelium GL-3 scores were reduced to zero or maintained at zero at all time points post-baseline upon treatment in 19/27 patients completing the study without a dose increase. Both baseline and 5-year kidney biopsies were obtained in a subset of 6 patients: in all, kidney capillary endothelium GL-3 scores were reduced to zero but highly variable effects were observed in podocyte GL-3, with a reduction in 3 patients. Ten (10) patients met per protocol dose increase criteria, two (2) had a dose increase to the recommended dose of 1.0 mg/kg every 2 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following an intravenous administration of agalsidase beta to adults at doses of 0.3 mg, 1 mg and 3 mg/kg body weight, the AUC values increased more than dose proportional, due to a decrease in clearance, indicating a saturated clearance. The elimination half-life was dose independent and ranged from 45 to 100 minutes.<br />After intravenous administration of agalsidase beta to adults with an infusion time of approximately 300 minutes and at a dose of 1 mg/kg body weight, biweekly, mean Cmax plasma concentrations ranged from 2000-3500 ng/ml, while the AUCinf ranged from 370-780 &mu;g min/ml. Vss ranged from 8.3-40.8 l, plasma clearance from 119-345 ml/min and the mean elimination half-life from 80-120 minutes.<br />Agalsidase beta is a protein and is expected to be metabolically degraded through peptide hydrolysis. Consequently, impaired liver function is not expected to affect the pharmacokinetics of agalsidase beta in a clinically significant way. Renal elimination of agalsidase beta is considered to be a minor pathway for clearance.<br /><em>Paediatric population</em><br />Fabrazyme pharmacokinetics was also evaluated in two paediatric studies. In one of these studies, 15 paediatric patients with available pharmacokinetics data, aged 8.5 to 16 years weighing 27.1 to 64.9 kg were treated with 1.0 mg/kg every 2 weeks. Agalsidase beta clearance was not influenced by weight in this population. Baseline CL was 77 ml/min with a Vss of 2.6 l; half-life was 55 min. After IgG seroconversion, CL decreased to 35 ml/min, Vss increased to 5.4 l, and half-life increased to 240 min. The net effect of these changes after seroconversion was an increase in exposure of 2- to 3-fold based on AUC and Cmax. No unexpected safety issues were encountered in patients with an increase in exposure after seroconversion.<br />In another study with 30 paediatric patients with available pharmacokinetics data, aged 5 to 18 years, treated with two lower dose regimens of 0.5 mg/kg every 2 weeks and 1.0 mg/kg every 4 weeks, mean CL was 4.6 and 2.3 ml/min/kg, respectively, mean Vss was 0.27 and 0.22 l/kg, respectively, and mean elimination half-life was 88 and 107 minutes, respectively. After IgG seroconversion, there was no apparent change in CL (+24% and +6%, resp.), while Vss was 1.8 and 2.2 fold higher, with the net effect being a small decrease in Cmax (up to -34% and -11%, resp.) and no change in AUC (-19% and -6%, resp.).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, single dose toxicity, repeated dose toxicity and embryonal/foetal toxicity. Studies with regard to other stages of the development have not been carried out. Genotoxic and carcinogenic potential are not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Sodium phosphate monobasic, monohydrate<br />Sodium phosphate dibasic, heptahydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products in the same infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Reconstituted and diluted solutions
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage and conditions prior to use are the responsibility of the user. The reconstituted solution cannot be stored and should be promptly diluted; only the diluted solution can be held for up to 24 hours at 2°C-8°C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fabrazyme 5 mg powder for concentrate for solution for infusion<br />Fabrazyme 5 mg is supplied in clear Type I glass 5 ml vials. The closure consists of a siliconised butyl stopper and an aluminium seal with a plastic flip-off cap.<br />Package sizes: 1, 5 and 10 vials per carton.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The powder for concentrate for solution for infusion has to be reconstituted with water for injections, diluted with 0.9% sodium chloride intravenous solution and then administered by intravenous infusion. Use Aseptic Technique&nbsp;Determine the number of vials to be reconstituted based on the individual patient&rsquo;s weight and remove the required vials from the refrigerator in order to allow them to reach room temperature (in approximately 30 minutes). Each vial of Fabrazyme is intended for single use only.<br />Reconstitution</p><p>Fabrazyme 5 mg powder for concentrate for solution for infusion<br />Reconstitute each vial of Fabrazyme 5 mg with 1.1 ml water for injections. Avoid forceful impact of the water for injections on the powder and avoid foaming. This is done by slow drop-wise addition of the water for injection down the inside of the vial and not directly onto the lyophilized cake. Roll and tilt each vial gently. Do not invert, swirl or shake the vial.<br />The reconstituted solution contains 5 mg agalsidase beta per ml, and appears as a clear colourless solution. The pH of the reconstituted solution is approximately 7.0. Before further dilution, visually inspect the reconstituted solution in each vial for particulate matter and discoloration. Do not use the solution if foreign particles are observed or if the solution is discoloured.<br />After reconstitution it is recommended to promptly dilute the vials, to minimise protein particle formation over time.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Dilution</p><p>Fabrazyme 5 mg powder for concentrate for solution for infusion<br />Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride intravenous solution, from the infusion bag.<br />Remove the airspace within the infusion bag to minimize the air/liquid interface.<br />Slowly, withdraw 1.0 ml (equal to 5 mg) of the reconstituted solution from each vial up to the total volume required for the patient dose. Do not use filter needles and avoid foaming.</p><p>Then slowly inject the reconstituted solution directly into the 0.9% sodium chloride intravenous solution (not in any remaining airspace) to a final concentration between 0.05 mg/ml and 0.7 mg/ml. Determine the total volume of sodium chloride 0.9% solution for infusion (between 50 and 500 ml) based on the individual dose. For doses lower than 35 mg use a minimum of 50 ml, for doses 35 to 70 mg use a minimum of 100 ml, for doses 70 to 100 mg use a minimum of 250 ml and for doses greater than 100 mg use only 500 ml. Gently invert or lightly massage the infusion bag to mix the diluted solution. Do not shake or excessively agitate the infusion bag.<br />Administration<br />It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 &mu;m filter to remove any protein particles which will not lead to any loss of agalsidase beta activity. The initial infusion rate should be no more than 0.25 mg/min (15 mg/hour) to minimise the potential occurrence of infusion-associated reactions. After patient tolerance is established, the infusion rate may be increased gradually with subsequent infusions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, The Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>